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Introduction: Tissue-engineered oral mucosa (TEOM) is increasingly being used to 
assess drug delivery and toxicity, as well as for modeling oral diseases. Current TEOM 
models are constructed using primary oral fibroblasts and keratinocytes that display 
donor-to-donor variability and whose widespread use is restricted by availability and 
ethic limitations. To address these issues, an attractive approach is the development 
of TEOM using immortalised cells.  
 
Aim: This study aimed to construct and characterise TEOM based on TERT2-
immortalised oral keratinocytes (FNB6) cells and use these TEOM to assess the toxicity 
and delivery of corticosteroids using a novel electrospun-based oral patch.  
 
Methods: TEOM were constructed by culturing immortalised FNB6 oral keratinocytes 
on top of a normal oral fibroblast (NOF)-populated collagen type 1 hydrogel in tissue 
culture transwell inserts at an air-to-liquid interface (ALI) for up to 14 days. The TEOM 
were characterised using histological, immunohistological, ultrastructural (TEM), 
tissue viability (AlamarBlue), trans-electrical resistance (TEER), and permeability (FITC-
dextran) analysis. Cytotoxicity assessment of seven corticosteroids was performed 
using MTT assay on monolayer cultures (FNB6 and NOF cells) and TEOM. Novel 
mucoadhesive bilayer patches containing clobetasol 17-propionate (CP) were 
subjected to morphological, physicochemical, drug release, swelling and cytotoxicity 
analysis. In vitro permeation studies of the corticosteroids against TEOM was 
measured using HPLC. The immunosuppressive effect of delivered CP against 
activated Jurkat T-cells was assessed by measuring changes in interleukin-2 (IL-2) 
release.  
 
Results: Histologically, TEOM mimicked native oral mucosa displaying a stratified 
epithelium, fibroblast-containing connective tissue and basement membrane. IHC 
revealed the expression markers for differentiation (cytokeratin 4,13,14), proliferation 
(Ki-67), cell adhesion (E-cadherin, claudin-4). Furthermore, TEM confirmed the 
presence of desmosomes and hemidesmosomes in the epithelium. Maximal TEOM 
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viability was found up to day 25 and maximal TEER value was exhibited at day 20 
(155.8 Ω.cm2). Permeability analysis showed that only small molecules (3 kDa) could 
pass through the epithelium. Differential drug sensitivity of corticosteroids against 
monolayer cultures was ranked as follow; CP > BU > BD > BV > TA > HV > HB by IC50 
value, and this was similar for TEOM although IC50 values were higher for 3D models. 
Novel mucoadhesive bilayer patches containing CP exhibited good physicochemical 
characteristics and drug release profiles. Toxicity testing to the OECD standard 
revealed that patch delivered CP was considered a non-irritant. Oral mucosal 
delivered CP using liquid or patch formulation into the TEOM tissue or receptive 
medium was both dose and time-dependent. In addition, both liquid and patch 
delivered CP significantly reduced the secretion of IL-2 by activated Jurkat T cells in a 
TEOM model replicating an oral inflammatory disease. 
 
Conclusion: FNB6 TEOM models are able to mimic the native oral mucosa and have 
the potential to be used for drug delivery and toxicity evaluation. Oral patch-delivered 
CP was able to cross the TEOM and inhibit the IL-2 secretion of activated T cells, 




  CHAPTER 1 
LITERATURE REVIEW 
1.1 Overview 
The development of tissue engineered oral mucosa (TEOM) has become an option 
available in pre-clinical studies (Moharamzadeh et al., 2007). The resemblance of 
TEOM structurally and physiologically to native oral mucosa has been valuable for 
various applications including drug toxicity and delivery evaluation (Edmondson et al., 
2014). Most TEOM models available have been developed using primary human cells, 
but the access to these cells is limited and differences of genetic background cause 
batch-to-batch variability (Dongari-Bagtzoglou and Kashleva, 2006; Southgate et al., 
1987). Recent research has moved to use immortalised human cells for tissue 
engineering as these cells can propagate almost indefinitely whilst retaining the 
morphology of normal cells, but very a few studies have conducted research on TEOM 
reconstruction using immortalised cells (Buskermolen et al., 2016; Jennings et al., 
2016; Dongari-Bagtzoglou and Kashleva, 2006).  
 
The administration of pharmaceutical agents through oral mucosal is an alternative 
route of both injectable/parenteral and enteral delivery (Zhang et al., 2002). The oral 
mucosal route offers localised delivery that may be preferential to other 
administration routes (Anoop, 2015; Sankar et al., 2011). Oral mucosal diseases are 
often treated using topical therapy approaches such as creams, ointments, sprays, 
gels etc. (Mehta et al., 2016; González-Moles, 2010). However, these formulations are 
affected by oral cavity conditions such as saliva flow and mechanical factors, causing 
short residence time of the drugs, and leading to unpredictable absorption and 
distribution, and thus low therapeutic efficacy (Paderni et al., 2012; Chinna Reddy et 
al., 2011). The possibility of local delivery through the oral mucosa has led to the 
development of new drug delivery formulations such as oral films or patches 
(Santocildes-Romero et al., 2017) that can increase the retention time of the drug at 
the affected area, increasing its absorption. These new delivery systems may be ideal 
for the treatment of mucosal diseases such as oral lichen planus (OLP) and recurrent 
aphthous stomatitis (RAS).  
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The further development of disease models of TEOM is an attractive strategy in 
evaluating the effectiveness of a novel formulation of the therapeutic agent. Instead 
of using animals, tissue engineered disease models may be suitable to study the 
clinical as well as mechanistic aspects of the disease (Van De Worp et al., 2010; 
Yamada and Cukierman, 2007) whilst also contributing to the ethos of reduction, 
replacement and refinement (3Rs) of the use of animals in research. The data 
presented in this thesis aims to contribute to the field of oral mucosal tissue 
engineering and its usefulness in evaluating novel modes of drug delivery. 
 
1.2 The oral mucosa 
The oral cavity encompasses a number of soft tissue structures including the gingiva, 
vermillion, buccal, hard and soft palate, floor of the mouth and tongue (Nguyen and 
Hiorth, 2015: Zhang et al., 2002). These areas are lined by epithelial mucosa that 
differs structurally and demonstrates differences in barrier properties (Gandhi and 
Robinson, 1994) depending on its location within the oral cavity. This oral mucosa has 
a variety of functions, including protection, sensation, secretion and thermal 
regulation (Çelebi and Yörükan, 1999; Squier, 1991). 
 
1.2.1 Organisation of the oral mucosa 
There are three types of the oral mucosa lining the oral cavity. These have been 
categorised according to their functions and characteristics into lining, masticatory 
and specialised mucosa (Smart, 2004; Rathbone and Hadgraft, 1991) and cover around 
60%, 25% and 15% of the total surface area of mucosal, respectively (Squier, 1991; 
Collins and Dawes, 1987). 
 
Lining mucosa is covered by a non-keratinised stratified squamous epithelium 
providing an elastic, deformable surface capable of stretching with movements 
during, for example, mastication and speech. It covers regions of the buccal and labial 
mucosa, vestibular, floor of mouth, ventral tongue and soft palate. Lining mucosa is 
attached by a loose, elastic connective tissue to underlying structures (Bhati and 
Nagrajan, 2012; Lesch et al., 1989). Masticatory mucosa covers the gingiva and hard 
palate areas. Mechanical forces of mastication at these areas causes abrasion and 
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shearing and therefore to withstand these forces the mucosa is comprised of a 
keratinised stratified squamous epithelium which is tightly attached to the underlying 
structures by a collagenous connective tissue (Sohi et al., 2010). Specialised mucosa 
has characteristics of both masticatory and lining mucosa and covers the filiform, 
fungiform and circumvallate papillae of the dorsal tongue. It has a surface comprised 
of areas of both keratinised and non-keratinised epithelium that are tightly bound to 
the underlying muscle of the tongue (Bhati and Nagrajan, 2012; Patel et al., 2011).   
 
1.2.2 Structure of the normal oral mucosa 
Morphologically, the normal oral mucosa is comprised of three distinct layers; namely 
the epithelium, connective tissue (lamina propia) and submucosa that are located as 
an outermost, intermediate and innermost layer, respectively. The epithelial and 
connective tissue layer is separated by a basement membrane (Dodla and 
Velmurugan, 2013; Winning and Townsend, 2000; Sudhakar et al., 2006) (Figure 1.1). 
 
The oral epithelium acts as a protective layer that provides protection against 
potentially harmful agents such as mechanical, microbial and chemicals (Squier et al., 
1975). The epithelium of the oral mucosa is classified as stratified squamous 
epithelium that is either keratinised and non-keratinised (Sankar et al., 2011; 
Sangeetha et al., 2010). Histologically, the oral epithelium is comprised as four distinct 
layers of keratinocytes: basal, spinous, granular (keratinised epithelium) or 
intermediate (non-keratinised epithelium) and superficial layers (Hand and Frank, 
2014; Squier and Kremer, 2001; Winning and Townsend, 2000). The superficial layer 
can be keratinised or non-keratinised, based on the area of the mouth. Structurally, 
the keratinocytes increase in size and become flatter as they move upward to the 
superficial layers undergoing differentiation before being shed from the surface of the 


























Figure 1.1: Composition of layers of mucosal epithelium: (A) keratinised tissue and (B) 
















Other cell types including melanocytes, Langerhans cells, lymphocytes and Merkel 
cells are also found, representing approximately 10% of the cell population within oral 
epithelium in both keratinised and non-keratinised forms (Hand and Frank, 2014; 
Squier and Kremer, 2001; Winning and Townsend, 2000; Squier and Finkalstein, 1998). 
All these cells lack desmosomal attachments to the neighbouring cells, except Merkel 
cells and these cells do not participate in the process of maturation seen in epithelial 
keratinocytes. Histologically, these cells exhibited as a small rounded cell with a clear 
halo around their nuclei and are classified as non-keratinocytes. The distribution and 
density of these cells are varied and dependent on the different oral regions (Squier 
and Kremer, 2001; Barrett et al., 1996; Ramieri et al., 1992; Barrett and Beynon, 1991). 
 
Desmosomes are junctional complexes that adhere epithelial cells together and so 
play an important role in tissue integrity. These complexes are mainly comprised of 
proteins from three major gene families: desmosomal cadherins (e.g. desmogleins and 
desmocollins), armadillo family proteins (e.g. plakoglobin and plakophilin) and the 
plakin family of cytolinkers (e.g. desmoplakin) (Kottke et al., 2006; Yin and Green, 
2004). There are two regions in the desmosome including a core region and plaque 
region, which mediates tight cell-cell adhesion and attachment to the intermediate 
filament cytoskeleton, respectively. The core region comprises the extracellular 
domains of the desmosomal cadherins members that are desmocollins and 
desmogleins. While the plaque region contains the C-terminal tails of the desmosomal 
cadherins, which associate directly and indirectly with various cytoplasmic proteins. 
The armadillo family proteins such as plakoglobin and plakophilins mediate the 
interactions between desmosomal cadherin tails and desmoplakin that binds directly 
to the intermediate filaments (Kottke et al., 2006). E-cadherin mediates cell-cell 
adhesion in a calcium-dependent manner (Kowalczyk et al., 1999). Intracellularly, E-
cadherin interacts with either β-catenin or plakoglobin that then combines with actin 
cytoskeleton filaments through α-catenin (actin-binding protein). E-cadherin also 
interacts with p120-catenin (Aktary and Pasdar, 2012) allowing tethering of the 
intermediate filaments to the plasma membrane (Bastos et al., 2014), to provide 
structural integrity and epithelial barrier function to tissue (Bardag-Gorce et al., 2016; 
Kottke et al., 2006) (Figure 1.2).  
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The basement membrane (approximately 1 µm in thickness) is a continuous layer of 
extracellular material that forms a distinguishing layer between the connective tissues 
and the epithelium (Winning and Townsend, 2000; Schroeder, 1981). It acts to anchor 
the underlying connective tissue to the epithelium and functions as a mechanical 
support (Dodla and Velmurugan, 2013; Shinkar et al., 2012). The basement membrane 
region has been implicated as the rate-limiting barrier to the passage of some 
molecules such as chlorhexidine and beta-blocking agents (Rathbone and Tucker, 
1993). The basement membrane is attached to the basal keratinocytes through 
protein complexes called hemidesmosomes (Garrod, 1993), to provide the stable 
cohesion of these cells to the underlying connective tissue, ensuring resistance to 
mechanical stresses (Walko et al., 2015; Litjens et al., 2006). The hemidesmosome is 
composed of anchoring fibrils (collagen VII) that attach to collagen fibres of the 
underlying connective tissue (Moll and Moll, 1998; Jones et al., 1993; Schroeder, 
1981). The core of the complex consists of integrin α6β4 that bind to the extracellular 
matrix protein laminin-332 (laminin 5) and plectin isoform 1a (P1a), forming a bridge 
to the cytoplasmic keratin intermediate filament network. Other important 
components of this complex include BPAG1e (the epithelial isoform of bullous 
pemphigoid antigen 1 also called BP230), BPAG2 (a collagen-type transmembrane 
protein also called BP180 or type XVII collagen), and the tetraspanin protein CD151 






























Figure 1.2: The schematic diagram of a desmosome and hemidesmosome and their 
















The connective tissue, also known as the lamina propria, provides mechanical support 
for the mucosa (Schroeder, 1991) and is the tissue where the blood vessels and nerves 
reside (Shinkar et al., 2012).  It consists mainly of several types of collagen (Sattar et 
al., 2014) and although it depends upon the location, collagen type I is the most 
abundantly found in the connective tissue along with collagen type III and elastic fibres 
(elastin) that is found in the deeper layers. Fibroblasts are the most common cells 
found in the connective tissue and are involved in producing and maintaining the 
collagen fibres (type I, III, V and VI) (Becker et al., 1986), proteoglycans (e.g. 
hyaluronan, heparan sulphate) (Oksala et al., 1995) and also glycoproteins (e.g. 
fibronectin) (Luomanen et al., 1997). Structurally, the collagen fibres appear thin and 
loose in the lining mucosa but arrange in bundles in masticatory mucosa (Winning and 
Townsend, 2000). The fibroblasts that synthesise collagen and promote cross-linking 
are therefore responsible for extracellular matrix (ECM) production can also 
differentiate into a myofibroblastic phenotype to facilitate wound closure (Wojtowicz 
et al., 2014; Schultz et al., 2011; Martin, 1997). Fibroblasts also secrete growth factors 
and interact with the epithelium via paracrine signaling that enables the keratinocytes 
to proliferate (Fusenig, 1994) while the differentiation of the epithelium continues 
(Smola et al., 1998). Macrophages, plasma cells, mast cells, lymphocytes, blood 
vessels, lymphatic vessels, and nerves are also found in the connective tissue in 
varying numbers depending on the site (Atkinson et al., 2000; Hilliges et al., 1996; 
Ramieri et al., 1990).  
 
The submucosa occurs in many regions (cheeks, vermillion) and comprises a layer of 
loose fatty or glandular connective tissue containing the major blood vessels and 
nerves supplying the mucosa that separates the oral mucosa from underlying bone or 
muscle (Squier and Kremer, 2001).  
 
1.2.3 Permeability of the oral mucosa 
The permeability barrier of the oral mucosa acts to prevent exogenous and 
endogenous materials from entering the body and prevents loss of fluid from the 
underlying tissues to the environment (Hearnden et al., 2012). There are significant 
differences in the permeability across different areas of the oral cavity, for example, 
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the epithelium of the floor of the mouth is much more permeable than that of the 
hard palate (Squier, 1991). The relative impermeability of the oral mucosa is 
predominantly due to the presence of lipid membrane coating granules (MCG) that 
are spherical or oval intracellular organelles (100-300 nm in diameter) that are located 
in the apical layers of the epithelium particularly in the prickle cell layer (Squier, 1977). 
As the mucosal cells move upward from the basal layer, the cells are differentiated 
and flattened. The accumulation of lipids occurs and concentrates in the MCG. The 
number of MCG within cells increases as the cells differentiate and move apically 
within the epithelium (Squier and Kremer, 2001; Matoltsy, 1976; Elias and Friend, 
1975). At the apical cell surfaces, the MCG fuse with the plasma membrane, emptying 
its lipid content via exocytosis into the intercellular spaces that are lined with lipid 
lamellae at the upper one-third of the epithelium (Sattar et al., 2014; Sankar et al., 
2011; Manganaro, 1997). Subsequently, the plasma membranes become thickened 
and coated by lipid lamellae that also play a role in the development of a protective 
layer (Matoltsy and Parakkal, 1965).  In addition to the presence of MCG’s, the 
variation in permeability across different regions of the oral mucosa is also due to the 
relative thickness and pattern of keratinisation of the epithelium (Satheesh Madhav 
et al., 2009). Whereas sublingual mucosa is relatively thin (100 – 200 µm) and non-
keratinised, the buccal mucosa is thicker (500 – 600 µm) and non- or para-keratinised, 
and the palatal mucosa is intermediate in thickness (250 µm) but keratinised 
(Satheesh Madhav et al., 2012; Patel et al., 2011), these tissues also differ in 
permeability levels.  
 
The distinctive feature between keratinised and non-keratinised oral epithelium is its 
lipid composition in MCG and the presence of keratin (Sankar et al., 2011). Although 
keratinisation is primarily concerned with increased resistance to abrasion, 
keratinised tissues also exhibit a lower permeability compared to non-keratinised 
tissues. Keratinised epithelium contains predominantly neutral lipids (e.g., ceramides 
and acylceramides) that have been associated with barrier function and decreased 
permeability to water. In contrast, non-keratinised epithelium has few polar lipids, 
particularly cholesterol sulphate and glucosylceramides and thus is considerably more 
permeable to water than keratinised epithelia (Hooda et al., 2012; Satheesh Madhav 
10 
 
et al., 2009). Therefore, it is suggested that the epithelium acts as a greater barrier to 
the permeation of hydrophilic compounds than to the relatively more lipophilic 
compounds (Kulkarni et al., 2009). 
 
1.2.4 Protein biomarker expression in the oral mucosa 
Immunohistochemistry (IHC) is a common method used to determine the expression 
of proteins in tissue sections. For the oral mucosa, there are a number of common 
biomarkers whose expression is used to classify the tissue.  
 
Cytokeratins are the most basic markers of epithelial differentiation and are found in 
all types of epithelia (Moharamzadeh et al., 2007). Cytokeratin (CK) 4 and 13 are 
expressed in the suprabasal cells in non-keratinised stratified epithelium (Moll et al., 
2008; Izumi et al., 2000), while CK1 and CK10 are expressed in the suprabasal cells in 
keratinised stratified epithelium (Yuspa et al., 1991). CK5 and CK14 are typically 
expressed in the basal cell layer and their expression is reduced in the differentiating, 
suprabasal cell layers (Alam et al., 2011; Fuchs and Green, 1980). CK19 is expressed in 
the basal keratinocytes of non-keratinising stratified squamous epithelia (Moll et al., 
2008). Another differentiation marker is filaggrin that has been suggested to define a 
premature keratinised state (Izumi et al., 2000). 
 
The expression of proliferation markers such as PCNA and Ki-67 can be found in the 
basal and in some instances, parabasal layers of the epithelium (Izumi et al., 2004). 
Protein laminin 5 and collagen IV are classical markers for the basement membrane 
of the oral mucosa (Kinikoglu et al., 2009; Tunggal et al., 2002; Sahuc et al., 1996). 
These proteins play a significant role in anchoring basal epithelial cells to the 
underlying extracellular matrix by contributing to the formation of hemidesmosomes 
(Kinikoglu et al., 2009; El-Ghannam et al., 1998). 
 
1.3 Tissue engineering 
Tissue engineering is a multi-disciplinary field that applies the principles of biology and 
engineering toward the development of biological equivalents that could restore, 
maintain, or improve tissue function following damage either by disease or traumatic 
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processes (Knight and Evans, 2004; Kaihara and Vacanti, 1999). Tissue engineering 
involves a number of disciplines including clinical medicine, mechanical engineering, 
materials science, genetics, and related disciplines from both engineering and the life 
sciences (O’Brien, 2011). According to Izumi et al., tissue engineering is defined as ‘the 
reconstitution of tissues and organs, in vitro, for use as model systems in basic and 
applied research or for use as grafts to replace damaged or diseased body parts or 
body functions’ (Izumi et al., 2004). 
 
Fundamentally, tissue engineering involves combining cells, signals and scaffold 
(Payne et al., 2014; Izumi et al., 2004) in order to fabricate biological substitutes that 
are similar in terms of function, structure and mechanical properties of the native 
tissue (Bhat et al., 2011; Knight and Evans, 2004). The fabrication of a tissue-
engineered three-dimensional (3D) model requires biomaterials such as cells, scaffold, 
growth factors and ECM (Knight and Evans, 2004). Typically, cells are seeded in a 
porous scaffold that acts as a template for tissue formation and to provide the 
appropriate environment for the regeneration of tissues and organs. Occasionally, the 
cells seeded in the scaffolds are stimulated chemically by growth factors and physically 
by culture in a bioreactor (O’Brien, 2011).   
 
1.3.1 Tissue engineering of the oral mucosa 
Clinically, TEOM has been utilised for the replacement of tissues damaged or removed 
as a result of disease or surgery (Rameez et al., 2008; Ohki et al., 2006). It also has 
been utilised to investigate disease phenomena, pathogenesis, and treatment aspects 
of oral epithelium (Moharamzadeh et al., 2012; Costea et al., 2003; Duong et al., 2005) 
and as a substitute to animal models to examine the safety and efficacy profiles of 
pharmaceuticals and other consumer products (Klausner et al., 2007; Schmalz et al., 
2002). The selection of biomaterials for TEOM is essential to ensure a good fabrication 
of oral mucosa tissue. Attempts to improve the oral mucosa equivalent fabrication 
have been conducted by investigators and different strategies have been undertaken 
to develop, optimise and characterise the cell types, scaffolds and cell culture media 




1.3.2 Biomaterials used for tissue engineered oral mucosa 
1.3.2.1 Scaffolds  
The choice of scaffold materials is essential since the success of tissue engineered 3D 
model fabrication mostly depends on it. Ideally, the scaffold should demonstrate 
properties including, biocompatibility, biostability and biodegradability 
(Moharamzadeh et al., 2007). Furthermore, it should be readily available and capable 
of being prepared and stored for a long shelf-life (MacNeil, 2007). Porosity is also a 
key element of the scaffold because a connective tissue equivalent should possess an 
optimum pore size and distribution to allow cell attachment and migration, delivery 
of biochemical factors and nutrients as well as cell-cell communication (Will et al., 
2008; Muschler et al., 2004).  
 
Many types of scaffold have been studied in fabricating tissue engineered 3D models 
such as fibroblast-populated skin substitutes (e.g. Dermagraft)  (Purdue, 1997), 
natural derived connective tissue  (e.g. De-epidermalised dermis (DED)) (Nakamura et 
al., 2003; Izumi et al., 1999), animal (rat or bovine) type 1 collagen-based (Moriyama 
et al., 2001; Masuda, 1996), fibrin-based (Ruszymah, 2004), gelatin-based (Mao et al., 
2003), synthetic (e.g. poly (lactic-co-glycolic acid-poly (caprolactone) (PLGA-PCL))(Ng 
et al., 2004) and hybrid scaffolds (e.g. poly (lactic-co-glycolic acid) (Ng et al., 2005). 
 
1.3.2.2 Cell types and sources  
The selection of the appropriate cell types or sources is another essential element in 
ensuring the successful development of oral mucosa equivalents. Fibroblasts and 
keratinocytes are two main cell types used in constructing 3D oral mucosal models. 
Fibroblasts and keratinocytes are commonly isolated from the gingiva, buccal, tongue 
or hard palate regions of oral mucosal biopsies from patients. These two cell types 
may be primary cells or immortalised cell lines (Moharamzadeh et al., 2007; Dongari-
Bagtzoglou and Kashleva, 2006).   
 
The interaction between epithelium and connective tissue are essential factors where 
the underlying fibroblasts in the connective tissue play a substantial role in epithelial 
proliferation and differentiation (Kriegebaum et al., 2012; Marionnet et al., 2006; 
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Costea et al., 2003; Mackenzie and Fusenig, 1983), formation of a basement 
membrane (Dongari-Bagtzoglou and Kashleva, 2006; Gallico and O’Conner, 1995), 
keratinocyte adhesion and formation of complex dermal-epithelial junction by 
synthesising ECM (Moharamzadeh et al., 2008b). In addition, culturing the mucosal 
models at an air-to-liquid interface (ALI) is another factor that influences epithelial 
morphogenesis in which the ALI condition encourages the stratification of epithelial 
cells and enhances the expression of differentiation markers (Bhargava et al., 2004; 
Feinberg et al., 2005). Typically, normal human cells can only divide a limited number 
of times, after which point they enter an irreversible state of growth arrest (Kassem 
et al., 2004). The keratinocyte and fibroblast cultures are employed in early passage 
and commonly cannot be propagated more than passage four for keratinocytes and 
up to 10 for fibroblasts (Moharamzadeh et al., 2007; Dongari-Bagtzoglou and 
Kashleva, 2006). 
 
The reconstituted human oral epithelial (RHOE) model is an example of tissue-
engineered oral mucosa that has been commercialised. This model is fabricated using 
a metastatic buccal carcinoma cell line (TR146) (Jayatilake et al., 2006; Rupniak et al., 
1985). It has been reported that carcinoma cell lines do not form a fully differentiated 
oral epithelium (Yadev et al., 2011) and therefore do not accurately represent normal 
epithelium due to its abnormal structures and functions. Furthermore, cancerous cells 
are abnormal and inappropriate for a clinical setting (Moharamzadeh et al., 2012; 
Dongari-Bagtzoglou and Kashleva, 2006). In contrast, the 3D model of the oral mucosa 
that has been fabricated using primary cells mimicks the human mucosa (Dongari-
Bagtzoglou and Kashleva, 2006). However, construction of oral mucosa equivalents 
using primary cells requires large quantities of resected tissues in order to ensure 
adequate numbers of keratinocytes for seeding onto scaffolds. Primary cells have a 
short lifespan and display variable numbers of epithelium layers because cells from 
different donors vary in their proliferation rates and longevity (Dongari-Bagtzoglou 
and Kashleva, 2006). 
 
An immortalised oral keratinocyte cell line is another type of cell that has been 
developed to overcome the limitation of carcinoma and primary cells in fabricating 
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the oral mucosa models. Overexpression of telomerase reverse transcriptase-2 (TERT-
2) allows cells to continually lengthen their telomeres during cell division, thereby 
avoiding cellular senescence and death via apoptosis, and enabling prolonged cell 
replication often termed immortalisation (Irfan Maqsood et al., 2013; Morales et al., 
1999). Examples of immortalised human oral keratinocyte cell line are OKF6 derived 
from floor of the mouth (Dickson et al., 2000) cells that have been developed to 
enhance the reproducibility of the 3D model of oral mucosa and to avoid dyskeratotic 
changes in oral mucosa equivalents (Moharamzadeh et al., 2007). Alternatively, 3D 
models of oral mucosa have also been recently developed using immortalised cells 
derived from the buccal mucosa of a female donor called FNB6 cells (Jennings et al., 
2016).  
 
The production of patient-specific induced pluripotent stem cells (PS-iPSCs) derived 
from patients is another type of cell that has been utilised to construct 3D skin 
equivalents. Thus far, this type of cells has not been utilised in developing the oral 
mucosal equivalents. The autologous PS-iPSCs have the potential to provide an 
unlimited source of cells and it is believed that this type of cells has the unlimited 
proliferative capacity and extensive differentiation capability into a wide range of cell 
types (Onder and Daley, 2012). A study conducted by Itoh et al., have succeeded in 
developing the full-thickness of skin model using iPSCs-derived keratinocytes and 
fibroblasts, enabling the development of iPSC-based cell and gene therapy for skin 
diseases such as recessive dystrophic epidermolysis bullosa (RDEB). In addition, they 
have proven that the differentiating human iPSCs into fully functional dermal 
fibroblasts, which can synthesize mature type VII collagen to treat RDEB (Itoh et al., 
2013). 
 
1.3.2.3 Cell culture medium  
Rheinwald and Green (1975) established a method for the isolation and cultivation of 
primary keratinocytes cells. They co-cultured keratinocytes with lethally irradiated 
3T3 (i3T3) cells as feeder layers that enhance proliferation of the epidermal cells 
(Kriegebaum et al., 2012). Rheinwald and Green also proposed the use of epidermal 
growth factors (EGF) as a medium supplement that delays cellular senescence 
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(Rheinwald and Green, 1977). Several investigators have developed and characterised 
the 3D model of oral mucosa using a serum-free culture medium where they remove 
the use of i3T3 feeder layers, in order to reduce the exposure of human graft 
recipients to xenogenetic DNA or viruses that might be present in serum (Khmaladze 
et al., 2013; Yoshizawa et al., 2004; Izumi et al., 2000).  
 
Currently, the contents of the medium have been modified by supplementing a few 
growth factors in Dulbecco's modified Eagle medium (DMEM)-Ham's F-12 medium 
(3:1), including fetal bovine serum (FBS), glutamine, EGF, hydrocortisone, adenine, 
insulin, transferrin, tri-iodothyronine, fungizone, penicillin, and streptomycin for oral 
mucosa reconstruction (Moharamzadeh et al., 2007).  
 
1.3.3 Applications of the tissue engineered oral mucosa 
1.3.3.1 Pre-clinical studies 
Under the Food and Drug Administration (FDA) regulations, it is necessary for 
investigators to perform thorough pre-clinical works either in vitro or in vivo before 
any substance can be introduced to humans. A Recent study was conducted on 
measuring the secretion of growth factors and chemokines of healthy tissue-
engineered oral mucosa prior to graft implantation into severely combined 
immunodeficiency mice (Kuo et al., 2015). Moharamzadeh and co-workers used tissue 
engineered oral mucosa to determine the safety of mouthwashes (Moharamzadeh et 
al., 2009) and dental materials (Moharamzadeh et al., 2008a). Moharamzadeh et al., 
have extended their study by assessing and comparing the cytotoxicity of ethanol-
containing solutions against tissue engineered oral mucosa with fresh oral mucosal 
biopsies and monolayer keratinocytes culture (Moharamzadeh et al., 2015). Chai and 
colleagues have also conducted a study on the dental implant treatment where they 
have worked on the implant-soft tissue interactions (Chai et al., 2010).  
 
Several investigators have developed an oral cancer model (Marsh et al., 2011; Colley 
et al., 2011; Gaballah et al., 2008; Gaggioli et al., 2007) that allows research on the 
pathogenesis, new treatment strategies, diagnostic tests and drug delivery for oral 
cancer. Oral infection models such as oral candidiasis have also been developed 
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(Yadev et al., 2011; Mostefaoui et al., 2004) that facilitate identifying the mechanisms 
of fungal pathogenesis and examine the interaction of oral microbes with the oral 
epithelium (Gursoy et al., 2010). Meanwhile, drug delivery mechanisms are another 
area which has the potential to be studied using TEOM (Hearnden et al., 2012). 
Hearnden and colleagues have shown that fluorescently labelled polymersomes which 
have been exposed to the TEOM can be traced using laser scanning confocal 
microscopy (Hearnden et al., 2009). Their findings have created opportunities for 
other investigators to explore the mechanism of drug delivery, screening drug toxicity, 
assessing novel dosage as well as to examine the therapeutic and adverse effects of 
drugs. 
 
The effectiveness of TEOM has also been assessed using animals (in vivo). Studies have 
used TEOM against athymic mice to examine the potential usefulness for repairing 
mucosal defects (Peña et al., 2011; Rouabhia et al., 2010; Garzón et al., 2009; Izumi et 
al., 2003). Several investigators have compared wound healing and tissue response 
after grafting TEOM with different cellular components using different types of animal 
such as athymic/nude mice, dogs, and rabbits, (Yoshizawa et al., 2012; Bornstein et 
al., 2011; Ophof et al., 2008; Imaizumi et al., 2004).  
 
 The efforts to develop improved oral mucosal models have been performed by 
incorporating other types of cells, including endothelial cells, which can promote the 
angiogenesis and revascularisation process (Sahota et al., 2004). In addition, the 
incorporation of immune cells in the oral mucosal models such as monocytes, 
Langerhans cells and lymphocytes would benefit in assessing the immune responses 
(Moharamzadeh et al., 2007). Therefore, these strategies provide a higher degree of 
complexity of oral mucosal models that could simulate as close as possible to native 
oral mucosa and broaden their applications. 
 
1.3.3.2 Clinical applications 
A few studies have utilised the TEOM for intra- and extra-oral clinical applications. In 
intraoral applications, engineered human oral mucosa has been applied in 
maxillofacial reconstructive surgery such as maxillary alveolar cleft (Chin et al., 2005), 
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mandibular defects (Herford et al., 2010; Chao et al., 2006; Warnke et al., 2004; 
Orringer et al., 1999) and maxillary sinus augmentation (Voss et al., 2010). In addition, 
a number of investigators have demonstrated that TEOM can be applied in 
periodontal therapy (Köseoğlu et al., 2013; Dominiak et al., 2012; Jhaveri et al., 2010; 
Murata et al., 2008; Mohammadi et al., 2007). GINTUIT® is the first product of oral 
mucosa tissue which has been approved by FDA. This tissue is an allogeneic 
cellularised scaffold product, where a thin cellular sheet composed of human 
fibroblasts, keratinocytes, human ECM proteins and bovine collagen. It is indicated for 
topical application to a surgically created wound bed in the treatment of mucogingival 
conditions in adults, but not intended for root coverage (Gupta et al., 2015; Schmidt 
et al., 2012). For extra-oral application, TEOM has been utilised for substitution 
urethroplasty (Bhargava et al., 2004), ocular reconstruction (Nakamura et al., 2003), 
eyelid reconstruction (Yoshizawa et al., 2004), burn wound (Iida et al., 2005), corneal 
(Nishida et al., 2004) and oesophageal repair (Takagi et al., 2012). 
 
1.4 Oral lichen planus  
Oral lichen planus (OLP) is a chronic autoimmune, mucocutaneous disease that affects 
various parts of the body including the oral mucosa, skin, genital mucosa, scalp and 
nails (Ismail et al., 2007). Commonly, OLP affects the stratified squamous epithelium 
in which auto-cytotoxic T lymphocytes trigger apoptosis of oral epithelial cells leading 
to chronic inflammation (Schlosser, 2010; Scully and Carrozzo, 2008).  
 
1.4.1 Epidemiology of oral lichen planus 
The onset of the disease usually occurs between 30 and 60 years of age (mean at 50 
years) and, in general, this disease affects approximately 0.5-2% of the adult 
population (Sonthalia and Singal, 2012). OLP occurs predominantly in adults over 40, 
however, it may occasionally affect younger adults and children (Scully and Carrozzo, 
2008; Sugerman and Savage, 2002). Based on gender, women have a slightly higher 
tendency than men to be affected with OLP with a ratio of 1.4:1 (Scully and Carrozzo, 
2008; Sugerman and Savage, 2002). According to the World Health Organization 
(WHO), OLP has been classified as a disease that has potential to cause malignant 
transformation, with reports suggesting that approximately 1–2% of OLP patients go 
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on to develop oral squamous cell carcinoma (OSCC) (Georgakopoulou et al., 2012; 
Warnakulasuriya et al., 2007).  
 
1.4.2 Clinical features 
OLP characteristically presents as symmetrical and bilateral lesions or multiple lesions 
that clinically present as white striations, plaques or papules, erosion, erythema or 
blisters (Figure 1.3). OLP may present as painless or painful lesions with features such 
as erythema, erosions and ulceration being the most painful OLP manifestations 
(Georgakopoulou et al., 2012; Ismail et al., 2007). The condition typically affects the 
buccal mucosa (90%), tongue (mainly the dorsum), gingiva, labial mucosa and lower 
lip (Schlosser, 2010; Eisen, 2002). Less common sites include the palate, upper lip and 
floor of the mouth (Schlosser, 2010; Bagan-Sebastian et al., 1992). Simultaneous 
association of extraoral sites (i.e., scalp, skin, nails, conjunctiva, esophagus, larynx, 
urethra, vulva and vagina, and perianal area) is common and results in severe 
morbidity (Schlosser, 2010; Eisen, 1999) (Figure 1.3). 
 
The classic histopathological features of OLP are characterised by a dense 
inflammatory infiltrate in the upper lamina propria, predominantly containing T-cells, 
degeneration of basal keratinocytes and basal membrane hyperkeratosis or atrophy 
of the keratin layer (Georgakopoulou et al., 2012; Thongprasom and Dhanuthai, 2008; 
Dorrego et al., 2002) and rare areas of atrophic epithelium where the rete pegs may 
be shortened and pointed (a characteristic known as ‘sawtooth’ rete pegs). In 
addition, eosinophilic colloid bodies (Civatte bodies), that demonstrate degenerating 
keratinocytes, are commonly visible in the lower half of the epithelium (Carozzo, 2014; 




































Figure 1.3: Clinical presentations of oral lichen planus with different forms: (A) 
gingival, (B) reticular palatal, (C) reticular tongue, (D) reticular buccal, (E) papular, (F) 
ulcerative tongue, (G) ulcerative erosive buccal, (H) ulcerative erosive tongue and (I) 
cutaneous. Images were kindly supplied by Dr. Sabine Jurge, Consultant in Oral 
Medicine, Sheffield Teaching Hospitals NHS Foundation Trust. (Images were taken 



























Figure 1.4: Histopathological features of oral lichen planus. (Image supplied by Oral 
Medicine, Charles Clifford Dental Hospital, Sheffield Teaching Hospitals 















1.4.3 Aetiology and Pathogenesis 
The exact aetiology of OLP is idiopathic. It is suggested that cell-mediated immunity 
plays a major role in the pathogenesis of OLP (Farhi and Dupin, 2010; Lodi et al., 2005). 
An immunological process is believed to be triggered by activation of antigen-
presenting cells (APC), most likely Langerhans or stromal dendritic cells (Sugerman et 
al., 2002) by viral infection (e.g. Hepatitis C virus) (Lodi et al., 2005), contact allergen 
(e.g. dental amalgam) (Carrozzo and Thorpe, 2009) or systemic drugs (e.g. NSAIDs) 
(Figure 1.5-1) (Thompson and Skaehill, 1994). The secretion of chemokines such as 
CCL5/CCL20/CCL19 by activated APCs and keratinocytes (Ichimura et al., 2006) 
attracts T lymphocytes into the developing OLP lesion. Both the activated APCs and 
keratinocytes present antigen associated with MHC class II to CD4+ T cells (Figure 1.5-
2a) and MHC class I to CD8+ T cells (Figure 1.5-2b), respectively (Carrozzo, 2014; 
Sugerman et al., 2002). The activated helper CD4+ T lymphocytes secrete IL-2, IL-12 
and IFN-gamma that bind to their respective receptors on CD8+ T cells promoting the 
cytotoxicity of CD8+ T lymphocytes (Figure 1.5-3a) (Shirasuna, 2014; Farhi and Dupin, 
2010). Activated CD8+ T cells then express cytotoxic and pro-apoptotic mediators 
(TNF-α, granzyme B, FasL  or perforin), that mediate apoptosis of basal keratinocytes 
causing pathology (Figure 1.5-3b) (Carrozzo, 2014; Iijima et al., 2003). In addition, 
degranulation by mast cells releases chymase, causing degradation of the basement 
membrane aiding the migration of lymphocytes to basal keratinocytes (Figure 1.5-4) 
(Zhao et al., 2001; Zhou et al., 2001; Farthing et al., 1990). 
 
The precise mechanism of OLP develops to OSCC remains poorly understood. 
However, investigators hypothesise that the chronic inflammation due to 
inflammatory cells, cytokines and other stromal cells provide signals that result in 
epithelial cells to derange their growth control and in combination with oxidative 
stress, which subsequently provokes DNA damage that may initiate neoplastic 
changes, hence the link to development of oral cancer (Ergun et al., 2011; Battino et 

























Although many alternatives for the treatment of OLP are available, no therapy is 
curative (Sonthalia and Singal, 2012). Current treatments are palliative and vary in 
efficacy (Schlosser et al., 2010; Sugerman and Savage, 2002). The aims of OLP 
treatment include diminishing symptoms, curing erosive lesions and reducing the 
functional impact of OLP (Schlosser, 2010). Treatment of OLP relies on symptoms, the 
extent of oral and extra-oral clinical involvement, medical history and other factors. 
Patients with reticular and other asymptomatic OLP lesions usually require no active 
treatment (Schlosser, 2010; Scully and Carrozzo, 2008). Good oral hygiene, together 
with the use of mouthwashes and plaque decrease, may have valuable effects on 
lesions (Córdova et al., 2014; Boorghani et al., 2010). Patients with symptomatic 
lesions may also need treatment, usually with steroids (Scully and    Carrozzo, 2008). 
 
1.4.4.1 Drug Treatment for OLP 
Corticosteroids are also known as glucocorticosteroids or glucocorticoids (Barnes, 
2006; Gibson and Ferguson, 2004). Corticosteroids are the first-line treatments of OLP 
since their topical form has better benefits and less adverse effects (Córdova et al., 
2014; Sonthalia and Singal, 2012). Drug treatments for OLP are topical and systemic 
agents that are immunosuppressive (Scully et al., 2000). Treatment with topical 
corticosteroids is preferred more than systemic corticosteroids because these have 
fewer side effects. However, systemic corticosteroids may be applied if lesions are 
widespread and there is a recalcitrant disease (Scully and Carrozzo, 2008; Scully et al., 
2000).  
 
Currently, topical corticosteroids are the agents that are being used for localised OLP 
treatment. The most effective topical corticosteroids in treating the OLP patients 
include triamcinolone (mid potency), fluocinolone acetonide and fluocinonide (potent 
fluorinated steroids) and clobetasol-17-propionate (CP) (superpotent halogenated 
steroids) (Carbone et al., 2009; Al-Hashimi et al., 2007; Lavanya et al., 2011). Patients 
with localised OLP are usually treated with potent steroids. Particularly, CP seems to 
be the most effective topical steroid, showing a high remission rate (56-75%) of OLP 
signs and symptoms. Furthermore, CP has shown to be more effective than 
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triamcinolone acetate and fluocinolone in comparative studies (Córdova et al., 2014; 
Carrozzo and Gandolfo, 1999). 
 
The topical corticosteroids have been formulated into a few types of dosage forms 
such as elixir, ointment, spray, mouthwash and adhesive bases (Thongprasom and 
Dhanuthai, 2008). Commonly, patients are instructed to apply the topical 
corticosteroids a few times daily and they should not eat or drink for 1 hour in order 
to maintain drug contact with the mucosal surface. Based on previous studies, the 
intake of topical corticosteroids is safe when applied to the mucosa membrane for 
short intervals and they can be applied for long time periods (up to 6 months) 
(Carbone et al., 2003). OLP patients are examined carefully and monitored regularly if 
they use the steroids for prolonged periods because this has the potential to lead to 
adrenal suppression (adrenal atrophy) (Scully and Carrozzo, 2008), which causes 
inadequate production of cortisol (adrenal insufficiency) (Younes and Younes, 2017; 
Broersen et al., 2015; Chrousos et al., 2000), leading to complications such as 
inhibition of growth, hypogonadism or osteoporosis (Uva et al., 2012; Schacke et al., 
2002). OLP patients are also at risk of developing mucocutaneous candidiasis, thought 
to be due to the weakened or undeveloped immune system (local 
immunosuppression) at the mucosal surfaces (Buhl, 2006; Hanania et al., 1995), which 
can be prevented by using antifungals such as miconazole gel or chlorhexidine rinses 
(Córdova et al., 2014; Van Boven et al., 2013; Thongprasom and Dhanuthai, 2008).  
 
Systemic corticosteroids are used to treat patients with generalised OLP where the 
lesions are recalcitrant, erosive, erythematous and also in the condition when the 
lesions are widespread to another area such as skin, genitals, oesophagus or scalp 
(Carbone et al., 2009; Scully and Carrozzo, 2008; Scully et al., 2000). Likewise, this type 
of corticosteroid treatment is reserved for cases when topical corticosteroid 
treatments have failed (Scully and Carrozzo, 2008). Prednisolone is an example of 
systemic corticosteroids that are used at 40 to 80 mg daily (Córdova et al., 2014; Scully 
and Carrozzo, 2008). This range of dose is commonly adequate to achieve a response 
and its toxicity requires to be used only when necessary, at the lowest dose, and for 
the shortest time possible (Scully and Carrozzo, 2008). Systemic steroids should be 
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taken either for brief periods of time (5–7 days) and then withdrawn abruptly, or the 
dose should be reduced by 5–10 mg/day gradually over 2–4 weeks (Carbone et al., 
2009; Scully and Carrozzo, 2008; Thongprasom and Dhanuthai, 2008; Scully et al., 
2000). 
 
Additionally, a range of other treatments also have been used, including oral steroids, 
topical and systemic retinoids, topical cyclosporine, oral dapsone, tetracycline, 
levamisole, antimalarials, azathioprine, enoxaparin, thalidomide, 
photochemotherapy, laser treatments, and surgery, all with variable outcomes 
(Schlosser, 2010; Lodi et al., 2005). 
 
1.4.4.1.1 Corticosteroids - mechanism of action 
Corticosteroids have various effects including anti-inflammatory, anti-proliferative, 
immunosuppressive and vasoconstrictive effects that are mediated by intracellular 
glucocorticoid-specific receptors (GR) expressed by immune cells as well as fibroblasts 
and keratinocytes (Van Der Velden, 1998; Marks et al., 1982; Ponec et al., 1981).  
 
Corticosteroids are lipophilic molecules that enter cells through the cell membrane by 
passive diffusion into the cytoplasm. Within the cell cytoplasm, GR bind with steroid 
ligands to form GR complexes that eventually translocate to the cell nucleus. Within 
the nucleus, these complexes bind to a region of DNA called the glucocorticoid 
responsive element (GRE) (Wiedersberg et al., 2008; Van Der Velden, 1998; Hughes 
and Rustin, 1997) and this interaction either up-regulates or down-regulates specific 
gene expression such as lipocortin and inflammatory cytokines (Burkholder, 2000).  
 
Corticosteroids act by suppressing the inflammatory process through several 
pathways (Burkholder, 2000). These include mediators of inflammation that are 
involved in phospholipid-arachidonic acid cascades such as phospholipase A2 (PLA2) 
and cyclooxygenase (COX). Expression of both enzymes is suppressed, causing the 
reduced formation of prostaglandins and thromboxanes (Mitchell et al., 1994; 
Schalkwijk et al., 1991). GR complex suppresses the expression of PLA2 by inducing 
the activity of a protein called lipocortin 1. This protein binds to the membrane 
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phospholipid, which is a substrate for PLA2, thus, reducing substrate availability to 
generate mediators like prostaglandins and leukotrienes (Uva et al., 2012; Rhen and 
Cidlowski, 2005; Burkholder, 2000; Ahluwalia, 1998). The GR complex is also 
suggested to suppress cytokine activity by blocking the effects of certain transcription 
factors such as nuclear factor kB (NF-kB) and activator protein 1 (AP-1), resulting in 
the reduction of IL-2, IL-6 and CXCL8 levels (Burkholder, 2000; Ray et al., 1995) (Figure 
1.6). 
 
Furthermore, the use of corticosteroids exhibits apoptotic and anti-apoptotic 
properties. Corticosteroids markedly reduce the number of inflammatory cells such as 
eosinophils and lymphocytes. The survival of eosinophils is dependent on the 
presence of cytokines such as IL-5 and granulocyte-macrophage colony-stimulating 
factor (GM-CSF). The blockade of IL-5 and GM-CSF by corticosteorids leads to 
eosinophil apoptosis (Barnes, 1998; Owens et al., 1991). In contrast, it has been 
suggested that the corticosteroid therapy enhances neutrophil survival by inhibition 
of apoptosis through various pathways including the upregulation of the anti-




















































1.4.4.1.2 Structure-activity relationship of corticosteroids 
The efficacy of corticosteroids is related to its level of potency and capability of the 
drug to reach its target site (Wiedersbeg et al., 2008; Federman et al., 1999). The 
potency of corticosteroids is influenced by several factors including chemical 
structure, concentration and its carrier vehicle (Wiedersbeg et al., 2008; Hengge et al., 
2006; Kansky et al., 2000; Pershing et al., 1994; Stoughton, 1987). 
 
Corticosteroids are comprised of a 21-carbon (C) structure that includes a 4-ring cyclo-
pentane-perhydro-phenanthrene nucleus and a 17, 21-dihydroxy (OH)-20-keto (O) 
side chain. The rings are designated as A – D, with 3 six-membered rings and one five-
membered ring. Also, these structures have a double bond between C4 and C5, 
hydroxyl (OH) group at C11, and ketone group at C3 that provide the glucocorticoid 
and mineralocorticoid properties (Kwatra and Mukhopadhyay, 2018; Mehta et al., 
2016). The hydroxyl (OH) group at C17 also increases the glucocorticoid effects 
(Burkholder, 2000) (Figure 1.7).  
 
The alteration or substitution of basic cyclo-pentane-perhydro-phenanthrene ring 
structures produces corticosteroids with varying potency (Gual et al., 2015; Hengge et 
al., 2006; Thorburn and Ferguson, 1994). In general, the potency of corticosteroids is 
dramatically augmented by introducing an unsaturated double bond between the C1 
and C2 position, removing the hydroxyl groups, introducing long carbon side chains 
especially at the C21 position or adding a halogen group at the C9 position (Gual et al., 
2015; Kansky et al., 2000; Burkholder, 2000). Modification of the corticosteroid 
chemical structure can be achieved by dehydrogenation, alkylation (e.g. methylation), 
halogenation and esterification reaction (Kerscher et al., 2006). It has been reported 
that halogenation increases the potency and adverse effects of corticosteroids (Gual 
et al., 2015) and also attributes to higher mineralocorticoid activity and greater 
cytotoxicity (Mehta et al., 2016). While the esterification reaction enhances the 
lipophilicity by adding lipophilic components such as acetonide, valerate or propionate 
(Gual et al., 2015; Kansky et al., 2000; Thorburn and Ferguson, 1994), improving the 
absorption of the corticosteroid (Kwatra and Mukhopadhyay, 2018). Esterification also 
improves the safety profile of corticosteroids (Gual et al., 2015).  
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Addition of an unsaturated double bond between C1 – C2 position in ring A enhances 
the glucocorticoids activity and anti-inflammatory effect, whilst simultaneously 
decreasing the cell metabolism rate and salt-retaining activities (Burkholder, 2000; 
Thorburn and Ferguson, 1994). All corticosteroids used in this study contain an 
unsaturated double bond between the C1 – C2 position except hydrocortisone 
valerate (HV) and hydrocortisone butyrate (HB). Hydrocortisone contains the basic 
corticosteroid structure with the addition of an ester group such as valerate and 
butyrate at the C17 position through esterification, forming HV and HB, respectively 
(Kansky et al., 2000; Bodor et al., 1983). The enhancement of glucocorticoid and 
mineralocorticoid activities is due to increased affinity of the molecules to the 
glucocorticoid receptors that can be achieved by halogenation at position 6 and/or 9 
(Kwatra and Mukhopadhyay, 2018; Thorburn and Ferguson, 1994). The modification 
of corticosteroid chemical structure by halogenation at the C9 position is present in 
most of corticosteroids used in this study except HV, HB and Budesonide (BU). 
Substitution of 16, 17-acetal molecule with butyraldehyde to non-halogenated 
corticosteroid forms BU (Szefler, 1999; Boobis, 1998).  
 
The combination of the unsaturated double bond between C1 and C2 and substitution 
at C16 to the halogenated corticosteroids can reduce the mineralocorticoid activity 
whilst simultaneously elevating the anti-inflammatory effects (Kwatra and 
Mukhopadhyay, 2018; Kerscher et al., 2006). These effects can be observed when the 
methyl group is inserted through methylation at C16 to the halogenated 
corticosteroids that forms betamethasone. The esterification of the hydroxyl group in 
betamethasone with valerate and propionate at C17 and, C17 and C21 forms 
betamethasone valerate (BV) and betamethasone dipropionate (BD), respectively 
(Kwatra and Mukhopadhyay, 2018; Burkholder, 2000). While, the combination of the 
unsaturated bond (C1 – C2) and the addition of acetonide at hydroxyl group on C16 
and C17 position to the halogenated corticosteroid forms Triamcinolone acetonide 
(TA) (Kwatra and Mukhopadhyay, 2018). Clobetasol-17-propionate (CP) has been 
classified as a di-halogenated corticosteroid (Zampetti et al., 2010) that contains a 
fluoride group in ring B at the C9 position. An additional augmentation potency of CP 
has been performed by adding the chloride group as a second halogenation that 
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distinguishes CP apart from other corticosteroids used in this study (Katz and Gans, 
2008; Burkholder, 2000). CP comprises a double bond between C1 and C2 position and 
substitution of the hydroxyl group with a propionate at the C17 position through 
esterification, which increases its cell absorption (Gual et al., 2015; Wiedersberg et al., 
2008). The combination of all these modifications has made CP a superpotent 
corticosteroid (Zampetti et al, 2010; Kerscher et al., 2006). CP has been described as 
1800 times more potent as compared to hydrocortisone (least potent) and is 
associated with a higher risk for adverse effects (Bassuoni et al., 2016; Zampetti et al., 
2010). Principally, non-halogenated corticosteroids (e.g. HV and HB) often result in 
fewer adverse effects than halogenated corticosteroids (e.g. CP) (Allenby and Saprkes, 
























1.4.4.1.3 Adverse effects 
Systemic side effects occur because the drug is being absorbed into the bloodstream 
and distributed to and affect other parts of the body, such as the adrenal gland 
(Mehdipour and Zenouz, 2012; Hengge et al., 2006). Systemic side effects can be 
serious and may include a hypothalamic-pituitary-adrenal axis, weight gain, 
osteoporosis, avascular necrosis, diabetes, Cushing's syndrome and hypertension 
(Mason et a., 2002; Bircher et al., 1996; Lozada-Nur 1991).  The long-term use of 
topical corticosteroids may have substantial local side effects although it 
demonstrates remarkable benefit in reducing inflammation. However, some side 
effects may be noticed within days of starting therapy. Local side effects may include 
tachyphylaxis, hypogeusia, burning mouth, skin atrophy, hypersensitive reactions and 
oral hairy leukoplakia (Baid and Nieman, 2006; Key et al., 2003). 
 
1.5 Drug delivery systems 
Drug delivery systems can be defined as the process of an active pharmaceutical 
ingredient (API) administration (Meehta et al., 2012) to the body in order to attain a 
therapeutic effect and also increases its effectiveness and safety by controlling the 
rate, time and place of release of drugs in the body (Tiwari et al., 2012). Once the API 
is inside the body the drug will cross the biological barrier such as ECM cells and 
intracellular compartments before it can reach target organs or tissues. Before it 
reaches the desired site, the API could be inactivated or become trapped at non-target 
sites and at the same time can produce undesirable effects on non-target organs or 
tissues. Therefore, efficient delivery of API to target tissues is critical to reduce 
unintended off-target toxicity to other organs, while delivering the drug in a cost-
effective manner (Mehta et al., 2012). 
 
1.5.1 Oral mucosal drug delivery 
The oral cavity is a potential route to deliver therapeutic agents either locally or 
systemically (Rathbone et al., 2015). Local administration of therapeutic agents may 
provide a more targeted and efficient drug-delivery option as well as reducing the side 
effects of systemic delivery for diseases of the oral mucosa (Nguyen and Hiorth, 2015; 
Sankar et al., 2011). However, drug absorption to the mucosa is often disrupted due 
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to several factors including saliva, mucus, membrane coating granules (apical layers), 
variable thickness and pattern of keratinisation of the epithelium and basement 
membrane. As a result, sometimes only small quantities of drug are able to penetrate 
through the oral mucosa epithelium (Hooda et al., 2012; Satheesh Madhav et al., 
2012; Verma and Chattopadhay, 2011; Sankar et al., 2011; Sudhakar et al., 2006) and 
therefore several challenges need to be addressed by researches for mucosal delivery 
to become the choice route of administration. The development of modern 
formulations is not only focussed on attaining the therapeutic aims of drug delivery 
but also to overcome unfavourable environmental conditions found in the oral cavity 
(Satheesh Madhav et al., 2012; Sudhakar et al., 2006). An ideal oral transmucosal drug 
delivery system should quickly attach to the mucosal surface and maintain a strong 
interaction to prevent displacement. In addition, the bioadhesive performance should 
not be impacted by the surrounding environmental pH (Shakya et al., 2011). Other 
desirable characteristics of an oral transmucosal drug delivery system include high 
drug loading, complete drug release and convenient administration (Satheesh 
Madhav et al., 2012; Sudhakar et al., 2006). 
 
1.5.2 Advantages and disadvantages of oral mucosal drug delivery 
Generally, the oral route (tablet formulation) is the first choice of patients and 
clinicians for drug administration as it is considered the most convenient route for 
drug delivery and therefore has the highest compliance rates. However, this route has 
several potential drawbacks, such as extensive hepatic first-pass metabolism and pre-
systemic drug degradation in the gastrointestinal tract, which results in compromised 
dosing accuracy, low drug availability at the site of action and the necessity for 
frequent administration (Singh et al., 2011; Scholz et al., 2008; Sudhakar et al., 2006).  
 
These restrictions have driven the development of alternative administration routes 
with the absorptive mucosae attracting extensive research. The oral mucosa has a 
number of advances as a drug delivery route such as a rich blood supply, being 
relatively permeable, robust, short recovery times after stress or damage and tolerant 
to potential allergens (Singh et al., 2011; Scholz et al., 2008). Delivering drugs across 
the oral mucosa shows rapid onset of effect, good bioavailability, bypasses the hepatic 
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first-pass metabolism, reduced amount of administered drug and low-dose related 
side effects (Sangeetha et al., 2010; Scholz et al., 2008). Likewise, it is non-invasive and 
less intimidating for many patients compared with other routes of administration 
particularly drug delivery by injection such as via intravenous, intramuscular or 
intraperitoneal routes. Therefore, this route could increase patient compliance and it 
is greatly acceptable by patients (Troung-Le et al., 2015; Satheesh Madhav et al., 
2012).  
 
1.5.3 Oral mucosa formulations 
The oral mucosal dosage form can be broadly classified into three major categories 
including liquid, semisolid and solid or spray dosage forms (Patel et al., 2011; Sudhakar 
et al., 2006). Liquid dosage forms can be formulated as solutions or suspensions in 
which the drug is solubilised or suspended into an appropriate aqueous vehicle. 
Application of such types of dosage can produce local action into the oral cavity and 
several antibacterial mouthwashes and mouth-freshener are commercially available 
for this purpose. The drawback associated with these types of dosage forms is that 
they are not readily retained or targeted to oral mucosa and can deliver relatively 
uncontrolled amounts of drug throughout the oral cavity. The absorption of the drug 
formulated into these types of dosage forms is enhanced by using polymers (Patel et 
al., 1999) or iontophoretic techniques (Jacobson, 2001; Campisis et al., 2010). Previous 
studies have shown that a novel bioadhesive liquid, the sodium alginate suspension 
has exhibited the capability to protect the oesophageal surface against reflux and 
delivering the drug at the affected mucosal area (Avinash et al., 2008; Santos et al., 
1999). 
 
Gels, creams, hydrogel, emulgels and ointments are examples of semisolid solid 
preparation that can be used topically on mucosal areas either to produce local or 
systemic effects. The advantages of semisolid dosage forms include ease of drug 
administration to the periodontal pockets (Needleman, 1991) and facilitating the 
dispersion of drug throughout the mucosal surface of the oral cavity (Squier and 
Kremer, 2001). Meanwhile, the disadvantage of semi-solid dosage forms is poor 
retention at the site of application. However, this disadvantage can be solved by the 
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integration of a bioadhesive polymer into the drug formulation (Jones et al., 1996). A 
study has recommended emulgels (gellified emulsion) form of flurbiprofen for buccal 
delivery. Perioli et al., have reported that the release of drug ranged from 50–80% 
within 100 minutes of administration. Moreover, it has also been reported that the 
application of emulgels on human buccal mucosa can be retained for approximately 
one hour (Perioli et al., 2008). 
 
Solid dosage forms are formulated into tablets, lozenges, patches, films and wafers. 
Drawbacks of tablets can include discomfort feeling to children and elderly, as they 
cannot be retained for long periods at the lesion site (Patel et al., 2011), patient 
acceptability and the non-ubiquitous distribution of the drug within saliva for local 
therapy (Squier and Kremer, 2001). Examples of tablets on the market are 
nitroglycerin (sublingual) and prochlorperazine (buccal) (Patel et al., 2011). The 
dissolution or disintegration of lozenges is usually controlled by the patient. 
Commonly increased sucking and saliva production causes uncontrolled swallowing 
and loss of drug down the GI tract. Therefore, solid dosage forms generally have a 
much higher inter- and intra-individual variation in absorption and bioavailability. 
Also, such systems are not able to provide unidirectional release of the drug. 
Continuous secretion of saliva is another major impediment to the performance of 
such dosage forms (Patel et al., 2011).   
 
Patches, films and wafers can be prepared with multidirectional or unidirectional 
release. The relative thinness of the films, however, means that they are more 
susceptible to over hydration and loss of adhesive properties (Squier and Kremer, 
2001). Patch form is an ideal formulation for a retentive delivery system as these types 
of formulations can be administered to the mucosal areas as it contains a large 
expanse of smooth and immobile tissue (Bruschi and Freitas, 2005).  
 
An aerosol spray is an alternative to the solid dosage form. This type of dosage form 
can deliver the drug in fine particulates or droplets onto the mucosal area. Therefore, 
it is readily available for the absorption and the lag time for the drug to be available 
for the site of the absorption is reduced. Previously, it has been reported that the 
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administration of insulin in spray form to the buccal mucosa has an effective 
therapeutic effect for diabetes. Generex's Oral-lyn™ is an example of an oral spray of 
insulin for treating the type I and II diabetes (Xu et al., 2002). In addition, another form 
of spray based on RapidMistTM technology by Generex also in clinical development 
which intended for buccal delivery of fentanyl citrate, morphine and low molecular 
weight heparin (Patel et al., 2011). 
 
1.5.4 Technologies for improving drug delivery 
In spite of obstacles in the oral mucosa drug delivery system, there are many emerging 
technologies that could enhance delivery of drugs across the oral mucosa. The various 
strategies for improvements have been carried out to increase the bioavailability of 
the drugs including the incorporation of permeation enhancers and enzyme inhibitors 
in the formulation as well as novel formulation strategies (Muheem et al., 2016; 
Sudhakar et al., 2006).  
 
Permeation enhancers are components that are incorporated in the formulation of 
the drug that could increase the permeability of normally impermeable drug 
molecules (e.g. proteins and peptides) through epithelia either transported via 
paracellular and/or the transcellular pathway (Mahato et al., 2003). Permeation 
enhancers are categorised into surfactants, bile salts, chelators, fatty acids, 
cyclodextrins, azone, ethanol, chitosans and lecithin (Troung-Le et al., 2015; Jani et al., 
2012; Sohi et al., 2010). The mechanism of permeation enhancer action is different 
between the category of enhancers. For example, the proposed mechanism of action 
for fatty acids is by disturbing the intracellular lipid packing through the interaction 
with either lipid or protein components which lead to increased fluidity of cell 
membranes (Reddy et al., 2011; Sohi et al., 2010). Bile salts decrease the viscosity and 
rheology properties of the mucus to help drug absorption whilst also increasing drug 
solubilisation by formation the micelles (creation of aqueous channels) leading to the 
permeation enhancement of hydrophilic molecules (Sohi et al., 2010; Lee, 1999; 




Enzyme inhibitors are other excipients that could be incorporated in drugs to protect 
against proteolytic inactivation in the GI tract. In the oral cavity, the enzymatic activity 
is relatively low than the GIT with enzymes such as aminopeptidase and 
carboxypeptidase being found in the buccal mucosa (Veuillez et al., 2001; Walker et 
al., 2002). Enzyme inhibitors include the aminopeptidase inhibitors (puromycin, 
aprotinin, bestatin, soybean trypsin inhibitor, and amastatin), sodium glycholate, 
camostat mesilate, 4-(4-isopropylpiperadinocarbonyl) phenyl 1,2,3,4-tetrahydro- 1-
naphthoate methanesulphonate (FK-448), camostatmesilate, and ovalbumin (Ueno et 
al., 2007; Yamamoto, 2001). For example, the soybean trypsin inhibitors act by 
inhibiting the serine protease chymotrypsi (Bruno et al., 2013), acting in the digestive 
system and enhancing the absorption of insulin (Fujii et al., 1985). 
 
Enteric coating can also be incorporated with tablets or capsules to prevent 
breakdown of the dosage presentation in the acidic compartment of the stomach and 
has been shown to have good results (Hussan et al., 2012). Common enteric coatings 
that have been used include methyl acrylatemethacrylic acid copolymers, sodium 
alginate, cellulose acetate succinate, polyvinyl acetate phthalate (PVAP), hydroxy 
propyl methyl cellulose phthalate, Shellac, cellulose acetate trimellitate, etc (Felton 
and Porter, 2013). In addition, plasticisers (e.g. glycerol, sorbitol, DMSO, etc.) are 
another group of excipients that can be added to special oral dosage forms to improve 
tensile strength, improve dissolution time, or change water vapour permeability and 
play a role in protein stabilisation (Leerahawong et al., 2012). 
 
1.5.5 Drug absorption mechanisms through the oral mucosa 
Drug absorption through a mucosal surface is more efficient when the stratum 
corneum, the major barrier to absorption across the skin, is absent (Satheesh Madhav 
et al., 2012; Motlekar and Youan, 2006; Lu and Low, 2002). The principle of drug 
absorption via the oral mucosa is a passive diffusion process (Shinkar et al., 2012) and 
includes transcellular (or intracellular) and paracellular (or intercellular) routes (Figure 
1.8). The transcellular route is where a drug permeates directly through a cell. While, 
paracellular transport is the transport of molecules around or between cells. Some 
researchers have suggested that hydrophilic molecules will permeate via the 
37 
 
paracellular route while lipophilic molecules will be absorbed preferentially via the 
transcellular route (Sattar et al., 2014; Deneer et al., 2002; Zhang and Robinson, 1996). 
 
The buccal, sublingual, palatal and gingival mucosae are regions in the oral cavity that 
can used to deliver the drug effectively (Shakya et al., 2011). Buccal and sublingual 
regions may be used as the most suitable areas to administer the drug for treating 
either local or systemic diseases (Satheesh Madhav et al., 2009; Scholz et al., 2008). 
The buccal mucosa is relatively permeable, robust and tolerant to potential allergens 
(Satheesh Madhav et al., 2012; Singh et al., 2011), and therefore a useful route for 
either local or systemic treatment (Shinkar et al., 2012; Satheesh Madhav et al., 2009). 
Also, the buccal mucosa has smooth and relatively immobile surface that is 
appropriate for the administration of a retentive sustained- or controlled-release 
system (Satheesh Madhav et al., 2009; Scholz et al., 2008).  
 
In comparison with the buccal mucosa, the sublingual mucosa is even more 
permeable, with a thinner epithelium and high blood flow. Therefore, the sublingual 
mucosa is a possible site for rapid onset of drug action. The sublingual route has been 
employed to administer drugs for acute disorders treatment such as angina pectoris 
and hypertension (Khan et al., 2017; John et al., 1992). However, it is difficult to place 
the dosage form for an extended period of time at the mucosa surface as it is affected 
by the condition of the oral cavity that is continuously washed by saliva and tongue 
activity (Satheesh Madhav et al., 2012; Scholz et al., 2008).  
 
The soft palatal mucosa is non-keratinised and has an intermediate thickness thus 
reducing its permeability. It offers numerous advantages over the buccal and 
sublingual route such as the performance of drug administered through soft palatal 
does not affected by salivary secretion and tongue activity (Satheesh Madhav et al., 
























Figure 1.8: A schematic diagram of drug permeation routes. 
 
 
1.5.6 Permeation studies 
Permeation studies are required in order to determine the feasibility of the oral 
mucosa route for the candidate drug. These studies involve methods that examine in 
vitro, ex vivo and/or in vivo buccal permeation profile and absorption kinetics of the 
drug (Patel et al., 2011). 
 
Identification and isolation of tissue from animals is an essential process because 
different species of animal have different patterns of keratinisation (Shojaei et al., 
1996; Squier and Wertz, 1993). Porcine mucosa is the most commonly employed 
tissue due to its relative resemblance to human tissue, ethical considerations and low 







of model diffusants (e.g. antipyrine, buspirone, bupivacaine and caffeine) on porcine 
mucosa was significantly higher in the region behind the lip when compared to the 
cheek region as the cheek has a thicker epithelium (Kulkarni et al., 2010).  A 
comparative study was conducted to examine the effects of compounds with a 
different level of lipophilicity using caffeine (hydrophilic molecule) and oestradiol 
(lipophilic molecule) on the porcine buccal tissue. They found that permeability via the 
buccal epithelium was 1.8-fold greater for caffeine and 16.7-fold greater for oestradiol 
as compared to full thickness buccal tissue (Nicolazzo et al., 2003). 
 
Buccal cell culture has been utilised as the in vitro model to investigate drug 
permeation.  A few studies have used the human buccal cancer cell line (TR146), which 
has been grown on transwell filters as a model to study the buccal experiments 
(Nielsen and Rassing, 1999; Nielsen et al., 1999; Jacobsen et al., 1995). For example, a 
study was carried out to investigate and compare the effect of pH and drug 
concentration on nicotine permeability across the TR146 cell culture model and 
porcine buccal mucosa in vitro. The investigators found that permeability of nicotine 
increased significantly with increasing pH in both models (Nielsen and Rassing, 2002). 
Another tumour cell line derived from sublingual squamous cell carcinoma (HO-1-u-1) 
(Miyauchi et al., 1985) seeded on cell culture inserts was evaluated as an in vitro model 
of the sublingual mucosa. This preliminary study demonstrated that this model 
differentiated into stratified epithelial-like morphology, resembling to the native 
sublingual epithelium. The permeation studies also confirmed that this model 
provides a permeability barrier to both hydrophilic and lipophilic molecules and beta-
blockers (Wang et al., 2007). Wang and co-workers also found that pH change 
appeared to be an efficient strategy to improve beta-blocker permeation (Wang et al., 
2009).  
 
1.6 Metabolising enzymes in the oral epithelium 
The liver is a primary site for drug metabolism, however, it can occur in extra-hepatic 
sites of the body including skin, intestinal walls, kidneys, lung and oral mucosa 
(McDonnell and Dang, 2013; Smith et al., 2006). Drug delivery through the oral 
mucosa may also encounter xenobiotic metabolising enzymes within the oral 
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epithelium that could affect the concentration of the drug. Metabolising enzymes 
called cytochrome P450 (CYP450) are family enzymes responsible for oxidative 
metabolism of endogenous and xenobiotic compounds (Benedetti et al., 2009; 
Gonzales and Tukey, 2005; Vondracek et al., 2001). CYP450 enzymes belonging to the 
CYP1, CYP2 and CYP3 families are responsible for metabolising most of the foreign 
compounds including approximately 70 – 80% of drugs in clinical use (Zanger and 
Schwab, 2013).  
 
The CYP3A sub-family contains three members; CYP3A4, CYP3A5 and CYP3A7 (Nelson 
et al., 1996) that have been associated with metabolism of corticosteroids (e.g. 
budesonide, dexamethasone) (Mortimer et al., 2006). Among the CY3A sub-family, 
CYP3A4 is the most abundant enzyme that can be found in human liver, accounting 
about 30% of CYP content and it metabolises the greatest number of drugs and other 
xenobiotics (Pelkonen et al., 2008; Aoyama et al., 1998). CYP3A enzymes show a great 
clinical importance as it metabolises approximately 60% of drugs (El-Sankary et al., 
2002; Cholerton et al., 1992) and it has been considered central in many clinically 
important drug interactions (Michalets, 1998). 
 
Vondracek et al., reported that the human buccal tissues from 13 individuals exhibited 
expression of CYP450 enzymes particularly CYPs 1A1, 1A2, 2C, 2E1, 3A4/7 and 3A5, 
whereas only 6 of the cases demonstrated CYP2D6 expression. The immortalised 
(SVpgC2a) and carcinoma (SqCC/Y1) buccal keratinocyte cell line expressed the same 
CYPs as seen in human tissues except for 3A4/7 and 3A5 (SVpgC2a) and 2C, 2D6 and 
3A4/7 (SqCC/Y1) (Vondracek et al., 2001). In addition, a few studies have 
demonstrated the expression of CYP3A4/5 in both human skin and tissue-engineered 
skin equivalents (TESE) (Smith et al., 2018; Wiegand et al., 2014; Luu-The et al., 2009). 
 
The family of CYP450 enzymes can be considered as the starting point for studying 
drug-drug interactions (Wilk-Zasadna et al., 2015). In general, drugs can be either 
inhibitor or inducer to one or more CYP450 enzymes during their interactions, which 
therefore markedly influence their metabolism and clearance leading to altered 
effectiveness of the drug or unanticipated adverse reactions due to increased 
41 
 
production of toxic metabolites (Wilk-Zasadna et al., 2015; Lynch and Price, 2007; 
Chang and Kam, 1999).  
 
The inhibition of CYP450 enzymes by certain particular drugs can lead to decreased 
metabolism of other drugs metabolised by the same enzyme, resulting in higher drug 
levels and drug toxicity or altered the effectiveness of the drug (Rainone et al., 2015; 
Pelkonen et al., 2008). For example, the administration of budesonide with cimetidine 
(a known inhibitor of CYP3A4) resulted in a 51% elevation of budesonide plasma 
concentration (US Food and Drug Administration, 2009). Therefore, the co-
administration of budesonide with cimetidine needs to be considered carefully by 
lowering the dose of budesonide (Chen et al., 2018). While the induction of CYP450 
enzymes by drugs caused an increased clearance and concurrent decrease in the 
pharmacologic effects of other drugs metabolised by the same enzyme (Rainone et 
al., 2015; Pelkonen et al., 2008). For example, rifampicin (an inducer of CYP3A4) 
accelerated the clearance of hydrocortisone that is a substrate for CYP3A4 (Chen and 
Raymond, 2006; Rendic, 2002).  
 
1.7 Hypothesis, aims and objectives 
1.7.1 Hypothesis: 
3D oral mucosal models based on immortalised keratinocytes (FNB6) can be used to 
examine novel mechanisms of corticosteroid drug delivery across the oral mucosa. 
 
1.7.2 Aims: 
Tissue engineered oral mucosa can be used as a model system to examine novel 
topical corticosteroids drug delivery strategies. 
 
1.7.3 Specific objectives: 
• To develop and characterise tissue engineered oral mucosa using human 
immortalised oral keratinocyte (FNB6) and primary normal oral fibroblasts 
(NOF). 
• To determine the cytotoxic effects of corticosteroids on monolayer 
cultures of epithelial cells (keratinocytes and fibroblasts) and TEOM. 
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• To assess novel drug delivery methods for mucosal delivery of 
corticosteroids.  
• To investigate the distribution and penetration capacity of a number of 
corticosteroids using TEOM models. 
• To develop a simple tissue-engineered model of OLP. 
• To assess the effects of clobetasol-17-propionate (CP) on interleukin–2 (IL-


























  CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 Materials 
The following are the materials used in this study. 




tetrazolium bromide (MTT) 
Sigma-Aldrich, UK 




Acetic acid  ThermoFisher scientific, UK 
Adenine  Sigma-Aldrich, UK 
Alamar Blue (AB) ThermoFisher Scientific, UK 
Aluminum Agar Scientific, UK 
Amphotericin B  Sigma-Aldrich, UK 
Apo-transferrin  Sigma-Aldrich, UK 
Cholera toxin  Sigma-Aldrich, UK 
Collagenase IV ThermoFisher Scientific, UK 
Copper  Sigma-Aldrich, UK 
Dextrans (3, 10 and 70 kDa) ThermoFisher Scientific, UK 
Diastase Sigma-Aldrich, UK 
Dibutyl phthalate polystyrene xylene (DPX)  ThermoFisher Scientific, UK 
Dimethylsulfoxide (DMSO)  Sigma-Aldrich, UK 
Dulbecco’s modified Eagle’s medium (DMEM) 
(1x and 10X) 
Sigma-Aldrich, UK 
Eosin  ThermoFisher Scientific, UK 
Epidermal growth factor (EGF)  Sigma-Aldrich, UK 
Ethanol ThermoFisher Scientific, UK 
Eudragit RS100® Evonik Industries AG, Germany 
Foetal bovine serum (FBS)  Sigma-Aldrich, UK 
Gold Denton Vaccum, Desk II, USA 
Glutaraldehyde ThermoFisher Scientific, UK 
Hank’s Balanced Salts solution (HBSS) Sigma-Aldrich, UK 
Haematoxylin ThermoFisher Scientific, UK 
Horse serum Sigma-Aldrich, UK 
Horseradish peroxidase (HRP)-streptavidin  Vector Laboratories Ltd, UK 
Hydrochloric acid (HCL)  ThermoFisher Scientific, UK 
Hydrocortisone  Sigma-Aldrich, UK 
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Hydrogen peroxide (H2O2)  ThermoFisher Scientific, UK 
Industrial methylated spirits (IMS)  ThermoFisher Scientific, UK   
Insulin  Sigma-Aldrich, UK 
Isopropanol  ThermoFisher Scientific, UK 
L-glutamine  Sigma-Aldrich, UK 
Lead citrate Sigma-Aldrich, UK 
Methanol  ThermoFisher Scientific, UK 
Neutral buffered formalin ThermoFisher Scientific, UK 
Nutrient mixture F12 (Ham’s F12) Biosera, UK 
Osmium tetroxide Sigma-Aldrich, UK 
Paraffin wax  ThermoFisher Scientific, UK 
Paraformaldehyde  Sigma-Aldrich, UK 
Penicillin and streptomycin  Sigma-Aldrich, UK 
Periodic acid ThermoFisher Scientific, UK 
Phorbol-12-myristate-13-acetate (PMA) Sigma-Aldrich, UK 
Phosphate buffer saline (PBS)  Oxoid Ltd, UK 
Phytohaemagglutinin (PHA) Sigma-Aldrich, UK 
Platinum Sigma-Aldrich, UK 
Polycaprolactone (PLC) Sigma-Aldrich, UK 
Polyethylene oxide (PEO) Sigma-Aldrich, UK 
Polyvinylpyrrolidone (PVP) BASF, UK 
Propylene oxide Agar Scientific, UK 
Rat tail collagen In-house 
Resin Agar Scientific, UK 
Roswell Park Memorial Institute (RPMI)-1640 Sigma-Aldrich, UK 
Schiff’s solution ThermoFisher Scientific, UK 
Sodium bicarbonate (NaHCO3) Sigma-Aldrich, UK 
Sodium citrate Sigma-Aldrich, UK 
Sodium dodecyl sulfate (SDS) ThermoFisher Scientific, UK 
Sodium cacodylate buffer VWR, UK 
Sodium hydroxide (NaOH) ThermoFisher Scientific, UK   
Trypan blue Sigma-Aldrich, UK 
Trypsin/ Ethylenediaminetetraacetic acid 
(EDTA) 
Sigma-Aldrich, UK 
Uranyl citrate Agar Scientific, UK 








Table 2.2: Drugs. 
Drugs Company/Source 
 
Betamethasone-17,21-dipropionate  Sigma-Aldrich, UK 
Betamethasone-17-valerate Sigma-Aldrich, UK 
Budesonide Sigma-Aldrich, UK 
Clobetasol-17-propionate  Sigma-Aldrich, UK 
Clobetasol-17-propionate (patch) DermTreat Aps, Denmark. 
Hydrocortisone-17-butyrate Sigma-Aldrich, UK 
Hydrocortisone-17-valerate Sigma-Aldrich, UK 
Triamcinolone acetonide Sigma-Aldrich, UK 
 
Table 2.3: Cells. 
Cell  Company/Source 
 
Human normal oral keratinocyte (FNB6) cell 
line 
Professor Dr. Keith Hunter 
Jurkat (T) cells American Type Culture 
Collection (ATCC), USA 
Primary normal oral fibroblasts (NOF)  Human Biopsy (reference 
number 09/H1308/66) 
 
Table 2.4: Kits. 
Kit Company/Source 
 
3,3'-Diaminobenzidine (DAB)Peroxidase (HRP) 
Substrate  
Vector Laboratories Ltd, UK 
Human IL-2 (DuoSet ELISA) R&D Systems, UK 
Vecstastain® Elite ABC  Vector Laboratories Ltd, UK 
 
Table 2.5: Consumables. 
Consumables Company/Source 
 
Centrifuge tubes Greiner Bio-One GmbH, 
Germany 
Centrifuge tubes (15 and 50 mL)  Becton Dickinson, UK 
Cryovials  Greiner Bio-One GmbH, 
Germany 





Table 2.6: Equipment. 
Equipment Company/Source 
 
Agilent Zorbax RX - C18 250 mm x 4.6 mm 
column  
Agilent Technologies, US 
CO2 incubator  Scientific-Lab Supplies, U 
Digital micrometre Digital Micrometers Ltd, UK 
Dissolution apparatus (Erweka DT80) ERWEKA GmbH, Germany 
Electronic balance Fisher Scientific, UK 
Embedding machine (Leica EG1160)  Leica Microsystems, UK 
Epithelial Volt Ohm Meter (EVOM) World Precision Instrument, Inc. 
US 
Freeze dryer  VirTis Benchtop, BioSurplus, US 
Freezer/Fridge Proline, UK 
High-performance liquid chromatography 
(HPLC) (Waters 2690) 
Agilent Technologies, US 
Microcentrifuge Fisher Scientific, UK 
Microplate reader (TECAN Infinite M200 Pro) LabX, Canada 
Microscope (Eclipse TS100-F)  Nikon, Japan 
Microscope (Olympus BX51 microscope and 
Colour view IIIu camera with associated Cell^D 
software)  
Olympus soft imaging solutions, 
GmbH, Germany 
Microtome blade (S35 type)  Feather, Japan 
Microtome machine (Leica RM2235)  Leica Microsystems, UK 
Mount water bath  Grant Instruments Ltd, UK 
Neubauer haemocytometer  Weber Scientific International, 
UK 
pH meter Fisher Scientific, UK 
Processing machine (Leica TP1020 benchtop 
tissue processor) 
Leica Microsystems, UK 
Scanning electron microscope (SEM) (Philips XL-
20) 
Electron Microscopy Unit, 
Department of Biomedical 
Science, University of Sheffield, 
UK 
Glass microscope slides (SuperFrost® Plus) VWR International, UK 
Histology cassettes  Wheaton, UK 
Microscope coverslips VWR International, UK 
Polyethylene terephthalate (PET) hanging cell 
culture inserts 
Millipore, Switzerland 
Serological pipette (5, 10 and 25 mL) ThermoFisher Scientific, UK 




Staining machine (Shandon linear UK) Department of Pathology, 
School of Clinical Dentistry, 
University of Sheffield 
Transmission electron microscope (TEM) (FEI 
Tecnai G2 Spirit) 
Electron Microscopy Unit, 
Department of Biomedical 






























2.2.1 Cell culture  
2.2.1.1 Preparation of reagents  
2.2.1.1.1 Phosphate buffer saline  
Phosphate buffer saline (PBS) was prepared by dissolving one tablet in 100 mL of 
distilled water in an autoclaving bottle to give a final concentration of 0.1 M. The PBS 
solutions stored at the room temperature. 
 
2.2.1.1.2 Trypsin/EDTA solution  
Trypsin/EDTA (0.05% trypsin/0.02% EDTA w/v) solutions was purchased as ready-to-
use and aliquoted in 5 mL tubes before storage at -20 °C. 
 
2.2.1.1.3 Foetal bovine serum  
Foetal bovine serum (FBS) was purchased as ready-to-use, aliquoted in 50 mL tubes 
and stored at -20 °C. 
 
2.2.1.1.4 Penicillin/streptomycin solution 
Antibiotic solutions contained penicillin (10,000 IU/mL) and streptomycin (10 
mg/mL) were bought as ready-to-use, aliquoted in 5 mL tubes and stored at -20 °C. 
 
2.2.1.1.5 Cryopreservation medium 
Cryopreservation medium was prepared using FBS containing 10% dimethyl sulfoxide 
(DMSO), (v/v) and stored at -20 °C before use. 
 
2.2.1.1.6 Trypan blue solution 
Trypan blue dye was purchased as ready-to-use and diluted with a cell suspension 








2.2.1.2 Preparation of cell culture growth medium 
2.2.1.2.1 Green’s medium 
Oral keratinocytes (FNB6) were cultured in an adenine-enriched medium as previously 
described (Allen-Hoffmann and Rheinwald, 1984) and will be referred to as Green’s 
medium. Green’s medium was prepared by mixing DMEM and Nutrient mixture F12 
(3:1, v/v), 50 ml FBS, 5 mL penicillin (10,000 IU/mL) and streptomycin (10 mg/mL), 1.25 
mL amphotericin B (250 μg/mL), 2 mL adenine (6.25 μg/ml), 2.5 mL insulin (1 mg/mL), 
0.5 ml 3, 3, 5- Tri-iodothyronine (1.36 μg/mL) and apo-transferrin (5 mg/mL), 80 µL 




NOF and 3t3 fibroblasts were cultured in DMEM supplemented with 10% FBS, 
penicillin (10,000 IU/mL and streptomycin (10 mg/mL). 
 
2.2.1.2.3 RPMI 
Jurkat T cells were cultured in RPMI supplemented with 10% FBS, penicillin (10,000 
IU/mL) and streptomycin (10 mg/mL). 
 
2.2.1.3 Cells used in the study 
2.2.1.3.1 Adherent cells 
The human normal oral keratinocyte cell line (FNB6) was a gift from Professor Keith 
Hunter. The cells, originally isolated from the buccal region of a healthy volunteer, 
were immortalised by ectopic expression of human telomerase reverse transcriptase 
(hTERT) (McGregor et al., 2002). 
 
Primary normal oral fibroblasts (NOF) were isolated from buccal or gingival biopsies 
collected with written, informed consent from patients undergoing routine dental 
procedures under ethical approval (reference number 09/H1308/66) and isolated as 





2.2.1.3.2 Suspension cell line 
Jurkat T cells are an immortalised T lymphocyte cell line. The cells were originally 
isolated from the peripheral blood of a 14 years old male suffering from acute T cell 
leukaemia (Schneider et al., 1977).  
 
2.2.1.4 Maintenance and passaging of cells 
FNB6 cells were cultured on previously prepared irradiated 3T3 (i3T3) cell feeder 
layers in Green’s medium and NOF cultured in DMEM. The cells were cultured in a T75 
cm2 flask at a density of 2.0 x 106 cells/mL in a humidified atmosphere (95% air, 5% 
CO2) at 37oC.  The medium was replenished every 2 days until the monolayer cultures 
reached 80-90% confluency. 
 
After the cells reached 80-90% confluency, they were sub-cultured to maintain cells in 
exponential growth.  For passaging, the medium was discarded and washed with 10 
mL of PBS to remove all dead cells and debris. The cells were then detached using 5 
mL of trypsin/EDTA and incubated for 5 minutes at 37oC. The flask was tapped gently 
until the cells detached as single cells, at which point 5 mL of medium was added to 
stop the trypsin activity. Cells were centrifuged for 5 minutes at 250 xg to pellet the 
cells, the resulting supernatant was discarded and the cells resuspended in a known 
volume of media and counted. 
 
Jurkat T cells were cultured in a T75 cm2 at a cell density of 0.5 to 1.5 x 106 cells/mL in 
Green’s or RPMI medium depending on the experiment performed. For continuous 











2.2.1.5 Counting cells 
Ten microlitres of cell suspension were used to determine cell numbers using a 
haemocytometer and inverted light microscope. The cells located in four 1 mm2 areas 
were counted and the average is taken. The cell number was calculated as follows: 
Cell number(cells mL⁄ )= (




× 10,000(2) × 
10(3) mL  
 
(1) = Average number of cells 
(2) = Number of cell per 1 mm2 square 
(3) = Amount of medium in the tube 
(4) = Number of 1 mm2 square counted 
 
 
2.2.1.6 Cryopreservation and thawing of cells 
Following trypsinisation, the cells were transferred into a 20 mL centrifuge tube and 
centrifuged for 5 minutes at 250 xg.  The supernatant was discarded, and the cell pellet 
resuspended in cryopreservation medium. The mixture was transferred to a cryovial 
and placed on ice before storage in a -80oC freezer overnight. The cryovial was then 
transferred to a liquid nitrogen dewar for long-term storage.  
 
To resurrect cells, a cryovial was thawed, added to 10 mL of medium and centrifuged 
for 5 minutes at 250 xg to obtain a cell pellet. The cell pellet was resuspended in fresh 
medium and transferred to a T75 cm2 flask. 
 
2.2.2 Preparation of tissue engineered oral mucosa 
2.2.2.1 Collagen extraction 
Rat tails were collected following Home Office guidelines and stored at -20 °C until 
use. Frozen rat tails were thawed overnight prior to use. The base of the tails was held 
firmly and manipulated backwards and forwards in order to break the bone and 
expose the tendons. The skin of the tail was removed and the tendons (string-like 
white fibres) collected (Figure 2.1). All tendons were washed in sterile PBS and placed 
in sterile 0.1 M acetic acid on a stirrer at 4°C until dissolved (approximately 7 days). 
Once dissolved, the collagen was freeze-dried. The resultant collagen was weighed 
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and stored at -20°C. Before use, the collagen was dissolved in 0.1 M acetic acid to a 
final concentration of 5 mg/mL. 
 
 
            
 
Figure 2.1:  String-like white fibres (tendons) are extracted from rat tails. 
 
2.2.2.2 Construction of tissue engineered oral mucosa in PET hanging cell culture 
inserts  
2.2.2.2.1 Addition of NOF cells to the collagen hydrogels 
Following trypsinisation, NOF cells were counted and transferred to a centrifuge tube 
and centrifuged at 250 xg for 5 minutes. The resulting supernatant was removed, and 
the cell pellet resuspended in DMEM medium to give a final cell count of 6.25 x 106 
cells per mL. The cells were kept on ice until use. 
 
The collagen hydrogel was composed of DMEM (10X), reconstitution buffer (10X), FBS, 
L-glutamine and collagen. The pH of the gel was adjusted to 7.4 using 1 M NaOH. The 
details of the collagen gel composition are described in Table 2.7.   
 
Forty µL of the NOF cell suspension were added to the collagen gel to give a final 
concentration of 2.5 x 105 cells per model and the tube inverted gently to evenly 
disperse the cells within the hydrogel. Nine hundred µL of the resultant collagen 
Rat tail tendons 
53 
 
solution was then added to the well of a hanging cell culture insert (Filter: PET, pore 
size: 0.4 µm and diameter: 12 mm) and incubated at 37oC for 2 hours to allow the 
hydrogel to set. Once the hydrogel had solidified, the medium was added on top (500 
µL) and underneath (1 mL) of the models and incubated at 37oC for 48 hours. 
 
Table 2.7: Hydrogel components. 
Items Volume (µL) 
(per model) 
DMEM (10X) 100 
Reconstitution Buffer (10X): NaHCO3 (2.2 g), 
Hepes (4.8 g), NaOH (0.248 g), 100 mL H20 
100 




2.2.2.2.2 Addition of FNB6 cells to the collagen models 
After 48 hours, FNB6 cells (2.5 x 105/model) were added to the surface of each model 
in 200 µL Green’s medium and incubated for a further 5 days. At which point all media 
was removed and replenished with fresh Green’s media and models brought to an air-
to-liquid interface (ALI) where the basement of the models was in contact with 
Green’s media and any excess of media on the top of the models was removed to 
expose the keratinocytes to the air. The models were cultured for a further 10 days at 
ALI with the media being replaced every 2 days. All experiments using TEOM were 
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After 10 days, the models were used in 
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2.2.3 Morphological analysis  
2.2.3.1 Histological processing and haematoxylin and eosin staining 
The microscopic structures of TEOM incubated for 5, 10 and 14 days at ALI were 
analysed using haematoxylin and eosin (H&E) staining. TEOM were fixed in 
paraformaldehyde (4%) solution for at least 24 hours at room temperature prior to 
histological processing (Table 2.8). The TEOM were processed using a benchtop tissue 
processor. Tissue samples were embedded in molten paraffin wax using an 
embedding machine. The blocks of tissues were sectioned with microtome blades 
using a microtome, 5 µm thick sections were mounted onto glass slides and stained 
using H&E staining (Table 2.9) in a Shandon linear staining machine. After staining, all 
slides were mounted with dibutyl phthalate polystyrene xylene (DPX) and a coverslip 
placed on the top of the sample. Images were captured using the microscope 
(Olympus BX51) and Colour view IIIu camera with associated Cell^D software. 
 
Table 2.8: Histological processing schedule. 
Solution Duration (min.) 
10% neutral buffered formalin 60  
70% alcohol 60  
70% alcohol 60  
90% alcohol 60  
90% alcohol 60  
Absolute alcohol 60  
Absolute alcohol 60  
Absolute alcohol 60  
Xylene 90  
Xylene 90  
Paraffin wax I 120  






Table 2.9: H&E staining procedure. 
Solution Duration (second) 
















Absolute alcohol I 
Absolute alcohol II 
70% alcohol 
Running tap water 
Harris’s Haematoxylin I 
Harris’s Haematoxylin II 
Harris’s Haematoxylin III 
Harris’s Haematoxylin IV 
Harris’s Haematoxylin V 
Running tap water I 
Running tap water II 
0.1% HCl in 70 % alcohol 
Running tap water 
Eosin I 
Eosin II 
Running tap water 
95% alcohol 
Absolute alcohol I 
Absolute alcohol II 
Absolute alcohol III 
Absolute alcohol IV 






2.2.3.2 Periodic acid-Schiff (PAS) staining 
Periodic acid-Schiff is a staining method used to detect polysaccharides such as 
glycogen and glycoproteins, and is often used to detect basement membranes within 
tissue sections. Paraffin-embedded TEOM sections were brought onto a Shandon 
Automated Stainer and passed through the following solutions for 15 seconds each 
incubation: xylene (3X), absolute alcohol (2X), 70% alcohol and running tap water. 
TEOM sections were removed from the stainer and placed in a coplin jar containing 
0.5% diastase solution diluted in distilled water and transferred into a waterbath for 
20 minutes. Afterward, the sections were rinsed in running tap water. The sections 
were stained with periodic acid for 5 minutes and then rinsed thoroughly in distilled 
water. The sections were then stained with Schiff’s Reagent for 10 minutes and 
washed in running tap water for 5 minutes. The sections were counter-stained with 
haematoxylin for 1 minute, rinsed in running tap water and passed through with the 
following solutions: acid alcohol (1%), running tap water, Scott’s tap water, 95% 
alcohol, absolute alcohol (4X) and xylene (2X) for 45 seconds each incubation. Finally, 
the sections were mounted with DPX and a coverslip placed on the top of the sample. 
The images of the section were viewed and captured under a light microscope 
(Olympus BX51) and Colour view IIIu camera with associated Cell^D software. 
 
2.2.3.3 Transmission electron microscope analysis 
The ultrastructures of TEOM incubated for 14 days at ALI were evaluated using 
transmission electron microscope (TEM). TEOM were cut into 2 mm sections and fixed 
in 3% glutaraldehyde diluted in 0.1 M cacodylate buffer at pH 7.4 for 2 hours at 4OC 
before rinsing twice in 0.1 M phosphate buffer (pH 7.4) with a 30-minute interval at 
4OC. TEOM were then post-fixed in 2% osmium tetroxide for 2 hours at room 
temperature and rinsed in 0.1 M phosphate buffer. Afterward, the TEOM were 
dehydrated in an ethanol gradient from 75% (1X), 95% (1X) and 100% (2X), dried 100% 
ethanol (2X) and propylene oxide (2X) for 15 minutes at room temperature. The TEOM 
were then incubated in a 50/50 mixture of propylene oxide/Araldite resin (v,v) 
overnight at room temperature. Following overnight incubation, excess resin mixture 
was removed by evaporation for 1 hour at room temperature. TEOM were next 
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incubated in 100% Araldite resin for 6 hours at room temperature and then finally 
embedded in fresh Araldite resin for 48 – 72 hours. The block was cut approximately 
70 – 90 nm thick using a diamond knife and the sections transferred to a copper circle. 
The section was then stained with 3% uranyl acetate (25 minutes) and Reynold’s lead 
citrate (5 minutes) and dried for 10 minutes. The sections were examined using TEM 
at an accelerating voltage of 80 kV. 
 
2.2.4 Protein expression analysis  
Expression of proteins within paraffin-embedded TEOM sections was determined by 
immunohistochemistry staining. Five micrometres sections were cut and mounted 
onto Superfrost glass slides. The slides were incubated in a warming oven at 60OC for 
30 minutes before being dewaxed in two changes of xylene for 5 minutes each. The 
tissue sections were then hydrated with graded ethanol (100%, 95%, and 70%) for 3 
minutes each and rehydrated in distilled water. Tissue sections were incubated in 
methanol that contained 3% hydrogen peroxide (H2O2) for 20 minutes in order to 
quench endogenous peroxidases that could affect the results of the hybridisation. 
After rinsing 3 times in PBS for 5 minutes each, all tissue sections were subject to heat-
mediated antigen retrieval in citrate buffer (pH 6). After cooling, the tissue sections 
were rinsed again in PBS for 10 minutes and any unspecific binding sites blocked with 
horse serum for 30 minutes at room temperature. Primary antibodies (Table 2.10) 
diluted in horse serum were then applied and incubated overnight at 40C. After 3 
rinses (5 minutes each) in PBS, the slides were incubated with biotinylated second 
antibody for 30 minutes at room temperature, followed by 2 rinses in PBS for 5 
minutes each. HRP-streptavidin reagent was applied for 30 minutes at room 
temperature and subsequently, 3 rinses in PBS (5 minutes each). Colour was 
developed by incubating the slides with DAB solutions for up to 10 minutes and 
transferred to distilled water. Finally, the slides were counterstained with 
haematoxylin and mounted in DPX and a coverslip applied. For a negative control, the 
primary antibody was emitted. Tissue sections were viewed and captured using the 














AE8 Mouse 1:300 0.4 
Anti-
cytokeratin 4 
6B10 Mouse 1:40 Not provided 
Anti-
cytokeratin 14 
LL002 Mouse 1: 1000 0.1 
Anti-Ki67 SP6 Rabbit 1: 100 Not provided 
Anti-claudin 4 EPRR17575 Rabbit 1:4000 Not provided 
Anti-E-
cadherin 
HECD-1 Mouse 1:200 Not provided 
 
 
2.2.5 Viability of TEOM analysis 
Measuring the reducing environment within the cytosol of living cells can assess cell 
viability. AlamarBlue® contains resazurin, a non-toxic, cell permeable compound that 
is blue in colour and non-fluorescent. Upon entering viable cells, resazurin is reduced 
to resorufin, to produce a compound that is red in color and highly fluorescent. 
alamarBlue® was used to determine the viability of the TEOM. Briefly, TEOM were 
rinsed with PBS and 1 mL alamarBlue® solution (10% v/v prepared in Green’s medium) 
was added to each TEOM in the insert and incubated for 5 hours. After the incubation, 
a triplicate 200 L solution from the apical compartment of the insert was removed 
and placed into the well of a 96-well plate. The fluorescence intensity was measured 
at an excitation wavelength of 550 nm and an emission wavelength of 590 nm using a 
microplate spectrophotometer. Transwell inserts without TEOM containing only 
alamarBlue® solution was also prepared and incubated for 5 hours and set as a 
background fluorescence. The background fluorescence was subtracted from the 




2.2.6 Barrier functional analysis 
2.2.6.1 Transepithelial electrical resistance analysis  
Transepithelial electrical resistance (TEER) is the measurement of electrical resistance 
across an epithelium and is a widely used quantitative technique to measure the 
integrity of epithelial tight junctions to confirm the integrity and permeability of the 
tissue. The barrier of TEOM was assessed using an Epithelial Volt Ohm Meter (EVOM) 
and electrode set at the room temperature. TEOM cultured in the insert was placed 
in a laminar flow hood for at least 15 minutes before the measurements were 
recorded to allow the cells to adjust from incubator to room temperature. 
Simultaneously, the EVOM electrodes were sterilised by immersing in ethanol (70%) 
for 15 minutes to ensure the sterility and left to air dry before rinsing in sterile medium 
prior to use (Buchert al., 2012). To measure the TEER of TEOM, 300 µL and 500 µL of 
PBS were added in the apical and basolateral compartment of the inserts, respectively. 
The setup for the TEER is shown in figure 2.3. The shorter electrode was placed in the 
insert while the longer electrode was placed between the insert and the outer wall of 
the plate. As a precaution, tips of the electrode should completely be covered in 
solutions and the shorter electrode should not touch the models in the inserts. The 
TEER value of a naked insert was measured and set as the blank and TEOM treated 
with SDS (5%) for 5 minutes to disrupt barrier function were used as a positive control.  
 
The unit of TEER is Ω.cm2. The following equations were used to measure the 
resistance of the models: 
 
Resistance (Tissue) = Resistance (Total) − Resistance (Blank) 

























Figure 2.3: Classical setup to measure transepithelial electrical resistance 
measurement using a Epithelial Volt Ohm Meter. 
 
2.2.6.2 TEOM permeability analysis 
Three different fluorescently-labelled dextrans all with different molecular weights 
(MW: 3, 10 and 70 kDa respectively) were used to evaluate the permeability of the 
TEOM at day 10 ALI culture. The dextran solution was prepared by mixing the three 
fluorescently labelled dextrans in Hank’s Balanced Salts solution (HBSS) to give a final 
concentration of 62.5 µg/mL for each dextran. The media in the apical and basolateral 
compartment of the inserts were removed and the TEOM washed with PBS. All TEOM 
were transferred to a new plate and refreshed with 500 µL of HBSS in the apical and 
basolateral compartment. All models were left to equilibrate in the incubator at 370C 
for 15 minutes on a shaker. After equilibration, the solutions in the apical 
compartment were replaced with 300 µL of HBSS solution containing 250 µg/mL of 
each fluorescently labelled dextran and incubated at 370C on a shaker (Figure 2.4A). 
The permeability of the TEOM was determined over time. Two hundred fifty µL of the 














collected at different time point (30, 60, 90, 120, 180, 240 and 300 minutes) (Figure 
2.4B) and 250 µL HBSS added to replace the removed solution. Solutions were 
transferred to microcentrifuge tubes and stored at -80oC before being analysed. The 
solutions taken from inserts without TEOM acted as controls. The permeability of 
TEOM was also determined after the models had been treated with SDS (5%) for one 
hour to disrupt barrier function and act as a positive control.  
 
The amount of dextran was measured using a microplate spectrometer with excitation 
and emission wavelengths: 3 kDa (excitation: 590 nm, emission: 620 nm), 10 kDa 
(excitation: 548 nm, emission: 578 nm) and 70 kDa (excitation:  495 nm, emission: 525 
nm). The value obtained from inserts without TEOM used as controls. The percentage 
of dextran was calculated as follows: 
 











































Figure 2.4: Permeability analysis of dextrans (3, 10 and 70 kDa) across TEOM. A: 
Dextran solutions were added to the apical surface of TEOM. B: Dextran diffusion 
through the TEOM was determined by molecular weight. Accumulated of the dextrans 
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2.2.7 Cytotoxic effects of corticosteroids solution on oral keratinocyte and 
fibroblasts in 2D and 3D  
2.2.7.1 Cytotoxic effects of corticosteroids solution on oral keratinocyte and 
fibroblast monolayers 
The corticosteroids (CS); betamethasone-17,21-dipropionate (BD), betamethasone-
17-valerate (BV), budesonide (BU), clobetasol-17-propionate (CP), hydrocortisone-17-
butyrate (HB), hydrocortisone-17-valerate (HV) and triamcinolone acetonide (TA), 
were used in this study to determine the cytotoxic effects on FNB6  and NOF cells.  
 
Stock solutions of CS were prepared by dissolving in DMSO to give a final 
concentration of 100 mM. The stock solutions were mixed with medium to prepare 
working solutions at various concentrations ranging from 0.01 µM to 500 µM. DMSO 
in medium acted as a vehicle control in all experiments. Cells were seeded into a 96-
well plate at a density of 5 x 104 cells/well and incubated for 24 hours to allow the cells 
to adhere. After incubation, the cells were treated with 100 µL of drug solutions in 
gradient concentrations. DMSO was used as a vehicle control. The cells were 
incubated in the presence of the CS for 24, 48 and 72 hours.  
 
The effect of CS against FNB6 and NOF cells was determined using a metabolic MTT 
assay according to Mosmann et al, (1983). This is a colourimetric assay for assessing 
cell metabolic activity and by extension cell viability. Cellular NAD(P)H-dependent 
oxidoreductases reduce the tetrazolium MTT substrate to an insoluble formazan 
product that is purple in colour and so can be measured spectrophotometrically. 
Following treatment, media was aspirated and the adhering cells in each well washed 
once with 100 µL of PBS. After washing, 100 µL of MTT solution (0.5 mg/mL in PBS) 
was added to each well and incubated for 2 hours at 37°C in 5% CO2. The MTT solution 
was removed and acidified isopropanol (50 µL/well) added to solubilise the formazon-
blue. Gentle shaking of the plates was applied for 15 seconds to completely dissolve 
the formazans. A microplate spectrometer was used to measure the optical density 
(OD) of the solution at 570 nm with a reference at 630 nm. Data were processed using 
Microsoft Excel, expressed as a percentage of cell viability relative to vehicle control 
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(DMSO only), and plotted in the dose-response curve using GraphPad Prism 6 
(GraphPad Software, Inc.), allowing derivation of IC50 values by non-linear regression.  
 
2.2.7.2 Cytotoxic effects of corticosteroids solution on TEOM 
The cytotoxic effects of CP, BV, and HV were selected and further analysed based on 
their relative potency ranking, highest, medium and lowest, respectively, obtained 
from the analysis in section 2.2.7.1. The working solutions of CP, BV, and HV were 
prepared from stock solutions (100 mM) at various concentrations ranging from 5 – 
400 µM. TEOM were topically exposed to various concentrations of CP, BV, and HV for 
60 minutes. After exposure to the test substances, TEOM were thoroughly rinsed using 
PBS and blotted with the absorbent tissue to remove the test substances. TEOM were 
transferred to a new 12-well plate and cultured with fresh medium for a further 42 
hours. TEOM treated with DMSO and SDS (5%) were used as a negative control (NC) 
and positive control (PC), respectively. 
 
Based on OECD Test Guideline 431 (OECD, 2004), 1 mL of MTT solution (1 mg/mL) was 
added on the TEOM and incubated for 3 hours.  After the MTT incubation, TEOM were 
blotted on the absorbent tissue to remove the excess liquid. The cultures were 
extracted in 2 mL of isopropanol for 2 hours while shaking at room temperature. A 
triplicate of 200 μL aliquots of blue formazan solution was then transferred to a flat 
bottom 96-well plate. The absorbance was recorded at OD 570 nm and the 
isopropanol was used as a blank correction. The relative percentage of TEOM viability 
was determined using the following formulas: 
 
Blank corrected at an OD 570 nm (OD570) of the individual TEOM was determined as 
follows: 
 









The individual relative TEOM viability was determined as follows: 
 
Relative viability of PC  (%) =  
OD570 (PC)
Mean OD570 (NC)
× 100%  
Relative viability of CS  (%) =  
OD570 (CS)
Mean OD570 (NC)
× 100%  
 
Based on the OECD guidelines, data was interpreted as follows: 
 
Mean relative tissue viability ≤ 50% = irritant  
Mean relative tissue viability ≥ 50% = non-irritant  
 
2.2.8 Mucoadhesive clobetasol-17- propionate patch formulations 
Mucoadhesive CP patches were a kind gift from Dermtreat Aps, Denmark. The patches 
had been fabricated by electrospinning as previously described (Santocildes-Romero 
et al., 2017). Briefly, the CP-loaded patches were loaded with CP, formulated into 
three concentrations 1, 5 and 20 µg/patch and a no drug, placebo patches. The surface 
area of the patches was 25.4 mm (length) x 12.7 mm (width). Structurally, the patches 
comprised of a dual-layer mucoadhesive system: an outer hydrophobic 
polycaprolactone (PCL) (backing layer) and an inner (non-backing layer), 
mucoadhesive components (polyvinylpyrrolidone (PVP), Eudragit® RS100 and 




















2.2.8.1 Characterisation of mucoadhesive clobetasol-17- propionate patches 
2.2.8.1.1 Physical characterisations – Weight and thickness 
The assessment of weight and thickness of the patch was completed on randomly 
selected patches from three independent batches. The weight of placebo and CP-
loaded patches (25.4 x 12.7 mm2) was measured using an electronic digital balance 
and an average weight of the patches calculated. The thickness of placebo and CP-
loaded patches (25.4 x 12.7 mm2) was measured using a digital micrometre at three 
different randomly selected areas. The average thickness of each type of patch was 
calculated. 
 
2.2.8.1.2 Chemical characterisation – pH 
The placebo and CP-loaded patches (25.4 x 12.7 mm2) were placed in a tube containing 
distilled water and submerged for 5 minutes. The pH of the whole patch was 
determined using a pH meter and the average pH of each type of patch calculated. 
 
2.2.8.1.3 Swelling index 
Placebo and CP-loaded patches (25.4 x 12.7 mm2) were placed in a pre-weighed 
weighing boat and weighed (W0). The weighing boat containing the patch was 
submerged with excess water (5 mL) at pre-determined time intervals (30 sec – 60 
minutes) until a constant weight was observed. The water was poured off and the 
patch was blotted with an absorbent tissue to remove any excess water. The weighing 
boat containing the patch was re-weighed (Wt). The same step was repeated for 
another interval. The percentage of patch swelling was calculated using the following 
equation: 
 
Swelling index (%) =  




where, Wt is the weight of the patch at time t and W0  is the weight of the patch 





2.2.8.1.4 Scanning electron microscopy  
The ultrastructure of the backing and adhesive layers of the patches were visualised 
using scanning electron microscopy (SEM). The patches (placebo, 1, 5 and 20 µg) were 
fixed in 3% glutaraldehyde for 24 hours and subsequently 1% osmium tetroxide for 1 
hour. The patches were rinsed several times (6 – 8 times) in PBS (0.1 M) before 
dehydration in graded ethanol solutions (20, 30, 50, 60, 70, 90 and 95%) for at least 
10 minutes in each. Finally, the patches were submerged in absolute alcohol, twice for 
30 minutes each. Afterwards, the samples were air dried and mounted on aluminum 
stubs (25 mm) using silver paste and sputter coated with gold for 90 seconds with 30 
mA currents. Images were captured using a scanning electron microscope (Philips 
XL20) at an accelerating voltage of 25 kV. 
 
2.2.8.1.5 Drug release analysis 
The release of CP from the mucoadhesive patches was determined using dissolution 
apparatus (Erweka DT80) in conjugation with paddle stirrers, according to Ph. Eur. 
method 2.9.3. In brief, the patches were attached to supports and lowered into the 
dissolution vessels containing dissolution medium (0.5 M phosphate buffer saline and 
0.5% sodium dodecyl sulfate, pH 6.8 at 37°C). The medium was stirred at a constant 
rate of 100 ± 2 rpm and at pre-determined intervals (15-360 minutes) samples of 
dissolution fluid (2 mL) were removed and replaced with an equal volume of fresh, 
pre-warmed dissolution fluid. The concentration of CP in the samples of dissolution 
fluid was analysed by reverse phase HPLC with reference to a previously constructed 
calibration curve (Section 2.2.9) (Colley et al., 2018). 
 
2.2.8.2 Cytotoxic effects of mucoadhesive clobetasol-17- propionate patches 
The cytotoxic effects of placebo and CP-loaded patches (1, 5 and 20 µg/patch) were 
determined, analysed and interpreted based on the OECD Test Guideline 431 (OECD, 
2004), as previously described in section 2.2.7.2. TEOM treated with either placebo 






2.2.9 Preparation of calibration standards for High-Performance Liquid 
Chromatography  
To generate a calibration curve, a series of calibration standards of CP, BV, and HV 
were prepared by serial dilution of the stock standard solution (100 mM) of 
compounds to produce solutions of a concentration of 0, 0.01, 0.05, 0.1, 1, 10 and 25 
µM in Green’s media. Compound analysis was performed using a Waters 2690 HPLC 
using a Zorbax RX-C18 250 mm x 4.6 mm column and a mobile phase composed of 
acetonitrile (ACN)/water: CP and BV (45% of ACN in water for 15 minutes, ramping to 
100% ACN after 16 minutes) and HV (40% of ACN in water for 20 minutes, ramping to 
100% ACN after 30 minutes) at 1 mL/min. UV detection was detected using Waters 
486 UV/dis detector at 240 nm (CP and BV) and 244 nm (HV).  For each concentration, 
a single injection was made to obtain the peak area for constructing the calibration 
curve.  
 
2.2.10 Drug permeation analysis 
2.2.10.1 Exposure of corticosteroids against the TEOM 
2.2.10.1.1 Permeation evaluation of corticosteroids solution through the TEOM 
As a preliminary test, TEOM were exposed to a single concentration of CP, BV, and HV 
(5 µM) (in solution) for one-hour. In brief, TEOM were transferred to a new plate and 
washed with PBS. After washing, TEOM were exposed to a single concentration of CP 
(5 µM) for one-hour. After one-hour exposure, media in the basolateral compartment 
of the inserts were collected and transferred to microcentrifuge tubes. TEOM were 
subsequently washed in PBS and weighed. TEOM were cut into smaller pieces (2 mm 
x 2mm), dissolved in collagenase IV (2 mg/mL), and centrifuged at 500xg for 5 minutes. 
All supernatants were collected, transferred to microcentrifuge tubes and stored at -
800C before analysing. 
 
In another experiments, (1) TEOM were exposed to a single concentration of CP (5 
µM) for three different time point (10, 30 and 60 minutes). Also, (2) TEOM were 
exposed to CP at increasing concentrations (5, 25 and 50 µM). After the incubation, 
media in the basolateral compartment of the inserts were collected and all tissues 
were processed as previously described. The presence of compounds in the 
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basolateral compartment and tissues were determined using HPLC (Section 2.2.9) 
(Figure 2.6). The concentration of compound recovered in the TEOM was calculated 
by normalising to the weight of the tissue and expressed as nM per mg of tissue. 
 
2.2.10.1.2 Topical delivery of clobetasol-17-propionate patches (1, 5 and 20 µg) for 
1 hour on the TEOM  
The CP-loaded patches (1, 5 and 20 µg) were applied to the TEOM. After one-hour 
incubation, the patches were removed and the media in the basolateral compartment 
of the inserts collected, transferred to microcentrifuge tubes and stored at -800C 
before analysing. TEOM were rinsed in PBS and weighed. The samples were analysed 
following procedures as previously described in section 2.2.10.1.1 (Figure 2.6). 
 
2.2.10.1.3  Topical delivery of clobetasol-17-propionate patches (20 µg) for 4 and 24 
hours on the TEOM  
In this experiment, only the 20 µg CP patch was further analysed by increasing the 
exposure time to 4 and 24 hours. At the respective time point, both the media from 
the basolateral compartment of the inserts and tissues were collected. All samples 
were processed and analysed following procedures as previously described in section 





























Figure 2.6: TEOM were exposed to corticosteroids (solution/patch) by topical delivery. 
The presence of corticosteroids in the tissues and basolateral compartment of the 
inserts was detected using HPLC. 
 
2.2.11 Viability of Jurkat T cell grown in different medium 
Jurkat T cells were cultured in RPMI and Green’s medium (excluding the cholera toxin 
and hydrocortisone) to determine the viability of the cells grown in the different 
medium.  
 
Jurkat T cells were seeded at 5 x 104 cells/well in the 6-well plate in the respective 
media and the viability of the cells determined every 2 days for 8 days. The trypan blue 
method was used to determine the viability of the cells grown in different medium 
and cell viability calculated using the following formula: 
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2.2.12 Stimulation of Jurkat T cells 
Phytohaemagglutinin (PHA) was used as the main stimulant and Phorbol-12-
myristate-13-acetate (PMA) as a co-stimulant to induce T cells to secrete interleukin-
2 (IL-2). Jurkat T cells grown in Green’s medium were treated with the combination of 
PHA and PMA at a concentration of 5 µg/mL and 100 ng/mL, respectively for 24 hours. 
Afterwards, Jurkat T cells were centrifuged at 250 xg for 5 minutes. The resultant cell 
pellets were resuspended in Green’s medium and seeded in 12-well plates at a cell 
density of 1.0 x 106/mL for use in future experiments. Following stimulation, the 
viability of the Jurkat T cells was also measured as described in section 2.2.11. 
 
2.2.13 Measuring IL-2 by enzyme-linked immunosorbent assay (ELISA) 
The production of IL-2 was determined using a commercially available enzyme-linked 
immunosorbent assay (ELISA) kit following the protocol according to the 
manufacturer’s instructions. Briefly, the capture antibody was diluted in PBS (without 
carrier protein) to a working concentration (4 µg/mL). Thereafter, a 96-well plate was 
coated with 100 µL of diluted capture antibody. The plate was then sealed and 
incubated overnight at room temperature. After overnight incubation with capture 
antibody, each well was aspirated and washed using 300 µL of wash buffer 3 times. 
After the last wash, the remaining wash buffer in each well was removed completely 
by inverting and blotting the plate on absorbent paper towels. Afterwards, 300 µL of 
block buffer were added to each well and incubated for 1 hour and the washing step 
repeated.  One hundred microliters of prepared standards (0, 15.6, 31.3, 62.5, 125, 
250, 500 and 1000 pg/mL) in reagent diluent and samples were pipetted into each 
well, sealed and incubated for 2 hours at room temperature. After 2 hours incubation, 
the content of each well was removed, and the washing step was carried out. 100 µL 
of detection antibody (100 ng/mL) in reagent diluent was added to each well, sealed, 
incubated for another 2 hours at room temperature and followed by a further wash 
step.  Next, 100 µL of streptavidin-HRP (1:40) was pipetted into each well, and sealed, 
incubated for 20 minutes at room temperature and washed. A hundred microliters of 
substrate solution were then added to each well, incubated again for 20 minutes at 
room temperature. It is crucial to avoid the direct light during the incubation with 
streptavidin-HRP and substrate solution. Finally, 50 µL of stop solution was added to 
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each well. Prior to measurement, the plate was tapped gently to ensure thorough 
mixing. The measurement was determined using a microplate spectrometer set to 450 
nm and corrected at 540 nm.  
 
2.2.14 Secretion of IL-2 at different time points 
After 24 hours stimulation with both stimulants, the stimulated Jurkat T cells were 
centrifuged at 250 xg for 5 minutes. The cell pellet was then resuspended in fresh 
culture media and seeded in a 12-well plate (2 mL/well) at a density of 1.0 x 106 
cells/mL. Subsequently, the media was collected and centrifuged (500xg, 5 min) at 4, 
8 and 24 hours. Jurkat T cells where the stimulants had been retained after 24 hours 
stimulation acted as controls. All the collected supernatants were further analysed for 
IL-2 by ELISA. 
 
2.2.15 Effects of clobetasol-17-propionate patch against the IL-2 level 
The construction of OLP-like model IL-2 were prepared as previously described 
(section 2.2.2.2) with slight modifications by incorporating the activated Jurkat T cells 
into the basolateral compartment medium, which the analysis was carried out at day 
10 post-ALI. Prior to analysis (day 9), Jurkat T cells were stimulated with 5 µg/mL PHA 
and 100 ng/mL PMA for 24 hours. After 24 hours stimulation, the stimulated Jurkat T 
cells were collected, centrifuged (250 xg, 5 minutes) and the cell pellet was 
resuspended in the fresh medium. The desired number of Jurkat T cells (1.0 x 106 
cells/mL) were seeded underneath the insert in 2 mL Green’s media for each well of a 












Table 2.11: Different treatment of the stimulated T cells. 
 Treatment 
Group Media Placebo  
(patch) 
20 µg CP 
 (patch) 
20 µg CP 
(solution) 
G1 + - - - 
G2 - + - - 
G3 - - + - 
G4 - - - + 
 
After 4, 8 and 24 hours treatment, 500 mL of media from the basolateral compartment 
of the inserts was collected and centrifuged (500xg, 5 minutes). The resultant cell 
pellets were resuspended with 500 µL fresh media and added back to the basolateral 












Figure 2.7: Effects of topical delivery of clobetasol-17-propionate (CP) using an 
















2.2.16 Data handling and statistical analysis 
Data were presented as mean ± standard deviation (SD). Analysis of variance, one-way 
(ANOVA) was carried out to compare the differences between more than two means 
and differences between individual means was performed using a post-hoc test. While 
the comparison between two means was performed using Student’s T test. A mean 
difference was considered significant when *p < 0.05, **p < 0.001 and ***p < 0.0001 
as compared to control. Statistical analysis was performed using Statistical Package of 

























       CHAPTER 3 
 
DEVELOPMENT OF A FULL-THICKNESS, TISSUE ENGINEERED ORAL MUCOSA 




TEOM is an example of a cell-based device that requires approval from the FDA before 
being applied clinically (Izumi et al., 2004). The use of tissue engineered epithelial 
models in biological research is now widely accepted and, due to European Union 
legislation, are the only model system that can be used to test cosmetic products. 
TEOM are increasingly used in various research areas including infection (Yadev et al., 
2011; Schaller et al., 2006), cancer (Colley et al., 2011; Gaballah et al., 2008; Nystrom 
et al., 2005), drug toxicity (Sun et al., 2006) and drug delivery (Hearnden et al., 2009). 
Many investigators have moved away from traditional monolayer cell culture systems 
to 3D oral mucosal model systems because of the high resemblance to the native oral 
mucosa and clinical relevance because these complex 3D models provide better, more 
relevant information when compared to monolayer systems (Moharamzadeh et al., 
2012).  
 
Construction of TEOM using primary oral keratinocytes and oral fibroblasts has been 
shown to be physiologically and histologically similar to the native oral mucosa 
(Yamada and Cukierman, 2007; Griffith and Swartz, 2006). Nevertheless, there are 
several disadvantages in constructing TEOM based on the use of human primary cells, 
which includes a limited supply of fresh tissue, the need for large numbers of cells, 
limited passaging, shorter lifespan and donor-to-donor variability (Dongari-
Bagtzoglou and Kashleva, 2006: Southgate et al., 1987). In order to address these 
drawbacks immortalised cells are now being used to generate TEOM. Immortalisation 
of epithelial cells has been achieved by the over-expression of TERT-2 (Lee et al., 2004) 
and now oral keratinocytes derived from normal, healthy individuals have been 
immortalised and characterised (McGregor et al., 2002). These cells have the 
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advantage of having longer lifespans, accessibility, reproducibility, and ease of culture 
(Kassem et al., 2004; Lee et al., 2004). 
 
The most well established immortalised oral keratinocytes are OKF6 cells and these 
have been used to make TEOM previously (Dongari-Bagtzoglou and Kashleva, 2006; 
Almela et al., 2016). However, TEOM based on OKF6 cells have not been characterized 
thoroughly and in some studies, these TEOM display poorly differentiated epithelium 
or epithelial layers that are only three to four cells thick (Almela et al., 2016; Mcleod 
et al., 2014). Therefore, well-characterised models developed using different 
immortalized keratinocytes are required. Once such possibility is the use of FNB6 
immortalised oral keratinocytes. These cells are derived from normal, healthy 
keratinocytes isolated from buccal keratinocytes of a female and then immortalised 
by over-expression of TERT-2, and have been shown to be morphologically very similar 
to normal oral keratinocytes (McGregor et al., 2002).   
 
The aim of this chapter was to develop and characterise TEOM using human FNB6 
TERT-2 immortalised oral keratinocytes and primary normal oral fibroblast cells, and 
validate its similarity to normal oral mucosal tissue by analysing the histological 
structure, expression of structural proteins by IHC, and comparing this to native oral 
tissue. This validation step is crucial to ensure that the developed TEOM is suitable for 
using in drug toxicity and drug delivery experiments.  
 
The specific objectives of this chapter were as follows: 
• To determine the morphology of TEOM as compared to native oral mucosa 
using haematoxylin and eosin (H&E) and Periodic-acid Schiff (PAS) staining. 
• To identify the expression of proteins involved in proliferation (Ki-67), 
differentiation (cytokeratin 14, cytokeratin 4 and cytokeratin 13) and adhesion 
(E-cadherin and Claudin-4) processes in the TEOM as compared to native oral 
mucosa using IHC staining. 
• To examine the ultrastructure of TEOM such as tight junction-related 
structures (desmosomes and hemidesmosomes) using TEM. 
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• To evaluate the viability of TEOM for 30 days in the culture using alamarBlue®. 
• To assess the electrical resistance of TEOM using transepithelial electrical 
resistance. 
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(IHC) staining (See 
section 2.2.4) 
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Construction of TEOM in cell culture inserts 
(See section 2.2.2.2) 
 
Preparation of tissue-engineered oral mucosa (TEOM)  
 
Collagen extraction from rat tails 





3.3.1 Morphology of tissue engineered oral mucosa using immortalised oral 
keratinocyte (FNB6) cells resembles the native oral mucosa 
Histological analysis was carried out on TEOM cultured for 5, 10 and 14 days at ALI in 
order to investigate the basic structure of TEOM using H&E staining. Structurally, 
TEOM were comprised of 3 distinct layers; epithelium, basement membrane and 
fibroblast-populated connective tissue at all time intervals examined that resulted in 
the formation of a full-thickness of TEOM (Figure 3.1B-D). Generally, the histological 
structure of the TEOM was very similar to that observed in the native oral mucosa 
(Figure 3.1A), although the TEOM demonstrated a thinner epithelium. The 
immortalised FNB6 keratinocytes seeded onto the surface of the connective tissue 
equivalents differentiated into multiple stratified epithelial layers that were observed 
at each time point examined. 
 
Culturing the TEOM over 14 days at ALI markedly affected the stratification pattern of 
the epithelium as well as its thickness (Figure 3.1B-D). After 5 days incubation, the 
epithelium consisted of a layer of basal cells (stratum basale) attached to the 
basement membrane, followed by the spinous/prickle layer (stratum spinosum) 
consisting of polygonal, densely packed keratinocytes that increased in size from basal 
layer apically. These cells became flattened to produce a non-keratinised superficial 
layer (stratum lucidum) (Figure 3.1B). The histology at this time point was very similar 
to the native buccal oral mucosa biopsy that also displayed a non-keratinised 
epithelium (Figure 3.1B).  After 10 days incubation the epithelium retained the basal 
and spinous cell layers, displayed a small granular layer as well as a distinct layer of 
more keratinised but still nucleated stratum corneum cells in the outermost superficial 
layers of the epithelium, giving the appearance of parakeratinised oral epithelium 
(Figure 3.1C). By 14 days the most superficial epithelial layers were more keratinised 
but still contained nuclei (parakeratinised) whilst the spinous layer appeared to be 
reduced in size (Figure 3.1D). These data show that the pattern of epithelium 
stratification, particularly in the superficial layer, changed from non-keratinised at 5 





















Figure 3.1: Morphology of native oral mucosa and TEOM stained using H&E staining.  
(A) The basic structure of native buccal oral mucosa comprises of non-keratinised 
epithelium (Epi), basement membrane (BM) and connective tissue (CT) - containing 
oral fibroblasts (Arrow). The epithelium constitutes a basal layer (BL), spinous/prickle 
layer (SPL) and superficial layer (SL). (B) At 5 days ALI the TEOM displays a non-
keratinised epithelium that is structurally similar to the native non-keratinised buccal 
oral mucosa. (C) by 10 days the superficial layer is more keratinised by still contains 
nuclei so can be defined as parakeratinised. (D) and 14 days parakeratinised is more 
prominent. (KL: Keratinised layer, GL: Granular layer) (A) Scale bar = 200 µm, (B-D) 




































Measurement of histological images showed that the thickness of the TEOM 
epithelium increased significantly (p< 0.0001) from 5 to 10 and 14 days incubation 
(Figure 3.2A) but no difference was observed between 10 and 14 days (Figure 3.2A). 
For the keratinised epithelium, there was a significant difference in the size of the 
parakeratinised layer between 5 and 10/14 days because the TEOM at 5 days was non-
keratinised. However, there was no significant difference between TEOM at 10 and 14 
days (Figure 3.2B). 
 
The fibroblast cells seeded into the rat-tail type 1 collagen in the TEOM were evenly 
able distributed within the substrate forming the connective tissue equivalents at each 
time interval (Figure 3.1B-D). The connective tissue equivalents in the TEOM were 
loosely formed whereas the connective tissue of native oral mucosa was more densely 





Figure 3.2: Thickness of the epithelium and keratinised layer of TEOM. (A) Epithelial 
and (B) keratinised layer thickness incubated for up to 14 days at ALI. Data were 
expressed as the mean ± SD for 3 independent experiments performed in triplicate. A 
mean difference was considered significant when * = p < 0.05, ** = p < 0.001 and *** 










3.3.2 Presence of basement membrane structure in TEOM  
 PAS staining was performed to confirm the presence of a basement membrane 
(arrow); a continuous thin positive pink colour staining between the epithelium and 
connective tissue (Figure 3.3B-D) that was similarly observed in the native oral mucosa 
(Figure 3.3A). Positive PAS staining was also observed in the superficial epithelial 
layers, in particular the parakeratinised layers, as this stain binds to glycogen within 


















Figure 3.3: Basement membrane detected using PAS staining. Presence of basement 
membrane in (A) native oral mucosa and (B) TEOM was identified between the 
epithelial and connective tissue layer at (B) day 5, (C) day 10 and (D) day 14 at ALI. 









3.3.3 Preservation of the essential markers in TEOM 
3.3.3.1 Cell differentiation markers 
3.3.3.1.1 Cytokeratin 14 
Cytokeratin 14 (CK14) is a member of the type I keratin family of intermediate filament 
proteins (Moll et al., 2008) and is a prototypic marker of dividing basal keratinocytes 
(Alam et al., 2011). Expression of CK14 in the native oral mucosa was more 
predominantly expressed in the basal layer than the suprabasal layer (Figure 3.4A). In 
contrast, the expression of CK14 in the TEOM displayed a similar level of intensity 
throughout the epithelium when cultured for 5 (Figure 3.4B), 10 (Figure 3.4C) or 14 
days (Figure 3.4D) at ALI, respectively. For TEOM at days 10 and 14, CK14 staining was 

















Figure 3.4: CK14 expression in native buccal mucosa and TEOM identified using IHC 
staining. CK14 expression was demonstrated in (A) native oral mucosa and TEOM 
cultured for (B) 5, (C) 10 and (D) 14 days at ALI. ((A) Scale bar = 100 µm, (B-D) Scale 





3.3.3.1.2 Cytokeratin 13 and cytokeratin 4  
Cytokeratin 13 (CK13) is a type I cytokeratin that is paired with cytokeratin 4 and found 
in the suprabasal layers of non-keratinised stratified epithelia. CK13 expression in the 
native buccal mucosa was limited to the all suprabasal layers and no expression found 
in the basal keratinocytes (Figure 3.5A). The same pattern of CK13 staining was 
observed in TEOM with intense CK13 stain for all suprabasal cells with only the basal 
cells being CK13-negative (Figure 3.5C). Expression of CK4 was less prominent in the 
native oral mucosa and staining restricted to the upper spinous and superficial layers 

























Figure 3.5: CK13 and CK4 expression in native buccal mucosa and TEOM identified 
using IHC staining.  Expression of (A) CK13 and (B) CK4 in native oral buccal mucosa 
and expression of (C) CK13 and (D) CK4 in TEOM cultured for 5 days at ALI. (A&B Scale 








3.3.3.2 Cell proliferation marker 
3.3.3.2.1 Ki-67 
Ki-67 is a protein that is only expressed during active phases of the cell cycle (Bruno 
and Darzynkiewicz, 1992) and is therefore, a marker for actively proliferating epithelial 
cells. In native oral mucosal tissue, only the basal cells are actively dividing and 
therefore ki-67 expression was restricted to the basal cells by IHC (Figure 3.6A). 
Similarly, ki-67-positive proliferating epithelial cells in the TEOM cultured for 5 (Figure 
3.6B), 10 (Figure 3.6C) and 14 days (Figure 3.6D) were restricted to the basal layer and 
occasionally the parabasal cells. The expression of this molecule was therefore 

















Figure 3.6: Ki-67 expression in native buccal mucosa and TEOM identified using IHC 
staining. Ki-67 expression is demonstrated in (A) native oral mucosa and TEOM 








3.3.3.3 Cell adhesion markers 
3.3.3.3.1 E-cadherin and Claudin-4 
E-cadherin and Claudin-4 are cell adhesion proteins of the tight junctions that are 
located between epithelial cells.  Their expression is crucial for structural integrity of 
the tissue. Distinctive plasma-membrane expression of both E-cadherin (Figure 3.7A) 
and Claudin-4 (Figure 3.8A) was observed for all the epithelium in the native oral 
buccal mucosa, although staining for E-cadherin was more intense than for Claudin-4. 
At day 5 ALI, expression of E-cadherin was also prominent and restricted to the 
epithelial plasma membrane (Figure 3.7B), whereas expression of Claudin-4 at this 
stage was more diffuse and ambiguous (Figure 3.8B). At 10 days ALI, membrane 
expression of E-cadherin and Claudin-4 was more pronounced and expression was not 
detected at the basement membrane interface or in the upper most superficial layers, 
which is in line with the native tissue (Figure 3.7C and Figure 3.8C). Similar 
observations were also seen at day 14 ALI for both E-cadherin and Claudin-4 (Figure 
3.7D and Figure 3.8D). In all cases, the intensity of Claudin-4 staining was weaker when 



























Figure 3.7: E-cadherin expression in native buccal mucosa and TEOM identified using 
IHC staining. E-cadherin expression was exhibited in the suprabasal layers at the 
plasma membrane in (A) native oral mucosa and TEOM cultured for (B) 5, (C) 10 and 































Figure 3.8: Claudin-4 expression in native buccal mucosa and TEOM identified using 
IHC staining. Claudin-4 expression was evident at the plasma membrane in (A) native 
oral mucosa and TEOM cultured for (B) 5, (C) 10 and (D) 14 at ALI. (A Scale bar = 100 

















3.3.4 Ultra-structural analysis of TEOM by TEM 
Ultrastructural analysis of the organisation of the TEOM was performed using TEM to 
confirm the histology and IHC staining. Figure 3.9A&B shows the flattened, elongated 
epithelial cell morphology in the superficial, stratum lucidium layer compared to the 
more rounded cell morphology in the basal cells (Figure 3.9C), confirming the 
histological images. Figure 3.9D shows alignment of the collagen fibres within the 
connective tissue component and the presence of a well-organised basement 
membrane separating the epithelium from the connective tissue (Figure 3.9E&F).  
 
The structural integrity of the oral epithelium is dependent on the presence of key 
structural motifs that hold epithelial cells tightly together (desmosomes) and firmly 
connect the basal cells to the basement membrane (hemidesmosomes). Figure 3.9G 
shows the presence of numerous desmosome structures between adjacent epithelial 
cells. At higher magnification (Figure 3.9H) desmosomes exhibited a bundle of keratin 
intermediate filaments (tonofilaments; arrow), joining the adjacent epithelial cells by 
anchoring to dense plaques. Hemidesmosomes were also detected at distinct focal 
points where integrins connect the basal cells to the basement membrane along with 



























Figure 3.9: Ultrastructural organization of TEOM identified using transmission electron microscope (TEM). (A) Epithelial cells (EC) in the 
superficial layer (scale bar = 2 µm), (B) epithelial cell (EC) in the superficial layer at higher magnification (scale bar = 1 µm), (C) Basal 
epithelial cell (scale bar = 1 µm), (D) collagen fibrils (CF) (arrow) within the connective tissue (CTE) appear straight and vary in size  (Scale 
bar = 0.5 µm), (E) basement membrane (BM) (arrows) structures between the connective tissue (CTE) and epithelium (scale bar = 0.5 
µm), (F) basement membrane (BM) structures between the connective tissue (CTE) and epithelium at higher magnification (scale bar = 
200 nm), (G) desmosome (De) structures and keratin filaments (tonofilaments) attach to dense plaques (Scale bar = 0.5 µm), (H) 
desmosomes (De) and keratin filaments (tonofilaments) (arrow) attach to dense plaque of desmosome at higher magnification (scale bar 































3.3.5 The viability of TEOM was maintained up to a month 
Mitochondrial metabolism of alamarBlue® by viable cells produces a fluorescent 
product. The levels of fluorescence are often used as an indirect measurement of cell 
viability and cell proliferation. The viability of TEOM was determined over time every 
5 days up to 30 days at ALI using alamarBlue®. The fluorescence intensity increased in 
a time-dependent manner from 5 (25049.3 ± 4068.1) to 15 days TEOM reaching a 
maximal value (35936.2 ± 3083.6) at day 15 of ALI culture, suggesting that the cells in 
the TEOM are viable and increasing in number up to day 15 (Figure 3.10). Thereafter, 
the fluorescence values gradually decline to 16871.9 ± 3689.7 by day 30, which is 
significantly less that the value observed at day 15 (p < 0.05); Figure 3.10), but not 
significantly less that day 5 TEOM. These data suggest that TEOM maintain viability for 
up to 30 days in culture but show differences in fluorescence values that are likely to 
represent a loss of cell numbers as the culture progresses.  
 
3.3.6 Electrical resistance reflects the integrity status of the epithelium of TEOM 
The electrical resistance across the epithelium was measured over time using an 
Epithelial Voltohmmeter (EVOM) in order to determine the resistance barrier of the 
epithelium in the TEOM. The value of electrical resistance was expressed as mean 
Ω.cm2. The electrical resistance across the epithelium of TEOM increased gradually 
from day 5 (92.4 ± 8.2 Ω.cm2) to day 20 ALI culture where it reached the maximal 
electrical resistance (155.8 ± 13.3 Ω.cm2). The TEER was significantly increase at day 
20 compared to day 5 (p<0.05) suggesting that the integrity of the tissue increases 
during this period (Figure 3.11). Thereafter, the TEER gradually declined to 114.03 ± 
5.4Ω.cm2 by day 30, a significant decrease (p<0.05) compared to values obtained at 
day 20, although still remaining above 100 Ω.cm2 and much higher than compared to 

















Figure 3.10: Viability profile of the TEOM determined using alamarBlue® for 30 days 
in the cultures. TEOM were cultured at ALI for up to 30 days and viability indirectly 
measured by reduction of alamarBlue® at indicated time points. The maximal viability 
is reached at day 15. Data were expressed as the mean ± SD for 3 independent 
experiments performed in triplicate. A mean difference was considered significant 
when *p < 0.05, **p < 0.001 and ***p < 0.0001 using One-way ANOVA with Tukey 











Figure 3.11: TEER profile of TEOM measured using an Epithelial Voltohmmeter 
(EVOM) over 30 days at ALI culture. The maximal viability is reached 155.8 Ω.cm2 at 
day 20. Data were expressed as the mean ± SD for 3 independent experiments 
performed in triplicate. A mean difference was considered significant when *p < 0.05, 
**p < 0.001 and ***p < 0.0001 using One-way ANOVA with Tukeypost-hoc multiple 








3.3.7 Integrity status of the epithelium influences the permeability of FITC-
dextrans and electrical resistance profile 
The permeability across the TEOM was performed using three different fluorescently 
labelled dextrans of increasing molecular weight (3, 10 and 70 kDa).  Dextrans at 3 kDa 
pass easily through the epithelium, 10 kDa less so, whereas 70 kDa dextrans have 
much restricted diffusion (Hoogstraate et al., 1994).  Firstly, TEOM were exposed to 
fluorescent dextrans for up to 300 minutes (Figure 3.12). The amount of each 
fluorescently labelled dextran that passed through the TEOM increased in a time-
dependent manner. From 60 minutes onwards, significantly (p < 0.05) more 3 kDa 
dextran was able to diffuse through the TEOM than either the 10 or 70 kDa fluorescent 
dextran. The permeability of the TEOM was 3>10>70 kDa at each time point tested. 
After 5 hours exposure, the amount of fluorescent 3, 10 and 70 kDa dextran that had 
permeated through the TEOM was approximately 17, 6 and 3 %, respectively (Figure 
3.12). 
 
Secondly, the permeability of TEOM was assessed by treating the TEOM using sodium 
dodecyl sulphate (SDS; 5%), a detergent that is known to disrupt the barrier of the 
epithelium in TEOM and evaluating the loss of permeability/integrity of the tissue by 
evaluating both the TEOM TEER and dextran permeability. It was noted that the 
impairment of epithelium barrier in the SDS treated group displayed significantly (p < 
0.05) increased permeability to all sizes of fluorescently labelled dextrans when 
compared to PBS treated, suggesting nearly complete loss of the permeability barrier 
of the TEOM epithelium (Figure 3.13A). Similarly, the TEER value was significantly 
reduced (p < 0.05) in the SDS, compared to PBS control treated TEOM (Figure 3.13B). 
Histologically, the treatment of TEOM with SDS (5%) caused tissue decellularisation 
with loss of integrity of all cells in both the epithelium and connective tissue. The 
detachment of the epithelia from the connective tissue is also evident in many parts 
of the TEOM, virtually destroying the structure of TEOM (Figure 3.14). 
 
Taken together, these data show that when the epithelial barrier is maintained, the 
permeation of all sizes of dextrans was low, especially the permeation of larger 
molecules such as 70 kDa dextran, whilst at the same time the TEER value increased. 
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In contrast, the addition of detergent to the TEOM completely disrupted the tissue 
architecture, allowing complete permeation of the tissue to all dextrans and 
decreased electrical resistance. These data show that the TEOM have good integrity 


















Figure 3.12: Permeability analysis of fluorescently labelled dextrans (3, 10 and 70 kDa) 
across the epithelium of TEOM. The permeability of TEOM against fluorescently 
labelled dextrans was increased in a size-dependent manner over time, particularly 
the permeability of TEOM against smaller (3 kDa) molecules. Data were expressed as 
the mean ± SD for 3 independent experiments performed in triplicate. A mean 
difference was considered significant when *p < 0.05, **p < 0.001 and ***p < 0.0001 
























































Figure 3.13: Comparison of the permeability and TEER value in TEOM between control 
and 5% SDS treated tissue.  (A) The permeability of TEOM is decreased against 
fluorescently labelled dextrans in a size-dependent manner when the barrier is 
maintained and concurrently, (B) elevation of TEER value is observed. Data were 
expressed as the mean ± SD for 3 independent experiments performed in triplicate. A 
mean difference was considered significant when *p < 0.05, **p < 0.001 and ***p < 































Figure 3.14: Morphology of TEOM treated with 5% SDS. The decellularisation of the 
epithelial and fibroblast cells and the detachment of the epithelium layer from the 





















Construction of a reliable TEOM that retains the structure, differentiation status and 
permeability of native oral mucosa remains a major challenge to investigators. 
Construction of a TEOM using immortalised keratinocytes whilst maintaining the 
viability, epithelial barrier functions and biological properties over a period of culture 
were the main driving force for the experiments described in this chapter. Extensive 
characterisation was performed to ensure that the TEOM was a reliable replica of oral 
mucosa and to ensure that it was fit to be used for downstream applications such as 
drug toxicity and drug delivery that are conducted over a long period of time. 
 
In the present work, the development of TEOM was based on the utilisation of FNB6 
cells and primary NOF, while the connective tissue scaffold was comprised of rat-tail 
type I collagen. The TEOM were cultured using commercially available culture inserts 
which contained a 0.4 μm porous membrane that permitted supply of nutrients to the 
basal side of the tissue and is commonly used for culture of 3D models (Chen et al., 
2015; Sanchez-Quevedo et al., 2007; Geroski and Hadley, 1992). The design of the 
culture inserts also permitted culture at an ALI (Bayar, 2012; Sanchez-Quevedo et al., 
2007; Reichl and Muller-Goymann, 2003; Richard et al., 1991). It has been reported 
that culture at ALI results in oxidative stress that produces a change in the cellular 
glutathione system (Kameyama et al., 2003; Tammi and Jansen, 1980), stimulating 
epithelial proliferation and differentiation (Bayar, 2012; Sanchez-Quevedo et al., 
2007; Kameyama et al., 2003; Izumi et al., 1999).  
 
The construction of a full-thickness TEOM based on immortalised oral keratinocytes 
and primary oral fibroblasts successfully generated a multi-layered epithelium 
consisting of stratified and differentiated epithelial cells that was histologically similar 
to the native oral mucosa. The thickness of the epithelium increased over time but 
was still thinner than native oral mucosa. Despite the difference in the epithelial 
thickness between native oral mucosa and TEOM, the structure and pattern of 
epithelial stratification were very comparable, which has been observed in previous 
studies (Buskermolen et al., 2016; Kinikoglu et al., 2009; Izumi et al., 2000). The 
interactions between keratinocytes, fibroblasts and the surrounding stroma are 
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thought to be the main influence over the thickness of the epithelium (Moharamzadeh 
et al., 2012; Liu et al., 2011; Costea et al., 2005). It may be that the factors in the in 
vitro model may not exactly replicate the in vivo situation, leading to slightly thinner 
epithelia.  
 
Interestingly, the TEOM displayed increased levels of keratinisation along with visible 
signs of epithelial shedding the longer they were cultured at ALI. Histologically, a 
shorter incubation time of TEOM at ALI displayed as a non-keratinised epithelium. 
While longer incubation time demonstrated a keratinised epithelium, with nuclei 
being retained in the superficial layer (parakeratinised), indicating the parakeratosis 
(Bayar et al., 2012). This is intriguing as the immortalised keratinocytes are derived 
from the buccal mucosa, a non-keratinised area of the oral mucosa. The fibroblasts 
used in this study were mainly from gingival tissue, an area of keratinised epithelium. 
It is plausible that factors released from these fibroblasts influence the oral 
keratinocytes and push them toward a more keratinised, albeit parakeratinised status. 
This transformation has also been observed by Izumi et al., 2000 and suggests that the 
origin of cells plays a key role in keratinisation. In addition, other studies also reported 
keratinised epithelium in TEOM as early as 7 days incubation at ALI (Bayar et al., 2012; 
Izumi et al., 2000), which similar to these findings showing keratinisation at day 10. 
However, the epithelium of TEOM in these studies showed only a few epithelial layers 
thick that were not well differentiated (Bayar et al., 2012; Izumi et al., 2000), possibly 
due to the lack of fibroblasts in these models.  A recent study constructed a TEOM 
using entirely immortalised of oral keratinocytes and fibroblasts derived from gingival 
biopsies (Buskermolen et al., 2016). Here the full-thickness TEOM displayed a 
keratinised epithelium after 10 days at ALI, which is in line with the findings in this 
study. The data presented here are also in line with another recent study published 
using immortalised FNB6 keratinocytes and primary gingival fibroblasts. Although less 
characterised than the data presented here, these TEOM displayed non-keratinised 
epithelium (Jennings et al., 2016) and were structurally comparable to the TEOM in 
this study. In addition, other researchers have generated TEOM using immortalised 
oral keratinocytes derived from the floor of the mouth (OKF6-TERT2). These cells 
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appear to produce poorly differentiated epithelium, sometimes only a few layers thick 
(Almela et al., 2016; McLeod et al., 2014 and Dongari-Bagtzoglou and Kashleva, 2006).  
 
The presence of non-keratinocytes, such as melanocytes (Yamazaki et al., 1991), 
Langerhans cells (Terris et al., 1995), Merkel cells (Harmese et al., 1999) and 
lymphocytes (Squier and Kremer, 2001) can also be found in the oral mucosa. These 
cells constitute approximately 10% of the oral epithelium in both non-keratinised and 
keratinised epithelium (Squier and Kremer, 2001; Squier and Finkalstein, 1998). All 
these cells, except Merkel cells, lack desmosomal attachments to neighbouring cells. 
Therefore, the cytoplasm of these cells shrink around the nuclei to generate a clear 
halo effect during the histologic processing. It is highly unlikely that these cells survive 
the isolation and culture process when keratinocytes are generated from tissue 
biopsies and therefore are not likely to be in the TEOM. Indeed, lack of other cell types 
is a criticism of TEOM and the development of advanced models to include immune 
cells is warranted.  
 
PAS staining and TEM analysis confirmed the presence of a basement membrane 
between the epithelium and connective tissue. The basement membrane is a region 
of attachment that is required as a mechanical support to endure the sheer stress 
occurred in the oral mucosa (Dodla and Velmurugan, 2013; Shinkar et al., 2012; 
Feinberg et al., 2005). The interplay of keratinocytes and fibroblasts together with the 
basement membrane components such as collagen type IV and laminin 5 are essential 
for the formation of functional basement membrane (Laverdet et al., 2014; Stephens 
and Genever, 2007; Marrionet et al., 2006). Keratinocytes are the main source of 
collagen type IV (Chen et a., 2002) and laminin 5 (Amano et al., 2001), in the absence 
of fibroblasts, whereas fibroblasts are the main source of collagen type IV in the 
presence of keratinocytes (Smola et al., 1998). The basement membrane also acts as 
a rate-limiting factor that affects the movement of the molecules in a size-dependent 
manner from the epithelium to the connective tissue and its presence is therefore 
important when analysing the movement of drugs across the tissue (Vllasaliu et al., 




A scaffold, as an artificial supporting structure for growing the cells, is another 
essential component for generation of TEOM. An ideal scaffold should be non-toxic 
(MacNeil, 2007), have porosity (Will et al., 2008; Muschler et al., 2004), 
biodegradability (Palsson and Bhatia, 2004), biostability (Ma et al., 2003), 
biocompatibility and the ability to mimic the native structure of the oral mucosa 
(Moharamzadeh et al., 2007). Collagen-based scaffolds possess most of these qualities 
(Parenteau-Bareil et al., 2010). In this study, the connective tissue scaffold was based 
on collagen I from rat tails that is widely utilised by researchers as it bio-mimics the 
human extracellular matrix (Parenteau-Bareil et al., 2010; Shoulders and Rainers, 
2009; Moharamzadeh et al., 2007). The fibroblasts in this study had proliferated, 
migrated and distributed evenly within the collagen-based connective tissue, similar 
to a previous study (Almela et al., 2016). It had been reported that this type of scaffold 
provides a suitable substrate for a communication between epithelial and fibroblasts 
cells, it avoids epithelial cell invasion and island formation in sub-epithelial layers 
(Moharamzadeh et al., 2007; MacCallum and Lillie, 1990). Thus far, collagen-based 
materials have shown favourable results in producing the TEOM in other studies 
(Luitaud et al., 2007). However, there are some drawbacks in using these types of 
scaffold including relatively weak mechanical properties (Roy et al., 2010), stability 
and degradation (Chen et al., 2005), and collagen contraction mediated by fibroblasts 
(Schoop et al., 1999; Bach et al., 2001; Chinnathambi et al., 2003).  Occasionally, these 
features were observed in this study. 
 
IHC staining of TEOM showed that these 3D models expressed a cytokeratin profile 
(differentiation markers) equivalent to that observed in the native oral mucosa (Yadev 
et al., 2011) and by other TEOM (Yadev et al., 2011; Moharamzadeh et al., 2007; 
Dickson et al., 2000). The expression of the cytokeratins reflects the differentiation 
stage of keratinocytes within different layers of the epithelium (Moharamzadeh et al., 
2007; Vaidya et al., 2000). CK14 is a differentiation marker that helps in maintaining 
cell shape and provides resistance to mechanical stress (Alam et al., 2011; Jacques et 
al., 2009). In this study, CK14 was expressed in the entire epithelium of TEOM, 
consistent with previous studies either developed using immortalised or primary-
based cells (Jennings et al., 2016; Yadev et al., 2011). CK14 expression in TEOM was 
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only partially in accordance to staining seen in the native oral mucosa (Blumenberg 
and Tomic-canic, 1997), where it is predominantly expressed in the basal cells and 
expression is gradually reduced as the cells move upward and differentiate in the 
suprabasal layer (Rao et al., 2014; Alam et al., 2011; Jacques et al., 2009; Moll et al., 
2008) of the non-keratinised and keratinised epithelium (Rao et a., 2014; Jacques et 
al., 2009; Presland and Dale, 2000). This may be due to the difference in the level of 
maturity of the epithelium between native oral mucosa and TEOM that only been 
developed over a few weeks. CK13 and CK4 are important components of the 
stratified squamous mucosal epithelium. Both CK13 and CK4 were expressed in 
suprabasal layers only of TEOM. Expression was directly in line with native mucosa 
where these cytokeratins are predominantly expressed in the suprabasal layers of 
non-keratinising stratified squamous epithelium such as the buccal mucosa (Sanchez-
Quevedo et al., 2007; Vaidya et al., 2000; Pang et al., 1993). Previously studies have 
reported the expression of CK13 in immortalised or primary-based TEOM 
(Buskermolen et al., 2016; Jennings et al., 2016). However, this study is the first to 
report the expression of CK4 in TEOM.  
 
Ki-67, a cell proliferation marker, was confined predominantly in the basal layer in 
both TEOM and native tissue, which is in agreement with previously studies 
(Yoshizawa et al., 2004; Izumi et al., 2000). The results indicate that the TEOM has the 
capability of self-renewal (Kinikogklu et al., 2009). These findings are consistent with 
previous studies of TEOM generated using immortalised or primary cells (Buskermolen 
et al., 2016; Jennings et al., 2016; Yadev et al., 2011; Dongari-Bagtzoglou and Kashleva, 
2006; Izumi et al., 2000).  
 
E-cadherin and Claudin-4 are molecules that form the tight junctions (De Vicente et 
al., 2015), confined in the cell membrane of the epithelial cells (Costea et al., 2005), 
and are essential for preserving the integrity of the epithelium (De Vicente et al., 
2015). E-cadherin and Claudin-4 were positive in all epithelial layers of the native oral 
mucosa and in the TEOM of the non-keratinised epithelium. Likewise, staining was 
observed in basal, spinous and granular layer of the TEOM of keratinised epithelium, 
but no staining was observed in the keratinised layer of 10 and 14 days TEOM (Ye et 
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al., 2000), suggesting loss of contacts between cells as they moved upward to the 
more differentiated cells in the superficial layer. The expression of E-cadherin in 
immortalised and primary-derived TEOM had been reported in previous studies 
(Buskermolen et al., 2016; Jennings et al., 2016; Dongari-Bagtzoglou and Kashleva, 
2006). While there was no report thus far on the expression of Claudin-4 in 
immortalised and primary-derived TEOM. The IHC results indicate that TEOM 
developed using immortalised (FNB6) cells exhibit a normal expression pattern of 
important proliferation, structural and integrity molecules that are comparable to the 
native oral mucosa.   
 
TEM analysis also validated the presence of ultrastructural organisation located in the 
cell membrane of the epithelial cells particularly the intercellular junction-related 
structures such as desmosomes and hemidesmosomes that bind cells to the basement 
membrane, all of which are important in cell-cell adhesion, regulation of epithelial 
permeability and barrier function (Squier and Brogden, 2011: Kinikoglu et al., 2009; 
Niessen, 2007). Abundant desmosomes were identified, indicating strong adhesion 
between cells in the epithelium of TEOM (Minin and Moldaver, 2008). The presence 
of hemidesmosomes and associated dense plaques reveals that basal cells were 
strongly attached to the underlying connective tissue (Borradori and Sonnenberg, 
1999), suggesting that the TEOM can resist functional stresses (Izumi et al., 2004). The 
presence of these structures confirms the well-developed integrity of the epithelium 
in the TEOM. Collagen fibrils were also detected deeper in the connective tissue 
equivalents of TEOM. The collagen fibrils were orientated straight, varying in size and 
loosely organised, and as a result, produced less densely packed connective tissue 
than native tissue. Nevertheless, the integrity of the connective tissue in TEOM 
remained intact; a finding also had been observed by Kinokoglu et al., 2009. 
 
It is crucial that the TEOM remain viable and keep their function throughout the 
course of development (Izumi et al., 2004) before being introduced in down-stream 
applications. Therefore, the viability of TEOM was assessed over time for up to 30 
days. It was noted that the viability of the TEOM remained stable up to 3 weeks in 
culture before the viability started to decline; data that is consistent with a previous 
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report (Antoni et al., 2015).  A recent study showed that the viability of oral mucosal-
bone equivalents, representing the alveolar bone with an overlying mucosa was 
preserved for a longer time (3 months) (Almela et al., 2016). This might be due to a 
variety of cell type in the cultures and the method used in culturing the substitutes, 
which differs from the model system in this study.  
 
The epithelium serves as a dynamic barrier that selectively restricts the movement of 
molecules across the epithelial layers (Rodgers and Fanning, 2011). The epithelial 
barrier function of the TEOM was assessed employing two methods: (i) electrical 
resistance using a TEER device and (ii) dye tracing method by 
fluorophotospectrometry. Firstly, the TEOM was assessed using a non-invasive TEER 
device. Here, the TEER profile reached its highest value at day 20 (155.8 Ω.cm2) before 
declining in subsequent days. Previously, TEER measurement of the immortalized cells 
derived from different origin showed TEER value of 28.2 ± 1.3 Ω.cm2 and 200 Ω.cm2 
for human brain endothelial cell (hCMEC/D3) and human immortalized colon cell 
(HCEC), respectively. Kimura et al., found that the highest TEER values of human oral 
mucosal models on insert membranes were 134.8 ± 7.0 Ω.cm2 at day 7 (Kimura et al., 
2002). Jacobsen et al., reported a maximal TEER value of 68.2 ± 2.3 Ω.cm2 using TR146-
based models at day 29 (Jacobsen et al., 1995). However, Nielsen & Rassing (1999) 
showed a larger variance of TEER value of 272 ± 132 Ω.cm2 using the same model and 
incubation time. Several studies demonstrated TEER values obtained from blood-
brain-barrier (BBB) models (Lippmann et al., 2014) pulmonary model (Mathias et al., 
2002) and GI tract model (Hilgendorf et al., 2000) exhibited higher TEER values as 
compared to data in this study. It is suggesting that the variability of TEER values of 
the models from different origin probably partly because of the varied composition of 
the tight junctions (desmosomes/hemidesmosomes) exist in each type of tissue.  
There are no reference values of TEER for native oral mucosa published elsewhere, 
probably because of the difficulty in getting the biopsies in sufficient sizes for TEER 
measurement.   
 
Epithelial barrier functions of TEOM were also evaluated using dextrans with different 
molecular weight (3, 10 and 70 kDa), to determine the size of molecules that can 
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permeate across the TEOM. Data presented in this study show that the permeability 
of TEOM was dextran size and time-dependent manner. Dextrans, as a model 
hydrophilic compounds, demonstrated that the smaller molecules especially 3 kDa 
were the most permeable, indicating that any hydrophilic drugs with a molecular 
weight of 3 kDa may be able to pass through the epithelial barrier of the TEOM. 
Previous studies reported that the permeation of dextran against porcine buccal 
mucosa was restricted to lower than 20 kDa through the paracellular route (Sandri et 
al., 2006; Hoogstraate et al., 1994), which is consistent with the findings reported here 
and suggest that TEOM display similar permeation to native tissue. It was also 
revealed that the permeability of TEOM against dextrans increased when the barrier 
function was impaired, regardless the size of molecules. As a result, the electrical 
resistance was also reduced. These phenomena occurred as a direct result of the loss 
of key structures that preserves the barrier of the epithelium such as basement 
membrane and tight junction-related structures (desmosomes and 
hemidesmosomes) upon treatment with a detergent (SDS) widely known for its cell 
destructive properties.  
 
3.5 Summary 
In summary, the data presented in this chapter show that TEOM based on 
immortalised buccal oral keratinocyte and primary normal oral fibroblasts are 
histologically and structurally equivalent to the native oral buccal mucosa. In addition, 
despite the use of immortalised keratinocytes, these TEOM display preserved 
expression of essential proteins involved in proliferation, differentiation and cell-cell, 
cell-basement membrane adhesion processes. These TEOM are a clear advancement 
on those developed using primary cells where the availability of these primary cells is 
limited.  
 
Moreover, these TEOM displayed longevity with good barrier and permeability 
properties, crucial aspects when TEOM are used in down-stream applications. Based 
on these results, the TEOM demonstrated robust characteristics that are highly 
desirable for testing candidate drugs and drug delivery systems intended for 
administration to the oral mucosa. The data strongly indicates that this TEOM has 
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potential to be utilised in a variety of research and pre-clinical settings and as an 



































CYTOTOXIC POTENCY OF CORTICOSTEROIDS AGAINST ORAL KERATINOCYTES 
AND FIBROBLASTS GROWN AS MONOLAYERS OR TEOM 
 
4.1 Introduction 
Corticosteroids are generally used for the treatment of inflammatory and 
autoimmune disorders in dermatology, such as psoriasis and atopic dermatitis (Kwatra 
and Mukhopadkyay, 2018; Alexandre et al., 2015), and mucosal disorders such as OLP 
(Córdova et al., 2014) and aphthous stomatitis (Scully and Porter, 2008). 
Corticosteroids have been categorised based on their potency using the 
vasoconstriction or skin-blanching assay (McKenzieE and Stoughton, 1962), which 
have been used as the gold standard in determining the anti-inflammatory efficacy of 
these drugs, and where it has been suggested that vasoconstriction is correlated with 
anti-inflammatory effects (Kwatra and Mukhopadkyay, 2018). However, often simpler 
in vitro assays are performed in pre-clinical screening. Cytotoxicity assays such as the 
MTT assay, measure the effect of a compound on cell mitochondrial metabolism as a 
surrogate marker for cell viability (Graham-Evans et al., 2003) and are widely used in 
in vitro toxicology studies as a tool to provide predictive evidence of compound safety 
(Miret et al., 2006). The MTT assay (or other such derivatives) has been used in 
countless studies as a measure of cell toxicity, particularly in monolayer studies for 
numerous cell types, including oral keratinocytes (Ji et., 2016; Alexandre et al., 2015; 
Chen et al., 2012). Moreover, the MTT assay is currently used to define compound 
irritation and corrosion on the tissue engineered skin (OECD guideline 3 and European 
Centre for the Validation of Alternative Methods, ECVAM) as a model system in the 
cosmetic industry to replace animal models.  
 
The efficacy of a corticosteroid is related to its level of potency and capability of the 
drug to reach its target site (Wiedersbeg et al., 2008; Federman et al., 1999). The 
potency of corticosteroids is influenced by several factors including chemical structure 
and concentration (Wiedersbeg et al., 2008; Hengge et al., 2006; Kansky et al., 2000; 
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Pershing et al., 1994; Stoughton, 1987). Formulation of corticosteroids using different 
vehicles may also influence their clinical efficacy (Uva et al., 2012; Schoepe et al., 
2006). These also play a significant role in their absorption to reach the site of action, 
influencing their bioavailability and potency (Mehta et al., 2016; Wiedersbeg et al., 
2008; Poulsen and Rorsman, 1980; Ayres and Hooper, 1978). Corticosteroids have 
been formulated in a variety of conventional vehicles such as ointments, creams, gels, 
lotions and foams (Mehta et al., 2016). 
 
Monolayer cell culture, which is the conventional cytotoxicity model system, has 
widely been utilised to determine the safety profile of compounds. Nevertheless, the 
data obtained from monolayer cultures is still debatable due to the dissimilarities in 
the structure and physiology found in normal human tissue compared to cells grown 
as sheets on tissue culture plastic. As a result, most of the tested compounds give 
unsatisfactory, misleading and non-predictive data for in vivo responses (Sun et al., 
2006). Due to the limitations in monolayer cultures, 3D model systems have been 
introduced as the promising model system for cytotoxicity testing as these systems 
are more structurally and physiologically relevant (Fang and Eglen, 2017; Edmondson 
et al., 2014). Monolayer and 3D culture systems often display different drug 
sensitivities, where 3D model systems are usually more resistant to therapeutic agents 
compared to monolayer cultures (Edmondson et al., 2014). The difference in 
resistance to therapeutic agents in 3D models is likely mediated by the complex, multi-
cellular 3D structure, as well as differences in the expression of proteins involved in 
growth and survival (e.g. EGFR family of receptors), drug transporters (e.g. P-
glycoprotein) and drug metabolising enzymes (e.g. CYP3A4) (Breslin and O’Driscoll, 
2016; Edmondson et al., 2014) that appear to be increased in 3D compared to 2D cell 
culture.  
 
The aim of the work conducted in this chapter was to determine the cytotoxic effects 
of seven topical corticosteroids representing different levels of potency on both 
monolayer culture of immortalised oral keratinocyte (FNB6), primary NOF and TEOM. 
The specific objectives of this study were as follows: 
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• To determine the cytotoxic effect of seven corticosteroids with increasing 
concentrations against FNB6 and NOF cells after 72 hours of incubation using 
an MTT assay and rank the potency of these corticosteroids based on the IC50 
values. 
• To choose three corticosteroids for further investigation representing high, 
medium and low potency and further analyse the cytotoxic effect of these 
compounds at increasing concentrations against FNB6 and primary NOF cells 
after 24 and 48 hours of incubation period using MTT assay. 
• To evaluate the cytotoxic effect of the three selected corticosteroids at 
increasing concentrations against TEOM using an MTT assay based on the 
OECD Test Guideline 431. 
• To optimise the permeation of corticosteroids against TEOM after one-hour 





























































Preparation of corticosteroid (solution) 
• Clobetasol -17-propionate (CP) 
• Betamethasone-17, 21-dipropionate 
(BD) 
• Budesonide (BU) 
• Betamethasone-17-valerate (BV) 
• Triamcinolone acetonide (TA) 
• Hydrocortisone-17-butyrate (HB) 
• Hydrocortisone-17-valerate (HV) 
(See section 2.2.7.1) 
MTT assay on monolayer cultures: 
Oral keratinocyte (FNB6) and oral 
fibroblast (NOF) cells (72 H) 
(See section 2.2.7.1) 
Three selected corticosteroids 
based on IC50 ranking: 
• Clobetasol-17-propionate (CP) 
(High potent) 
• Betamethasone-17-valerate 
(BV) (Medium potent) 
• Hydrocortisone-17-valerate 
(HV) (lowest potent) 
 
(See section 2.2.7.1) 
MTT assay on monolayer cultures: 
Oral keratinocyte (FNB6) and oral 
fibroblast (NOF) cells (24 and 48 H) 
(See section 2.2.7.1) 
MTT assay on TEOM:  
Based on OECD Test Guideline 431 
 (See section 2.2.7.2) 
Permeation study (Preliminary):  
Exposure of TEOM against CP, BV 





4.3.1 Corticosteroids cytotoxicity against oral keratinocytes and fibroblasts is 
dose-dependent 
The cytotoxic potency of seven topical corticosteroids often used to treat OLP and 
representing different levels of potency were tested against immortalised FNB6 and 
primary human NOF cells using an MTT assay. IC50 values, defined as the corticosteroid 
concentration that was cytotoxic to 50% of the cells were obtained from dose-
response curves. FNB6 cells exposed to all seven corticosteroids for 72 hours showed 
concentration-dependent cytotoxicity profiles, presenting typically as sigmoid-shaped 
curves (Figure 4.1), allowing IC50 values to be calculated. Some of the curves, in 
particular for BD, displayed viability levels above 100% for cells treated with the drug 
at low concentrations, although the increases in cell viability at these concentrations 
were not statistically significant compared to untreated controls (Figure 4.1). 
According to Lopez-Garcia et al., (2014) cell viability above 80%, within 80-60%, 60 – 
40% or below 40% are considered as either non-cytotoxic, weak, moderate or having 
strong cytotoxicity, respectively. From the findings, the range of concentrations for 
each corticosteroid that showed strong cytotoxicity against FNB6 cells are as follows: 
50-500 µM (CP), 100-500 µM (BD and BU), 250-500 µM (BV and HB), and 500 µM (TA 
and HV) (Figure 4.1). The IC50 values for each corticosteroid against FNB6 cells are 
provided in Table 4.1. The most potent corticosteroid with the greatest toxicity was 
CP with an IC50 of 32.1 ± 0.9 µM whereas the least potent in terms of toxicity to FNB6 
cells was HB with an IC50 of 340.9 ± 20.3 µM. The ranking of corticosteroid cytotoxic 
potency against FNB6 keratinocytes was: CP > BU > BD > BV > TA > HV > HB. 
 
Similar concentration-response profiles were observed when the corticosteroids were 
tested against NOF cells for cytotoxicity and once again cytotoxicity profiles presented 
typically as sigmoid-shaped curves (Figure 4.2). The IC50 values for each corticosteroid 
against NOF cells are provided in Table 4.1. Similar to FNB6 cells, the most potent in 
terms of cytotoxicity was CP with an IC50 of 40.3 ± 2.1 µM, whereas, in contrast to 
FNB6 cells, the least cytotoxic corticosteroid for NOF cells was HV with an IC50 of 314.3 
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± 52.1 µM. The ranking of corticosteroid cytotoxic potency against NOF was: CP > BD 
> BV > BU > TA > HB > HV. 
 
The potency of CP, BD, BU, TA, BV and HV were greater (i.e. caused more cytotoxicity) 
for FNB6 cells than for NOF cells, suggesting that keratinocytes are more affected by 
these corticosteroids than fibroblasts in a like-for-like comparison. HB was more toxic 
toward NOF cells than FNB6 cells, although cytotoxicity levels were low for both cell 




















































Figure 4.1: The IC50 values for human normal keratinocytes (FNB6) cells treated with 
increasing concentrations of corticosteroids: (A) clobetasol-17-propionate (CP), (B) 
betamethasone-17, 21-dipropionate (BD), (C) budesonide (BU), (D) betamethasone-
17-valerate (BV), (E) triamcinolone acetonide (TA), (F) hydrocortisone-17-valerate 
(HV) and (G) hydrocortisone-17-butyrate (HB) from 0.01 to 500 μM for 72 hours. Cell 
viability was measured by MTT assay. Each value represents the mean ± SD of three 
independent experiments with each experiment performed in triplicate. *p < 0.05 
indicative of significant differences as compared to control analysed using One-way 
ANOVA with Tukey post-hoc multiple comparison tests. 
* 
* 













































Figure 4.2: The IC50 values for primary human normal oral fibroblast (NOF) cells treated 
with increasing concentrations of corticosteroids: (A) clobetasol-17-propionate (CP), 
(B) betamethasone-17,21-dipropionate (BD), (C) budesonide (BU), (D) 
betamethasone-17-valerate (BV), (E) triamcinolone acetonide (TA), (F) 
hydrocortisone-17-valerate (HV) and (G) hydrocortisone-17-butyrate (HB) from 0.01 
to 500 μM for 72 hours. Cell viability was measured by MTT assay. Each value 
represents the mean ± SD of three independent experiments with each experiment 
performed in triplicate. *p < 0.05 indicative of significant differences as compared to 






















Table 4.1: The IC50 values for FNB6 and NOF cells treated with different corticosteroids for 72 hours reveals different levels of potency. 
Each value represents the mean ± SD of three replicates. A mean difference was considered significant when *p < 0.05, **p < 0.001 and 
***p < 0.0001 as compared to clobetasol 17-propionate (known as the most potent corticosteroids) using One-way ANOVA with Tukey 
post-hoc multiple comparison tests. 
  IC50 value (µM)  
(Mean ± SD) 
                                                                                  Cell type 
Drugs 
Oral keratinocyte (FNB6) cells Oral fibroblast (NOF) cells 
Clobetasol-17-propionate  32.2 ± 0.9  40.3 ± 2.1  
Budesonide 46.4 ± 5.2 150.9 ± 17.7* 
Betamethasone-17,21-dipropionate 59.2 ± 5.9 74.8 ± 1.71 
Betamethasone-17-valerate 92.8 ± 17.3 103.7 ± 7.2 
Triamcinolone acetonide 194.8 ± 41.6***  259.5 ± 24.3*** 
Hydrocortisone-17-valerate  261.3 ± 28.9*** 314.3 ± 52.1*** 





4.3.2 The cytotoxic potency of corticosteroids is more pronounced in a 
concentration rather than time-dependent manner 
Based on the initial screening experiments of seven corticosteroids for 72 hours, three 
corticosteroids identified as having strong (CP), moderate (BV) or mild (HV) potency 
were selected to take forward for further experiments. FNB6 keratinocytes or NOF 
were cultured with each of these three corticosteroids for 24, 48 and 72 hours at 
increasing concentrations to determine if the cytotoxic response was time-dependent.  
 
Similar to data obtained for 72 hours, the exposure of CP, BV and HV against FNB6 
cells caused a concentration-dependent reduction in cell viability at all time-points 
tested (Figure 4.3A-C). The results displayed in figure 4.3 show that for CP, BV and HV 
the IC50 tended to be greater at 24 hours compared to values at 48 hours, suggesting 
that these drugs are less toxic at shorter incubations, although this was not statistically 
significant. For CP and BV, the IC50 values at 48 hours were very similar to 72 h (≈ 31 
µM (CP), ≈ 93 µM (BV)), suggesting equal FNB6 cells cytotoxicity between these two 
time-points, whereas cytotoxicity appears lower after 72 hours (≈ 261 µM) for HV than 
at 48 hours, although again these values were not statistically significant (Figure 4.3).  
 
A similar trend was also observed for the time-dependent cytotoxicity effects of these 
three compounds (CP, BV, HV) against NOF cells (Figure 4.4A-C). Once again there was 
a concentration-dependent cytotoxic effect on NOF cells at all time-points tested. NOF 
cells also displayed IC50 values less than those observed for FNB6 cells for CP and BV 
but not for HV, at all time-points examined, once again suggesting that FNB6 cells are 
more sensitive to the effects of the more potent corticosteroids than NOF cells. For 
CP, the IC50 value at 24 (113.4 µM) hours was much higher than for both 48 and 72 
hours (52.7 µM (48 h) and 40.3 µM (72 h)) suggesting that this corticosteroid has a 
time-dependent effect on NOF cells cytotoxicity, whereas this trend was not observed 













































Figure 4.3: The IC50 values for human normal keratinocytes (FNB6) cells treated with 
increasing concentrations of (A) clobetasol-17-propionate, (B) betamethasone-17-
valerate and (C) hydrocortisone-17-valerate (0.01 to 500 μM) against FNB6 cells for 
24, 48 and 72 hours. Cell viability was detected using an MTT assay. Data were 
expressed as the mean ±  SD for 3 independent experiments performed in triplicate. 
There was no significant difference between different incubation time for each 





24 h = 43.9 ± 4.9 
48 h = 31 ± 7.3 




24 h =  98.7 ± 4.7 
48 h = 93.9 ± 9.1 
72 h = 92.8 ± 17.3 
IC50value 
 
24 h = 235.7 ± 20.6 
48 h = 215.1 ± 23.1 












































Figure 4.4: The IC50 values for primary human normal oral fibroblast (NOF) cells treated 
with increasing concentration of (A) clobetasol-17-propionate, (B) betamethasone -
17-valerate and (C) hydrocortisone -17-valerate (0.01 to 500 μM) against NOF cells for 
24, 48 and 72 hours. Cell viability was detected using an MTT assay. Data were 
expressed as the mean ± SD for 3 independent experiments performed in triplicate. 
There was no significant difference between different incubation time for each 




















24 h = 113.4 ± 64.6 
48 h = 52.7 ± 5.7 
72 h = 40.3 ± 2.1 
IC50 value 
24 h = 119.5 ± 15.7 
48 h = 114.1 ± 4.6 
72 h = 103.7 ± 7.2 
IC50 value 
24 h = 259.7 ± 16.6 
48 h = 276.3 ± 16.6 




4.3.3 Effect of corticosteroids on TEOM viability 
CP, BV and HV, each representing strong, medium and low potency corticosteroids 
respectively were used to test the cytotoxic effects of these drugs on TEOM (that are 
composed of both FNB6 and NOF cells). In these experiments, corticosteroids were 
added topically to the surface of the TEOM, incubated for 1 hour, removed, incubated 
further for 42 hours and then the viability of the tissue measured using an MTT assay 
based on the OECD Test Guideline 431 protocol that is used as an industrial standard 
to identify potentially irritant compounds using tissue-engineered skin. Figure 4.5A-C 
shows the concentration-dependent effect of these three corticosteroids on TEOM. In 
these experiments, 5% SDS was used as a positive control as this compound is known 
to destroy the tissue, causing complete loss of cell viability, whereas untreated TEOM 
served as negative controls displaying 100% viability. Exposure of TEOM to CP caused 
a concentration-dependent loss of tissue viability with gradual reduction. The viability 
of TEOM at 5, 50, 100, 200 and 400 µM CP were 78.7 ± 0.08% (p < 0.05), 75.8 ± 2.38% 
(p < 0.001), 69.8 ± 4.05% (p < 0.0001), 65.3 ± 6.25% (p < 0.0001) and 52.5 ± 8.44% (p 
< 0.0001), respectively as compared to control.   
 
Likewise, exposure of TEOM to BV had a similar pattern of viability reduction where 
the viability of TEOM decreased gradually as the concentration of BV was increased. 
The reduction of TEOM viability at 5 µM (87.4 ± 7.01%) and 50 µM (87 ± 6.42%) was 
not significant as compared to controls. The viability of TEOM at 100, 200 and 400 µM 
was significantly decreased further to 82.7 ± 8.11% (p < 0.05), 71.2 ± 6.55% (p < 0.001) 
and 68.4 ± 3.22% (p < 0.0001), respectively as compared to controls.  
 
In contrast, TEOM cultured with 5-50 µM HV had little effect on viability and ≈99% 
viability values were close to untreated controls. However, as the concentration of HV 
was increased the viability of TEOM decreased. Incubating TEOM with 100, 200 and 
400 µM decreased TEOM viability by 71.9 ± 7.21%, 65.9 ± 7.08% and 71.8 ± 7.62% 
respectively, all significantly decreased from untreated controls (p < 0.05). Exposure 
of TEOM to 5% SDS (positive control) lead to a dramatic and significant reduction (p < 








































Figure 4.5: The cytotoxic potency of different corticosteroids on TEOM. TEOM were 
incubated with increasing concentrations (5 to 400 µM) with (A) clobetasol-17-
propionate, (B) betamethasone-17-valerate and (C) hydrocortisone-17-valerate. 
TEOM viability was measured using an MTT assay. Data were expressed as the mean 
± SD for 3 independent experiments performed in triplicate. A mean difference was 
considered significant when *p < 0.05, **p < 0.001 and ***p < 0.0001 as compared to 




















It must be noted that none of the corticosteroids tested reduced the viability of the 
TEOM to less than 50%, even at the highest concentrations tested. This is particularly 
important because the OECD guidelines for irritancy and corrosive testing on tissue-
engineered skin state that compounds that reduce tissue viability by more than 50% 
can be considered as an irritant, whereas compounds that reduce tissue viability by 
less than 50% can be considered as non-irritant and therefore safe. Using these 
definitions, the data provided here show that at the concentrations tests all the 
corticosteroids would be deemed safe by OECD guidelines.  
 
Figure 4.6 shows a comparison of cytotoxic potency between three corticosteroids 
(CP, BV and HV).  At low corticosteroid concentrations (5 µM), there was a significant 
reduction in TEOM viability between CP and HV, with CP being most potent (p < 0.05), 
although viability levels were not different for CP and BV at this concentration. At 50 
µM there was a significant difference (p < 0.05) in TEOM viability between at three 
corticosteroids with CP having the greatest effect on TEOM viability (75.8 ± 2.4%), 
followed by BV (87 ± 6.4%) then HV (98.9 ± 2.4%). This is agreement with data on 
monolayers showing that the potency of CP > BV > HV is also the same for TEOM. 
TEOM incubated with concentrations of 100-400 µM displayed similar potency levels 
for all corticosteroids tested. 
 
Interestingly, the viability of TEOM was above 50% at all concentrations tested for all 
corticosteroids and therefore IC50 values (the value at which 50% tissue viability would 
be observed) could not be determined accurately.  These data infer that the IC50 values 
for TEOM is greater than 400 µM for corticosteroids tested. This is a huge difference 
to the same corticosteroids when cells were treated as monolayers (Table 4.2) and 
suggests that monolayer cultures are more sensitive to the actions of drugs than 








Table 4.2: The summary of the IC50 values of FNB6 monolayer, NOF monolayer and 
TEOM for clobetasol-17-propionate, betamethasone-17-valerate and hydrocortisone-
17- valerate. 
 









43.9 ± 4.9 (24 h) 
31 ± 7.3 (48 h) 
32.2 ± 0.9 (72 h) 
113.4 ± 64.6 (24 h) 
52.7 ± 5.7 (48 h) 
40.3 ± 2.1 (72 h) 
˃ 400 µM 
Betamethasone-17-
valerate 
98.7 ± 4.7 (24 h) 
93.9 ± 9.1 (48 h) 
92.9 ± 17.3 (72 h) 
119.5 ± 15.7 (24 h) 
114.1 ± 4.6 (48 h) 
103.7 ± 7.2 (72 h) 
˃ 400 µM 
Hydrocortisone-17- 
valerate 
235.7 ± 20.6 (24 h) 
215.1 ± 23.1 (48 h) 
261.3 ± 28.9 (72 h) 
259.7 ± 16.6 (24 h) 
276.3 ± 16.6 (48 h) 
314.3 ± 52.1 (72 h) 
















Figure 4.6: Comparison of the cytotoxic potency between clobetasol-17-propionate, betamethasone-17-valerate and hydrocortisone-17- 
valerate at increasing concentrations (5 to 400 µM) against TEOM.  Data were expressed as the mean ± SD for 3 independent experiments 
performed in triplicate. A mean difference was considered significant when *p < 0.05, **p < 0.001 and ***p < 0.0001 using One-way 








4.3.4 Different corticosteroids with varying levels of potency showed a different 
pattern of permeation into TEOM 
A comparison of tissue permeation of the three different corticosteroids (CP, BV and 
HV) at 5 µM, each having different levels of potency was performed after one-hour 
exposure. The levels of corticosteroids in the TEOM tissue and in the medium bathing 
the basolateral compartment (and therefore had traversed the tissue) were measured 
by HPLC. Data presented in figure 4.7 show that CP was highest in the TEOM tissue at 
approximately 2.59 ± 0.25 nM/mg and this was significantly greater (p < 0.0001) than 
the levels for both BV (0.299 ± 0.05 nM/mg) and HV (0.297 ± 0.03 nM/mg; Figure 4.7A). 
In contrast, the amount of CP accumulating in the basolateral compartment of the 
tissue culture system was significantly lower (111 ± 11.63 nM) compared to HV (215.3 
± 36.6 nM) (p < 0.001) but comparable to BV (85 ± 18.59 nM; Figure 4.7B). These data 
indicate that after one-hour CP is mainly retained in the tissue with little drug entering 
the medium, whilst HV rapidly crosses the tissue and is found at higher concentrations 
in the medium. This difference in tissue penetration is likely to reflect the different 
physiochemical properties of the different corticosteroids, such as the addition of 




































Figure 4.7: Different permeation pattern of CP, BV and HV in (A) the tissue and in (B) 
the basolateral compartment after 1 hour. Data are expressed as the mean ± SD for 3 
independent experiments performed in triplicate. A mean difference was considered 
significant when *p < 0.05, **p < 0.001 and ***p < 0.0001 using One-way ANOVA with 


















In this chapter, the cytotoxic potency of corticosteroids was assessed against oral 
keratinocytes and fibroblasts cultured as monolayers and as 3D TEOM. Oral 
keratinocytes and fibroblasts were utilised, as these cells are the major constituent 
cells that make up the oral mucosa and are therefore clinically relevant. FNB6 cells are 
immortalised keratinocytes (McGregor et al., 2002) and are suitable substitutes for 
primary oral keratinocytes because these cells can be easily grown and passaged 
indefinitely and, as shown in the previous chapter, generate a stratified squamous 
epithelium that is histologically similar to native oral epithelium when cultured in 
tissue models.  
 
In monolayer culture, the effects of seven corticosteroids were examined against 
FNB6 and NOF using the MTT assay; a method that is commonly employed for the 
determination of cell cytotoxicity or viability following exposure to toxic substances 
(Sathisha et al., 2008; Ulukaya et al., 2008). All corticosteroids tested reduced viability 
of both cell types in a concentration-dependent manner. The level of potency was 
similar for both cell types, which was generally CP > BD > BV > BU > TA > HB > HV. This 
level of potency is in agreement with evaluation of these drugs in a clinical setting. For 
example, CP is known to be one of the most potent topically applied corticosteroids 
clinically available. Betamethasone is often classified as having moderate-to-potent 
potency, whilst hydrocortisone has mild-to-moderate potency (National Eczema 
Society, 2016). This shows that the data generated for monolayers, as far as 
cytotoxicity is concerned, is clinically representative. The data presented here do not 
measure the immunological action of these corticosteroids, which may be different in 
potency.  
 
This study also revealed that some corticosteroids, when used at lower 
concentrations, caused an apparent increase in cell viability, while at higher 
concentrations they exhibited cytotoxicity and loss of cell viability. These findings are 
in agreement with previous work performed by Alexandre and co-workers (Alexandre 
et al., 2015). The apparent increased cell viability at lower concentrations is associated 
with increased cell metabolism as a cell stress response toward the toxic compound. 
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Addition of a foreign chemical to cells often stimulates these cells to increase 
membrane pumps in order to transport these chemicals out of the cells thereby 
promoting cell survival (Fulda et al., 2010). This process requires additional ATP that 
is supplied by increased cell metabolism. This increase in mitochondrial metabolic 
output also reduces MTT into a colour product; therefore, increases in MTT may be 
due to increased metabolism due to a toxic response rather than alterations in cell 
number. At higher compound concentrations the toxic effects of the chemical affect 
the cells quicker than the cells response and so a decrease in viability is observed. 
Although not performed, a trypan blue exclusion assay could have been undertaken 
to show that the effects of the corticosteroids were due to toxicity and not on 
metabolism or cell proliferation.  
 
Previously, the potency of corticosteroids was classified based on the vasoconstrictor 
assay as the gold standard, which uses skin pallor as a measure of drug potency 
(McKenzie and Stoughton, 1962). In addition, the potency of a compound could also 
be determined either using a single-dose technique or dose-response curve (Van 
Rossum, 1962). Alexandre et al., 2015 determined the potency of corticosteroids 
against keratinocyte cells based on a single concentration (used the highest 
concentration) (Alexandre et al., 2015). On contrary, in this study, the potency of CS 
in monolayer cultures was determined using IC50 value as an indicator of toxicity 
obtained from dose-response curve, which is therefore more scientifically determined 
and so informative.   
 
The potency of corticosteroids has also been characterised by their formulation. 
(Wiedersberg et al., 2008; Ference and Last, 2009) based on WHO classification. In this 
classification, corticosteroids have been categorised into seven potency classes 
ranging from super-potent (class I) to least potent (class VII) (Habif, 1990). The same 
drug can also be classified in different potency classes depending on the formulation 
of the drug (World Health Organisation, 2018). In contrast, the British National 
Formulary (BNF) recommended only four classes ranging from mild to potent and here 
the drugs are classified regardless of the formulation used (British National Formulary, 
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2016). Our findings showed that most of the corticosteroids that were ranked based 
on their toxic potencies in vitro are similar with aforementioned classification.  
 
The monolayer result revealed that CP was the most cytotoxic and potent compound 
where it showed strong cytotoxicity (<40% of cell viability) at low concentrations and 
also exhibited the lowest IC50 value against both cell types as compared to other 
corticosteroids. In contrast, Alexandre and co-workers reported that BD was the most 
potent corticosteroid when incubated with human immortalized non-tumorigenic skin 
keratinocytes (HaCaT). This discrepancy may be due to the different method applied 
in assessing the cytotoxicity of corticosteroids. Here, Alexandre et al., determined 
potency using the percent viability of cells when using corticosteroids at a single 
highest concentration only (Alexandre et al., 2015). In contrast, this study used a dose-
response to generate IC50 values as an indicator of cytotoxic and potency to rank the 
corticosteroids. Similar to our data Alexandre et al., showed that HB and HV were 
among the least potent corticosteroids as evidenced by high IC50 values as compared 
to other compounds (Alexandre et al., 2015).  
 
CP, BV and HV that represent different classes of potency were selected for further 
evaluation against both cell types and TEOM. In monolayer cultures, exposure of these 
compounds at increasing times against both keratinocytes and NOF had no substantial 
effects indicating that the action of the corticosteroids appeared not to be time-
dependent. These data suggest that higher concentrations of corticosteroids induce 
rapid cytotoxicity, whereas cells can tolerate lower levels and indicate that drug 
concentration rather than incubation time is more important. The cytotoxic potency 
of CP, BV and HV was also assessed against TEOM in a concentration-dependent 
manner. CP was the most potent compound as compared to BV and HV, which is in 
line with the monolayer culture results. Previously, it has been demonstrated that the 
IC50 values of compounds tested on 3D models are higher than for monolayer cultures 
(Moharamzadeh et al., 2015, Sun et al., 2006). Although IC50 values of corticosteroids 
against TEOM were higher than in monolayer cultures, a direct comparison of drugs 
efficacy between monolayer culture and TEOM cannot be drawn as both systems were 
exposed at different concentrations and incubation times.  As far as known, this is the 
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first study to measure the cytotoxicity of corticosteroids on TEOM. Our findings 
determined CP as a non-irritant corticosteroid based on a TEOM viability of >50% and 
in accordance with the OECD guidelines.  
 
A comparative permeation analysis was conducted between corticosteroids 
representing different levels of potency to investigate any differences in their 
penetration capability. Interestingly, a differential permeation pattern was found 
between CP, BV and HC, suggesting that the physicochemical properties of these 
molecules such as the molecular weight and lipophilicity characteristics influence 
tissue absorption (Sudhakar et al., 2006). Generally, drugs with molecular weight less 
than 500 Da are easily transported through tissue (Uva et al., 2012; Bos and Meinardi, 
2000) and all the molecular weight of the tested compounds are below 500 Da. 
Esterification and addition of components such as valerate or propionate enhances 
the lipophilicity of the corticosteroid proportionally, increasing their tissue absorption 
(Kwatra and Mukhopadhyay, 2018; Gual et al., 2015; Kansky et al., 2000; Thorburn 
and Ferguson, 1994; Ponec et al., 1986). Indeed, CP exhibited higher tissue 
penetration than BV, which was also greater than HV. Moreover, chemical 
modification also enables molecules to be held for longer within the mucosal tissue, 
providing a reason as to why HV passed through the TEOM into the receptive medium 
quicker than both CP and BV.  
 
4.5 Summary 
Data presented in this chapter demonstrates that the ranking of cytotoxic potencies 
based on the IC50 exhibited very similar ranking to the potency levels based on the 
vasoconstrictor assay that is still used in clinical practice as the gold standard in 
potency assessment. In addition, potency levels found in the monolayer and TEOM 
experiments were in line with potency ranks described by WHO and BNF for the 
corticosteroids tested.  Importantly, we found that cytotoxicity levels were much 
higher for keratinocyte and fibroblast monolayers than observed for TEOM and this is 
in line with clinical data. TEOM showed good sensitivity in dose-dependent toxicity 
models, displaying decreased viability with increasing corticosteroid concentration. 
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Preliminary study of corticosteroids permeation showed that CP displayed higher 
tissue penetration and retention through the TEOM. Taken together, these data 
provide good evidence that TEOM are the most suitable in vitro experimental model 
to perform drug toxicity and drug activity studies, and therefore will be taken forward 






























  CHAPTER 5 
 
ORAL PATCH CHARACTERISATION AND CYTOTOXICITY 
 
5.1 Introduction 
A drug formulation should have the capability in delivering an active compound to the 
affected site at a therapeutically relevant dose without discomfort and adverse effects 
(Zhang and Smith, 2010). Formulation strategies for oral mucosal delivery have gained 
considerable attention because this site offers advantages including sustained release, 
targeted drug delivery and prolonged contact time with enhanced drug absorption 
(Mojtahedi et al., 2017; Paderni et al., 2012). These features of mucoadhesive drug 
delivery would be beneficial for oral mucosal diseases such as OLP and RAS. Studies 
have shown that high-potency topical corticosteroids are a good treatment for these 
lesions. For example, patients presenting with OLP showed a 95% improvement 
following 2 months of therapy with CP (Conrotto et al., 2006) and patients with RAS 
showed complete remission with no major adverse effects after treatment with this 
corticosteroid (Lozada-Nur et al., 1991).  
 
Currently, CP has been formulated as topical preparations such as ointment or 
emollient cream that have minimal oral bioavailability and low aqueous solubility 
(Varoni et al., 2012). These preparations have been designed for application to the 
skin and not the oral mucosa, so these dosage forms in addition to mouthwashes that 
are administered topically to the oral cavity generally have unpredictable absorption 
and distribution due to saliva flow and mechanical factors within the oral cavity (Reddy 
et al., 2011). CP has also been formulated in nanoencapsulation formulations including 
lecithin/chitosan nanoparticles (Senyigit et al., 2010), polymer-coated lipid 
nanocapsules (Fontana et al., 2011), liposomes (Rao and Murthy, 2005), lipid 
nanoparticles (Hu et al., 2006) and nanostructured lipid carriers (Silva et al., 2012) with 
the intention to improve the safety of the corticosteroids by increasing the 
accumulation of the drug in the skin while lowering the permeation of the drug to 
reduce systemic side effects (Silva et al., 2012; Senyigit et al., 2010). Recently, oral 
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patches as a mucoadhesive device have been developed using electrospinning 
technology (Santocildes-Romero et al., 2017). These patches comprise of an outer 
hydrophobic backing layer and a highly mucoadhesive inner layer, with each layer 
being manufactured from FDA-approved polymer formulations. These patches may 
dramatically improve oral mucosal drug delivery by prolonging the residence time 
between the drug and the mucosal lesion providing localised controlled drug delivery. 
 
The purpose of the experiments performed in this chapter was to characterise oral 
patches loaded with CP. The specific objectives of this study were as follows: 
• To examine the physicochemical characteristics (weight, thickness and pH) of 
the oral patches. 
• To evaluate the swelling capability of placebo and CP-loaded patches 
• To assess the surface morphology of placebo and CP-loaded patches using 
SEM. 
• To determine the cytotoxicity effects of placebo and CP-loaded patches using 
TEOM generated in chapter 3 following the OECD guidelines. 
• To investigate the morphology of the TEOM following treatment with placebo 















































Histological examination of 
TEOM 
Patch characterisation: 
Weight          Thickness       pH         Swelling        SEM 
Drug release 
See section 2.2.3.1 
Patch formulations: 
A kind gift from Dermtreat A/S, Denmark 
See section 2.2.8 
See section 2.2.8.1 




5.3.1 Physicochemical characterisation 
The physicochemical characteristics of mucoadhesive oral patches were assessed 
using 3 different batches made on different days. Dermtreat A/S provided both 
placebo and CP-loaded oral mucosal patches. The amount of CP within each of the 
patches (1, 5 or 20 µg per patch, respectively) was calculated by Dermtreat A/S using 
HPLC analysis prior to shipment.  The average weight of the placebo patch was 55.3 ± 
5.18 mg, while CP-loaded patches had an average weight of 67.4 ± 5.1 mg, 59 ± 3.72 
mg and 53.3 ± 3.3 mg for 1 µg, 5 µg and 20 µg patches, respectively (Figure 5.1A). The 
weight of the patches between samples and batches was not significantly different.  
The average thickness of the placebo patch was 0.43 ± 0.03 mm, while the average 
thickness of CP-loaded patches was 0.51 ± 0.05 mm, 0.36 ± 0.02 mm and 0.45 ± 0.03 
mm for the 1 µg, 5 µg and 20 µg patch, respectively (Figure 5.1B). In addition, the pH 
values between the different types of patches, either placebo or loaded with CP, were 











































Figure 5.1: Mucoadhesive placebo and CP-loaded (1, 5 and 20 µg) patches are 
characterised from three different batches for (A) weight (B) thickness and (C) pH. 
Data were expressed as the mean ± SD for 3 independent experiments performed in 
triplicate. There was no significant difference for (A) weight (B) thickness and (C) pH 
between each type of patch, analysed using One-way ANOVA with Tukey post-hoc 






5.3.2 Swelling profile of patches 
The speed of hydration for polymer-based patches is crucial for their adhesiveness; 
therefore, patch swelling was examined over time. The degree of swelling for placebo 
patches was fast with patches taking on 50% of their weight within 3 minutes. This 
was followed by a steady swelling rate where patches increased in weight by 65% after 
60 minutes. The degree of swelling for the CP-loaded patches was slightly slower, 
although not significantly, as compared to the placebo patches. The 1 µg CP patches 
increased 50% of its weight within 24 minutes, while both the 5 and 20 µg CP patches 
took 14 minutes to increase to this weight. Overall, both placebo and CP-loaded 
patches increased in weight by approximately 70% of their own weight within 60 
















Figure 5.2: Swelling pattern profile of placebo and CP-loaded patches. Data were 

















5.3.3 Surface morphological analysis of oral patches 
 SEM analysis of the oral patches showed that the PCL backing layer exhibited a 
smooth surface for both placebo and CP-loaded patches (Figure 5.3A). SEM images of 
the electrospun mucoadhesive layer showed that the inner surface of the patches 
displayed nanofibers that were homogeneous in number, alignment and diameter 
regardless of whether they were loaded with CP or placebo (Figure 5.3B). SEM cross 
sectional analysis also revealed that the PCL backing layer was adhered tightly to the 













































Figure 5.3: Representative surface images of placebo and CP-loaded patches analysed 
using a scanning electron microscopy (SEM). Images revealed (A) a smooth PCL 
impermeable backing layer, (B) a homogenous bioadhesive layer of the patch 
containing nanofibers and (C) a cross section of patch showing tight adherent between 
the impermeable backing layer and bioadhesive layer. Scale bar = 20 µm. 
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5.3.4 Drug release profile of CP-loaded patches 
Next, the ability of the electrospun oral patches to release CP over time into a receiver 
liquid was examined by HPLC analysis. There was no significant difference in the drug 
release profiles for patches loaded with 1, 5 and 20 µg of CP over time. After 6 hours, 
it was observed that all patches loaded with a different dose of CP had released the 
drug slowly in a sustained manner with approximately 20%, 50% and 80% of CP 












Figure 5.4: Sustained release profile of patches loaded with increasing doses of 
clobetasol 17-propionate (1, 5 and 20 µg) over a 6-hour period. Data are expressed as 














5.3.5 Cytotoxicity profile following treatment with patches against TEOM 
To ensure that the oral patches are not toxic to oral mucosa, a MTT cytotoxicity assay 
was performed for the placebo patch against TEOM following OECD guidelines. MTT 
analysis showed that the viability of TEOM following one-hour exposure to the 
placebo patch (90 ± 2.3%) was similar to the medium alone control (100%) suggesting 
that the polymers used to make the patches are non-toxic to the oral mucosal tissue 
(Figure 5.5A). In contrast, treatment with 5% SDS, used as a positive control, caused a 
significant reduction in cell viability (2.3 ± 1.0 %, p < 0.0001; Figure 5.5A). There was a 
non-significant reduction in viability of TEOM following treatment with CP-loaded 
patches to 76.8 ± 10.3%, 71.2 ± 18.4% and 74.6 ± 24.4% for the 1, 5 and 20 µg patches, 
respectively (Figure 5.5B). According to the OECD irritancy assay guidelines, the 
placebo and CP-loaded patches can be considered as non-irritant as the viability of 
















































Figure 5.5: Cytotoxicity assay of placebo and CP-loaded patches against TEOM using 
an MTT assay. (A) placebo patches do not cause cytotoxicity compared to control 
(media only); SDS treatment was used as positive control. (B) CP-loaded patches 
showed a small reduction of viability as compared to placebo patches but were not 
considered cytotoxic/irritant as the percentage is above 50% according to OECD 
guideline. Data were expressed as mean ± SD for 3 independent experiments 
performed in triplicate. A mean difference was considered significant when *p < 0.05, 
















5.3.6 Morphological examination following treatment with patches against TEOM 
Data from the MTT cytotoxicity assay was supported by histological examination of 
the TEOM in the absence or presence of the oral patch. The morphology of TEOM that 
had placebo or CP-patch treatment was less well defined than the TOEM treated with 
medium alone, with some slight changes evident in keratinocyte morphology and loss 
of the superficial layers making the epithelium thinner than controls. This may be 
because these uppermost layers have been lost upon removal of the patch before 
fixing and histological processing. There is no evidence of damage or loss of integrity 
of the epithelium following treatment with placebo compared to CP-loaded patches 
with all these models displaying a full thickness, stratified squamous epithelium 
(Figure 5.6). In contrast, treatment of TEOM with 5% SDS as a positive control caused 
complete decellularisation of the TEOM with mucosal models displaying a complete 
loss of nucleated cells, loss of epithelial attachment to the connective tissue and loss 
















































 Figure 5.6: Histological examination of TEOM following treatment with placebo or   
CP-loaded patches performed using H&E staining. (A) TEOM treated with medium 
alone control shows complete integrity and a full-stratified squamous epithelium 
whilst treatment with (B) 5% SDS caused complete loss of viability with 
decellularisation. Treatment with (C) placebo control patch or (D) 1 µg (E) 5 µg and (F) 
20 µg patches showed similar histology to medium only controls, suggesting no 













Corticosteroids applied topically are commonly used for the treatment of mucosal 
lesions (Mehdipour and Zenouz, 2012) and CP, as a potent topical corticosteroid, has 
been shown to effectively treat mucosal lesions including OLP and RAS (Bagan et al., 
2012; Belenguer-Guallar et al., 2014). Thus, CP was selected as the model 
corticosteroid to be formulated as an oral patch intended for localised, controlled drug 
delivery to the oral mucosa. In previous studies, CP has been formulated as 
nanosystems intended for drug delivery to the skin, including polymer-coated 
nanocapsules (Fontana et al., 2011), lipid nanoparticles (Kalariya et al., 2005) and 
lecithin/chitosan nanoparticles (Senyigit et al., 2010). This is the first study to use 
corticosteroid-loaded electrospun patches for oral drug delivery.  
 
The CP-loaded patches were formulated with 1-20 µg/patch doses based on the 
current dosing regimens of gels or creams used in the topical delivery for treatment 
of dermal inflammatory lesions. These topical preparations that contain 0.05% CP 
when applied as a fingertip unit to treat and area of 1.33 – 2.5 µg/cm2. In order to 
produce the same dosage, 3.1 cm2 patches were manufactured with 0.0004%, 0.002% 
or 0.008% CP to produce CP-loaded patches that contained total drug content of 1, 5 
and 20 µg/patch, respectively when analysed by HPLC. 
 
Current oral drug formulations have poor residence time resulting in inefficient drug 
delivery to target tissue. To address this Santocildes-Romero and colleagues (2017) 
have recently developed an innovative dual-layered electrospun mucoadhesive patch 
made from adhesive polymers in order to improve the adhesion of the patch to the 
biological surfaces whilst also controlling drug release. The use of electrospun 
nanofibres has the advantage of increased surface area and high porosity (Zafar et al., 
2016; Ramakrishna et al., 2006). The patches, recently developed by Dermtreat A/S in 
collaboration with researches at The School of Clinical Dentistry, are a complex 
mucoadhesive electrospun dual-layer system comprised of an impermeable backing 
layer made of thermally-treated PCL nanofibres and a bioadhesive layer made from 
Eudragit®RS100, PVP and PEO nanofibers (Santocildes-Romero et al., 2017). 
Differential thermal and X-ray diffraction analysis show that the CP within the 
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electrospun patches is in an amorphous rather than crystalline state. The amorphous 
state possesses several advantages over a crystalline state including enhanced 
solubility, increased dissolution rate and enhancing drug delivery (Colley et al., 2018). 
 
The placebo or CP-loaded mucosal patches had no significant effects on any of the 
physicochemical properties studied including weight, thickness or pH. The patches 
exhibited a uniform and consistent weight and thickness. Furthermore, the pH of the 
placebo and CP-loaded patches was between 8 - 8.2 which is slightly alkali than the pH 
of saliva (5.6 – 7.9). However, the slight deviation was insufficient for the patches to 
cause irritation or cytotoxicity in a human volunteer study (Colley et al., 2018). The 
nanofibre structures of all types of patches analysed was homogenous with no 
apparent defects observed under scanning electron microscopy. 
 
Nanofibre swelling is an essential property for mucoadhesion as successful patch 
adhesion is dependent on the rapid hydration and gelation once the patch is applied 
to the moist mucosal surface (Smart, 2005). This study showed that all patches 
demonstrated extremely quick swelling that was maintained for up to 60 minutes, 
suggesting that the patches had a profile suitable for rapid and prolonged residence 
to mucosal surfaces. In a volunteer human study, Colley et al., (2018) observed that 
when the placebo patches were applied with gentle pressure, they adhered quickly to 
the gingival, buccal mucosa, and tongue epithelium that are common sites for OLP and 
RAS lesions. The residence time of the placebo patches was 118, 93 and 43 minutes 
for gingivae, buccal mucosa and tongue, respectively (Colley et al., 2018). From these 
data, it could be suggested that the adhesion strength is correlated to the level of 
epithelial keratinisation in a different region of the oral mucosa. In a previous study, 
oral patches made from thiolated-chitosan sulphate blended with polyvinyl alcohol 
(PVA) exhibited rapid swelling properties but only adhered to human buccal mucosa 
for approximately 5 minutes (Samprasit et al., 2015), suggesting that the polymer 
blend produced by electrospinning could increase the surface area, crucial for the 
adhesion to human mucosal surfaces. In other studies, in vivo adhesion analysis on 
adhesive films manufactured using various polymers and blends showed various 
residence times either at similar times or lower as compared to the Colley et al study 
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(Kumria et al., 2016; Yehia et al., 2009; Perioli et al., 2004). The presence of food whilst 
wearing the oral patch may reduce the adhesiveness of the patch, which must be 
taken into consideration in future studies or clinical trials.  
 
Drug release of CP from loaded patches was initially fast and then the drug was 
released in a sustained manner. Approximately 80% of the loaded CP was released 
from the patch within 360 minutes. Previously, it was reported that the release of the 
antihistamine diphenhydramine from PVA electrospun patches was rapid with almost 
86% of the drug released after 3 minutes (Dott et al., 2013). While a patch 
manufactured using PCL electrospun fibres containing dexamethasone exhibited 50% 
drug release after 20 minutes and 100% after 90 minutes. In contrast, dexamethasone 
manufactured within poly(L-lactic) acid fibres showed a much slower release profile 
with 100% release after 1 month (Vacanti et al., 2012). In another study, α-mangostin 
incorporated into thiolated chitosan (CS-SH) blended with polyvinyl alcohol (PVA) as 
the mucoadhesive polymers exhibited rapid burst release from the nanofibres 
regardless of the concentration. The release of the compound reached 80% within 60 
minutes and the release completed within 240 minutes (Samprasit et al., 2015). These 
data suggest that the polymer blend is crucial in determining the drug release profile 
from oral patches, with slight differences in polymer mix allowing rapid or sustained 
drug release. Moreover, the addition of Eudragit RS100 to electrospun nanofibres has 
been shown to prolong the release of drugs for up to several hours compared to 
nanofibres alone (Colley et al., 2018; Karthikeyan et al., 2012), indicating that the 
presence of this polymer in electrospun nanofibres can improve sustained release of 
the drug as compared to previous drug-loaded systems. 
 
TEOM was used to assess the potential irritancy and toxicity of unloaded or CP-loaded 
patches. Following the European Union directive on the use of animals for cosmetic 
testing, effectively banning their use; tissue engineered skin models have become the 
principle way of testing drug toxicity. There are now several OECD protocols for the 
standardised use of tissue engineered skin models for compound irritancy and toxicity 
testing. Several laboratories have extensively validated these tests, which include use 
of MTT as a cell viability marker, across Europe and the US. However, to date, there is 
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no official way to test drugs aimed at the oral mucosa. Since oral mucosal models are 
very similar to those of the skin it was decided to use the OECD skin irritancy test but 
instead using tissue engineered oral mucosa to test if CP-loaded oral patches were 
cytotoxic or irritant. Interestingly, using the exact methodology for skin irritancy 
testing, CP-loaded patches containing up to 20 µg of CP were found not to be irritant 
as defined by OECD guidelines, which state that a compound is not irritant/toxic if the 
viability of the tissue engineered model is maintained above 50% (OECD, 2015). These 
cytotoxicity data suggest that even at high doses CP-loaded patch do not damage the 
structure and integrity of the epithelium and so their use can be considered for the 
treatment or oral lesions.  
 
Skin atrophy is the most common adverse effect following treatment with topical 
glucocorticoids and relies on level of drug potency, duration of exposure, frequency 
of application and concentration of treatment (Schoepe et al., 2006; Rhen and 
Cidlowski: 2005). Irreversible adverse effect of glucocorticoid-induced skin atrophy is 
characterised by a fragile, thinned skin and diminished barrier function (Uva et al., 
2012; Schoepe et al., 2006). Histopathological analysis shows that exposure of mucosa 
with CP results in markedly thinner epithelium (Schoepe et al., 2006; Mills and Marks, 
1993), attributable to cellular atrophy where the size of keratinocytes is reduced 
(Kolbe et al., 2001; Delforno et al., 1978). Glucocorticoids also reduce the intercellular 
lipid in the upper epidermal layers by diminishing lipids synthesis such as ceramide, 
cholesterol and fatty acids (Kolbe et al., 2001; Sheu et al., 1997). As a consequence, 
these changes cause increased permeability and water loss (Kolbe et al., 2001), 
indicators of disruption of skin barrier function (Kao et al., 2003).  
 
In addition to their actions on epithelial cells, glucocorticoids can also reduce 
fibroblast numbers in the connective tissue (Schoepe et al., 2006; Kolbe et al., 2001; 
Saarni and Hopsu-Havu, 1978), resulting in dysregulated ECM turnover (e.g. collagen, 
proteoglycans and elastin) (Nuutinen et al., 2001; Cutroneo et al., 1981) leading to the 
decreased dermal thickness and disruption of the tensile strength and elasticity of the 
skin. Previously, glucocorticoid-induced skin atrophy had been assessed in animal 
models such as rats, mice, pigs and dogs where marked epidermal and dermal thinning 
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had been observed (Schoepe et al., 2006). Although the skin is different to the oral 
mucosa the tissues have many similarities, and so it is believed that the adverse 
actions of corticosteroids on the oral mucosa are similar to those observed for the skin 
(Mehdipour and Zenouz, 2012).  
 
Histological data for patch-treated TEOM appear to show slight differences in 
keratinocyte histology compared to medium alone controls but this may be due to 
loss of the uppermost-stratified epithelium during processing. There was no 
difference in the epithelial histology of placebo versus CP-loaded patches. The CP-
treated TEOM was examined over a relatively short period of time so any CP-induced 
changes in tissue morphology may not have yet occurred. Moreover, tissue integrity 
or permeability using TEER or dextran was not assessed. It would be interesting to 
examine the long-term effects of CP use on TEOM in terms of TEER, permeability, 
keratinocyte and fibroblast proliferation, epithelial thickness and so further detailed 
dose and time-dependent studies are warranted in this area.  
 
5.5 Summary  
In conclusion, the data presented in this chapter show that the corticosteroid, CP can 
be effectively incorporated into electrospun polymer fibres and made into a 
mucoadhesive patches that have consistent properties. Moreover, these patches can 
rapidly release the steroid, suggesting that they have properties favourable for oral 
mucosal patches to target oral lesions like OLP and RAS. However, data showing that 
the drug is released into the mucosal tissue and is able to exert its effects on target T 













EVALUATION OF THE PERMEATION AND 




OLP is an autoimmune disease that affects the stratified squamous epithelium where 
auto-cytotoxic T lymphocytes trigger apoptosis of epithelial cells leading to chronic 
inflammation and pathology (Schlosser, 2010; Scully and Carrozzo, 2008). The host 
inflammatory response is the primary defence mechanism triggered following injury 
or infection (Coutinho and Chapman, 2011) and as part of this response T cells are 
activated and recruited to the sites of inflammation (Rauch et al., 2009). The activated 
T cells are known to produce mediators such as IL-2, an important regulator of 
lymphocyte proliferation and differentiation into effector T cells, via activation of the 
transcription factors NFAT, NFκB and AP-1 (Bianchi et al., 2000). IL-2 is an important 
biomarker used as an indicator of several pathological conditions including multiple 
sclerosis, rheumatoid arthritis and systemic lupus erythematous (Sedighi et al., 2014).  
 
The anti-inflammatory and immunosuppressant effects of corticosteroids are 
remarkably efficient at managing the manifestations of inflammatory and 
autoimmune conditions (Coutinho and Chapman, 2011; Chatham and Kimberly, 
2001). Corticosteroids such as CP elicit both anti-inflammatory and 
immunosuppressant effects on many types of immune cells including T cells (Chatham 
and Kimberly, 2001). They act by binding to intracellular glucocorticoid receptors that 
then bind to regulatory sites on the DNA, altering gene transcription in favour of an 
anti-inflammatory response, such as increased expression of phospholipase A2 
inhibitory proteins that reduce the release of arachidonic acid as well as decreasing 




The work described in this chapter aim to develop an oral mucosal diseased model 
representing OLP in order to assess the absorption and immunosuppressant 
properties of CP both as a free solution or in patch-loaded form. The specific objectives 
of this study were as follows: 
• To assess the distribution and penetration capability of CP (solution form) 
using TEOM in both a time (10, 30 and 60 minutes) and concentration (5, 25 
and 50 µM) dependent manner using HPLC. 
• To assess the distribution and penetration capability of CP (patch form) in 
different doses 1 µg (1 hour), 5 µg (1 hour) and 20 µg (1, 4 and 24 hours) in 
TEOM using HPLC. 
• To evaluate the viability of a T cell line (Jurkat) in different growth media using 
a trypan blue exclusion assay.  
• To determine the optimal concentration of PMA and PHA as stimulants for 
activating T cells using an IL-2 ELISA. 
• To investigate IL-2 secretion by activated T cells over time (4, 8 and 24 hours) 
using ELISA. 
• To establish the OLP-like model by incorporating the activated T cells. 
































































Exposure HPLC Analysis 
 
Accumulation of CP: 
1. Tissue  




Accumulation of CP: 
1. Tissue  




Jurkat (T) cells  




T cell stimulation:  
1. PMA alone 
2. PHA alone 




points (4, 8 





Expose to CP at 
different time points 
(4, 8 and 24 H) 
Incorporate 
















See section 2.2.2 
See section 2.2.10.1.1 See section 2.2.9 – 2.2.10.1.1 
See section 2.2.10.1.2 – 2.2.10.1.3 
See section 2.2.9 – 2.2.10.1.1 
See section 2.2.11 
See section 2.2.12 See section 2.2.13 
See section 2.2.13 
See section 2.2.12 
See section 2.2.13 
See section 2.2.15 
See section 2.2.14 




6.3.1 Permeation of CP into TEOM in solution form was time and concentration-
dependent manner 
TEOM were exposed to a single dose of CP (5 µM) at increasing exposure times (10, 
30 and 60 minutes) and the presence of CP within the tissue and receptive medium of 
the basolateral compartment of the transwell culture analysed using HPLC. 
Accumulation of CP increased steadily in a time-dependent manner in both the tissue 
and receptive medium. In the tissue, the CP concentration measured after 10 minutes 
exposure was 6.08 ± 1.66 nM/mg that increased to 8.03 ± 1.81 nM/mg and 10.89 ± 
0.1 nM/mg after 30 and 60 minutes, respectively (Figure 6.1A). The presence of CP in 
the receptive medium of the basolateral compartment of the culture system could not 
be detected after 10 minutes exposure but 21.67 ± 12.18 nM was detected after 30 
minutes and this increased to 91.5 ± 7.51 nM after 60 minutes (Figure 6.1B). For all 
subsequent permeation tests, the TEOM was exposed for one hour, as this was the 








































Figure 6.1: Time-dependent increase in the amount of CP within (A) TEOM tissue and 
(B) in the receptive medium of the basolateral compartment after 10, 30 and 60 
minutes exposure to CP (solution). Data are expressed as the mean ± SD for 3 
independent experiments performed in triplicate. A mean difference was considered 
significant when *p < 0.05, **p < 0.001 and ***p < 0.0001 using One-way ANOVA with 













To determine the effects of drug concentration on permeation, TEOM were exposed 
to increasing concentrations of CP (5, 25 and 50 µM) for one hour. HPLC analysis 
revealed that the accumulation of CP in both the tissue and receptive medium 
increased in a concentration-dependent manner. The CP levels measured in the tissue 
were approximately 0.84 ± 0.14 nM/mg after 5 µM exposure and increased to 1.5 ± 
0.21 nM/mg at 25 µM. At 50 µM, the CP levels increased significantly to 4.21 ± 0.37 
nM/mg (p < 0.0001) compared to the CP levels at 5 and 25 µM (Figure 6.2A). CP 
accumulation in the receptive medium of the basolateral compartment was 
approximately 87.67 ± 12.14 nM after exposure to 5 µM, increasing significantly to 
192.33 ± 18.55 nM (p < 0.05) with 25 µM exposure as compared to the CP level at 5 
µM. Moreover, the level of tissue CP after 50 µM exposure was drastically increased 











































Figure 6.2: Amount of CP in the (A) TEOM tissue and (B) the receptive medium of the 
basolateral compartment after one-hour exposure with 5, 25 and 50 µM CP (solution). 
The amount of CP detected in tissue and receptive medium increased in a 
concentration-dependent manner. Data are expressed as the mean ± SD for 3 
independent experiments performed in triplicate. A mean difference was considered 
significant when *p < 0.05, **p < 0.001 and ***p < 0.0001 using One-way ANOVA with 














6.3.2 The penetration of clobetasol-17-propionate delivered via loaded 
mucoadhesive patches through TEOM was concentration and time-
dependent 
CP-loaded mucoadhesive patches containing 1, 5 and 20 µg of active drug were 
applied to the epithelial surface of TEOM for one hour. The concentration of CP that 
had permeated into the tissue was measured by HPLC and found to be 0.04 ± 0.04 
nM/mg from the 1 µg patch, increasing to 0.06 ± 0.07 nM/mg when a 5 µg patch was 
applied to the TEOM and to 0.15 ± 0.14 nM/mg from the 20 µg patch (Figure 6.3A). 
Interestingly, CP was only detected in the receptive medium when a 20 µg patch was 
applied to the epithelium, the amount detected was low at 5.33 ± 8.26 nM (Figure 
6.3B). For all subsequent experiments, only the 20 µg patch was used as this 
concentration showed the capability in penetrating and traversing the TEOM and 
reached to the basolateral compartment within 1 hour. Although it is the highest 
concentration, this CP-patch did not induce toxicity in the TEOM, which was confirmed 







































Figure 6.3: The amount of CP in (A) the TEOM tissue and (B) in the receptive medium 
of the basolateral compartment after one-hour exposure to either a 1, 5 or 20 µg CP-
loaded patches. The amount of CP detected increased in a concentration-dependent 
manner in the tissue. Whilst the presence of CP was only detected in the receptive 
medium when a 20 µg CP patch was applied to the TEOM. Data are expressed as the 
mean ± SD for 3 independent experiments performed in triplicate. A mean difference 
was considered significant when *p < 0.05, **p < 0.001 and ***p < 0.0001 using One-






The capability of CP released from the 20 µg patch in penetrating the tissue was 
further analysed by applying the patch topically to the surface of the TEOM for two 
additional time points, 4 and 24 hours. In general, the data in figure 6.4 shows that 
the amount of CP detected in the tissue and receptive medium increased when the 
incubation time was extended. The amount of CP detected in the tissue was 
approximately 0.22 ± 0.11 nM/mg after 1-hour exposure. It increased slightly to 0.25 
± 0.03 nM/mg after 4 hours exposure and the amount of CP detected was significantly 
increased (p < 0.05) to 0.94 ± 0.13 nM/mg after 24 hours incubation (Figure 6.4A). 
Similarly, the amount of CP present in the receptive medium was 16 ± 18.48 nM after 
1 hour exposure and increased to 31 ± 2.31 nM after 4 hours incubation and then 











































Figure 6.4: The amount of CP in (A) the TEOM tissue and (B) in the receptive medium 
of the basolateral compartment when a 20 µg CP patch was applied topically for either 
1, 4 and 24 hours. The amount of CP detected increased in a time-dependent manner 
in both the tissue and receptive medium. Data are expressed as the mean ± SD for 3 
independent experiments performed in triplicate. A mean difference was considered 


















6.3.3 Culture of Jurkat T cells in different medium  
The experimental plan was to develop a tissue engineered mucosal model to 
incorporate T cells in order to assess the biological effects of topically applied CP. 
However, Jurkat T cells (the cell line to be used) are routinely cultured in different 
medium (RPMI) to TEOM (Green’s medium). RPMI is the standard culturing medium 
for Jurkat T cells. Therefore, the viability of Jurkat T cells grown in RPMI medium was 
compared with cells grown in Green’s medium that is commonly used for culturing 
TEOM and required for epithelial differentiation. Jurkat T cell viability was assessed 
for up to 8 days in continuous culture (Figure 6.5).  
 
The viability of the Jurkat T cells cultured in Green’s medium was 95.17 ± 3.35%, 90.41 
± 3.42%, 86.14 ± 2.11%, 91.08 ± 1.12% at day 2, 4, 6 and 8 respectively. While the 
viability of the Jurkat T cells cultured in RPMI was 96.34 ± 4.14, 87.36 ± 1.53%, 89.51 
± 1.43%, 88.15 ± 0.1% at day 2, 4, 6 and 8 respectively. A significant difference in Jurkat 
T cell viability was observed at day 6 (p < 0.05) and 8 (p < 0.05) when compared 
between both media. Overall, the percentage of Jurkat T cell viability cultured in both 
media was maintained above 86% at all time points tested. 
 
Figure 6.5: Jurkat T cell viability when grown in RPMI and Green’s medium cultured 
for 8 days.  The data shows that culture in Green’s medium was comparable with RPMI 
medium. Data are expressed as the mean ± SD for 3 independent experiments 
performed in triplicate. A mean difference was considered significant when *p < 0.05, 




6.3.4 Activation of Jurkat T cells was more pronounced using a combination of PHA 
and PMA compared to a single stimulant alone 
Jurkat T cells can be activated and induced to secrete IL-2 either by direct activation 
of the T cell receptor using stimulating monoclonal antibodies or indirectly by 
stimulating the protein kinase C signal transduction pathway using PMA, PHA or a 
combination of these two molecules. Jurkat T cells at a cell density of 1.0 x 106/mL 
were stimulated with PHA and PMA alone or with combinations of these two 
stimulants for 24 hours. Optimisation of the most suitable concentration required to 
activate the Jurkat T cells (quantified by IL-2 release) without causing cell toxicity was 
performed. As a preliminary study, concentrations of 1 µg/mL PHA and 50 ng/mL PMA 
were used as recommended in the literature (Manger et al., 1986). However, these 
concentrations either added alone or in combination failed to activate the cells to 
release IL -2 (data not shown).  
 
Further optimisation was therefore performed with various doses of the two 
stimulants. Two concentrations of PHA (2 and 5 µg/mL) and a single PMA 
concentration (100 ng/mL) were tested for their ability to activate Jurkat T cells. By 
measuring the release of IL-2, it was shown that PHA alone at 2 and 5 µg/mL activated 
the cells with IL-2 secretion measured at 13.01 ± 20.16 pg/mL and 264.31 ± 34.83 
pg/mL, respectively. PMA alone (100 ng/mL) had no effect on T cell IL-2 secretion. 
However, when a combination of PHA and PMA was applied the secretion of IL-2 was 
significantly increased. The combination of 2 µg/mL PHA and 100 ng/mL PMA 
increased the release of IL-2 73-fold to 962.03 ± 153.41 pg/mL (p < 0.0001).  
Furthermore, elevation of PHA concentration to 5 µg/mL and co-stimulation with 100 
ng/mL PMA induced IL-2 secretion by a further 6-fold to 1626.34 ± 311.36 pg/mL (p < 
0.0001).  As a result, the co-stimulation of Jurkat T cells with 5 µg/mL PHA and 100 
ng/mL PMA was selected as the optimal concentrations to activate Jurkat T cells to 
secrete high levels of IL-2 and therefore used for subsequent experiments (Figure 6.6). 
 
In addition, cell viability was determined to ensure that there was no adverse cytotoxic 
effect caused to the Jurkat T cells when the stimulants were applied. Cell viability was 
maintained above 82% after exposure to PMA and PHA when applied either alone or 
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in combination with no statistically significant different between all groups of 
stimulants investigated (Figure 6.7). 
 
 
Figure 6.6: The activation of Jurkat T cells was tested by stimulation with PHA as a 
main stimulant and PMA as a co-stimulant. Stimulation of Jurkat cells was conducted 
either using a single or combination of the two compounds for 24 hours. The co-
stimulation of Jurkat cells induced a significant increase of IL-2 secretions compared 
to stimulation with either PHA or PMA alone. Therefore, the co-stimulation of PHA 
and PMA at 5 µg/mL and 100 ng/mL, respectively were chosen as the optimal 
concentration to activating Jurkat cells. Data are expressed as the mean ± SD for 3 
independent experiments performed in triplicate. A mean difference was considered 
significant when *p < 0.05, **p < 0.001 and ***p < 0.0001 using One-way ANOVA with 

















Figure 6.7: The effect of the different concentrations of the stimulants either applied 
alone or in combination on cell viability measured. No significant different between 
each group was observed, with cell viability remaining above 82% for each group 
tested. Data are expressed as the mean ± SD for 3 independent experiments 
performed in triplicate. A mean difference was considered significant when *p < 0.05, 
**p < 0.001 and ***p < 0.0001 as compared to control (media only) using One-way 




6.3.5 Sustained IL -2 release from activated T cells over time with stimulants  
The efficiency of activated Jurkat T cells to sustain release of IL-2 post-24 hours 
stimulation was investigated with IL-2 being measured after 4, 8 and 24 hours once 
the stimulants were removed. This analysis was crucial to ensure that the Jurkat T cells 
are able to release of IL-2 in a sustained manner prior to another experiment being 
conducted particularly in assessing the efficiency of CP treatment against IL-2 levels 
experiment. The data showed the secretions of IL-2 were 799.67 ± 114.74 pg/mL, 713 
± 98.77 pg/mL, 664.79 ± 98.27 pg/mL after 4, 8 and 24 hours, respectively. IL-2 
secretions were decreasing over time. However, the reduction of IL-2 levels was slight 




Figure 6.8: The level of IL-2 secretion by activated Jurkat T cells following 24 hours of 
stimulation was assessed over time. The insignificant reduction of IL-2 levels was 
observed in a time-dependent manner. Data are expressed as the mean ± SD for 3 
independent experiments performed in triplicate and analysed using One-way ANOVA 






6.3.6 Clobetasol-17-propionate-mediated inhibition of IL-2 production by the 
activated Jurkat T cells in OLP-like model 
To model OLP in vitro, Jurkat T cells were stimulated with a combination of PMA and 
PHA as previously described, the stimulant removed and the activated cells then 
added into the basolateral compartment of the TEOM. The TEOM were treated with 
different treatment strategies; namely control (media only, no patch), placebo 
(patch), 20 µg CP (patch) and 20 µg CP (solution) for 4, 8 and 24 hours and then the 
levels of IL-2 measured in the medium of the basolateral compartment of the tissue 
culture model where the Jurkat T cells resided.  
 
Data in figure 6.9 shows that IL-2 levels in the basolateral compartment of TEOM 
treated with medium alone were elevated and constant at 427.17 ± 53.58 pg/mL over 
24 hours, showing that the activated T cells secrete significant amounts of IL-2 over 
this time period.  The treatment of both the CP-loaded patch and CP solution reduced 
the level of IL-2 in a time-dependent manner, but only significant reduction was 
observed following treatment with CP solution after 24 hours treatment compared to 
IL-2 level after 4 hours treatment (p < 0.05). Interestingly, treatment with just a 
placebo patch containing no CP reduced the levels of IL-2 in the receptive medium 
that was significant (p < 0.05) at 4 hours but not so at 8 or 24 hours when compared 
to the medium only control (Figure 6.9).  
 
After 4 hours treatment, both the 20 µg CP-loaded patch and 20 µg CP added in 
solution form significantly (p < 0.05) reduced the IL-2 levels secreted by activated 
Jurkat T cells to 352.94 ± 65.57 and 319.72 ± 54.80 pg/mL, respectively, in the 
basolateral compartment compared to TEOM treated with control medium alone 
(528.28 ± 43.38 pg/mL). In contrast, no significant difference in IL-2 levels was 
observed between the CP-treated TEOM and the placebo patch treated TEOM (390.06 
± 41.17 pg/mL) at this time point (Figure 6.9). By 8 hours, levels of IL-2 in the 
basolateral compartment of both the CP-loaded patch (261.83 ± 23.18 pg/mL) (p < 
0.05) and the CP solution (230.64 ± 2.16 pg/mL) (p < 0.001) treated TEOM were 
significantly lower than the medium only control (421.83 ± 57.38 pg/mL) and more 
importantly the placebo control patch treated TEOM (356.50 ± 44.18 pg/ml) (Figure 
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6.9). The reduction in IL-2 levels in the CP treated groups continued in a time 
dependent manner and by 24 hours the level of IL-2 in the basolateral compartment 
had declined further to 230.17 ± 98.36 pg/mL for the CP-loaded patch and 164.61 ± 
62.29 pg/mL for the CP applied in solution form. These levels were significantly lower 
(p < 0.05) than those of both the medium only control (427.17 ± 53.38 pg/mL) and 
importantly, the placebo patch treated TEOM (376.61 ± 10.96 pg/mL) (Figure 6.9). 
These data show that CP either delivered in solution or in patch form penetrate and 
cross the TEOM models, enter the basolateral compartment where the T cells reside 
and then exert their anti-inflammatory actions by inhibiting IL-2 release from the 
activated T cells. These anti-inflammatory actions appear to take in excess of 4 hours, 
most likely due to the time taken for the corticosteroid to affect IL-2 gene transcription 




Figure 6.9: Treatment of OLP-like model using either media alone (control) placebo 
(patch), 20 µg CP (loaded-patch) or 20 µg CP (solution) at (A) 4, (B) 8 and (C) 24 hours. 
Data are expressed as the mean ± SD for 3 independent experiments performed in 
triplicate. A mean difference was considered significant when *p < 0.05, ** p < 0.001 
and ***p < 0.0001 as compared to control (media only) using One-way ANOVA with 















To confirm that the CP had penetrated and traversed the TEOM, the levels of CP in the 
medium of the basolateral compartment was also measured at each time-point. After 
treatment with the 20 µg CP-loaded patch, the amount of CP detected after 4, 8 and 
24 hours was 0.016 ± 0.002 µM, 0.032 ± 0.003 µM and 0.08 ± 0.003 µM, respectively 
(Figure 6.10A). After treatment with the 20 µg CP in solution, the amount of CP 
detected was significantly higher with 0.49 ± 0.02 µM, 1.19 ± 0.03 µM and 2.35 ± 0.09 
µM after 4, 8 and 24 hours, respectively (Figure 6.10B). Although the accumulation of 
CP increased overtime for both CP treatments, the amount of CP measured in the 
medium of the basolateral compartment when delivered in solution form was 
significantly greater (p < 0.0001) than when the CP was delivered in patch form at all 
time points tested, although the amount of CP in the patch and solution are not 
comparable, with solution containing more CP. These data show that the CP is able to 
traverse the TEOM models in both solution and patch form although levels are much 
higher when CP is applied as a solution. However, even though CP is in greater quantity 
when delivered in solution form in the basolateral compartment, data in figure 6.9 
show that both CP solution and patch-loaded CP decreased IL-2 levels to a similar 
degree. These data indicate that the levels delivered by the CP-loaded patches are 















Figure 6.10: Accumulation of CP in the basolateral compartment medium 
increased after 4, 8 and 24 hours exposure for both treatments using (A) 20 µg CP 
(patch) and (B) 20 µg CP (solution). The penetration capability of 20 µg CP 
delivered in (solution) was greater compared to the 20 µg CP (patch). Data are 
expressed as the mean ± SD for 3 independent experiments performed in 
triplicate. A mean difference was considered significant when *p < 0.05, **p < 




















In the past several approaches for assessing drug transport across the oral mucosa 
have been performed including use of animals or healthy human volunteers (Sohi et 
al., 2010), excised animal tissues (Hoogstraate et al., 1993), cell cultures (Nielsen and 
Rassing, 1999) and reconstituted tissue models (Odraska et al., 2011; Sohi et al., 2010). 
In this study, the permeation of corticosteroid had been optimised using TEOM based 
on FNB6 immortalised keratinocytes as a reproducible model system to assess drug 
delivery (chapter 4). To our knowledge, these are the first studies performed to assess 
drug delivery using an immortalised keratinocyte cell-based TEOM. 
 
Absorption of molecules through the oral mucosa occurs mainly by passive diffusion 
via either paracellular or transcellular pathways (Sudhakar et al., 2006; Rossi et al., 
2005). These pathways, for drug absorption into the oral mucosa, rely on the 
lipophilicity of the drug (Deneer et al., 2002); the paracellular pathway favours 
hydrophilic and small molecules (≤ 300 Da) whilst the transcellular pathway is 
preferential for lipophilic molecules (Rossi et al., 2005, Patel et al., 2011). CP is a 
lipophilic molecule with a molecular weight of 466.97 g/mol (Barange and Asghar, 
2017) and therefore, the transcellular pathway is the likely dominant pathway for its 
transport. 
 
In this study, the transport of CP either in solution or patch form into and across the 
TEOM was assessed. The penetration capabilities of CP and its distribution were 
determined in the tissue and receptive medium of the basolateral compartment of 
the transwell tissue culture system using HPLC. At lower concentrations, the CP in 
solution form was detected in the TEOM tissue but it did not penetrate to reach the 
receptive medium after 10 minutes exposure. It is revealing that this duration of 
treatment was the minimal time for the CP to be detected in the tissue. However, 
when a higher concentration was applied at the same time point, the CP was detected 
in both the tissue and the receptive medium. Accumulation of CP into the TEOM tissue 
and receptive medium was both time and concentration dependent. In contrast, the 
minimal contact time of CP in the patch form that was sufficient to be detected in the 
tissue was one hour for all concentrations analysed. Results also demonstrated that 
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only CP released from 20 µg patches accumulated in the receptive medium after one-
hour exposure. Studies examining the adsorption of CP into any epithelial tissue are 
sparse. Previous CP permeation tests on porcine skin showed that the minimal time 
for the drug to permeate the skin was 3 hours and the accumulation of drug increased 
up to 6 hours yet no CP was detected in the receptive medium after 6 hours, 
irrespective of dosage form being used (Silva et al., 2012; Senyigit et al., 2010). 
Compared to the TEOM model system structure, it can be postulated that the 
complexity, thickness and keratinisation of the porcine skin limited the transport of 
CP, regardless of the physicochemical properties of the molecule (Kulkarni et al., 
2009), increasing the duration of time for the compound to penetrate and traverse 
the tissue. The penetration of CP into the TEOM was fast, irrespective of being in the 
soluble or patch-loaded formulation as the drug permeated the tissue in 10 minutes. 
This is likely to be due to a combination of the high lipophilicity of CP and the lack of 
keratinisation and lower level of permeability barrier in the TEOM than found in 
porcine skin. 
 
Previously, researchers have utilised Jurkat T cells, originally isolated from a patient 
with leukaemia, as a surrogate for normal T cells in experimental studies (Basak and 
Banerjee; 2016; Seggewiss et al., 2005; Yiemwattana et al., 2012). Although Jurkat T 
cells differ in some aspects from normal peripheral blood T cells, they serve as a good 
model cell system and profit from ease of culture and the lack of requirement to 
isolate the cells from peripheral blood. Previous studies have shown that these cells 
can be activated using PHA or PMA either singularly or as a combination with various 
concentrations and incubation periods described in the literature (Basak and 
Banerjee, 2016; Fernández-Riejos et al., 2008). Analysis in this study showed that 
Jurkat T cells treated with a combination of PHA and PMA cultured in Green’s medium 
caused a marked activation of the cells, inducing significant levels of IL-2 secretion that 
were consistent over time up to 24 hours. Thereby, indicating that this type of 
activation, although not entirely realistic of T cell activation in OLP, is sufficient enough 




Activated T cells were added to the lower chamber of a transwell system with the 
upper well containing the TEOM in order to mimic in vitro OLP, or at least a T cell 
mediated mucosal immune disease. OLP is associated with T cell-mediated immunity 
(Sato et al., 2015). Therefore, the OLP-like model was developed using activated IL-2 
releasing T cells since elevated expression of IL-2 levels has been reported in OLP 
lesions previously (Piccinni et al., 2014; Hasseus et al., 2001). Increased IL-2 levels also 
reflect the immune dysregulation status that is associated with the 
immunopathogenesis of OLP (Alikhani et al., 2017; Lu et al., 2015). IL-2 is essential for 
the development, proliferation and survival of T cells (Gutsol et al., 2015) and 
mediates its effects by binding to the IL-2 receptor (IL-2R) on T cells in an autocrine 
manner (Lu et al., 2015). The decreased expression of a few cytokines relevant to 
inflammatory diseases, including IL-2, following treatment with CS had been reported 
in several previous studies (Uva et al., 2012; Bianchi et al., 2000; Barnes, 1998). In 
general, the therapeutic effect of corticosteroids includes the depletion of circulating 
T cells which results in the inhibition of IL-2 secretion as well as signal transduction via 
the IL-2R (De Jong et al., 1999; Paliogianni et al., 1993). Other immunosuppressive 
agents besides CP such as dexamethasone and cyclosporin A are also reported to 
inhibit T cell IL-2 secretion (Lu et al., 2015; Malek, 2008), suggesting that IL-2 is a useful 
biomarker which can be used to evaluate the efficiency of immunosuppressive 
molecules.  
 
The results described in this chapter revealed that the efficiency of CP in reducing IL-
2 levels in the in vitro TEOM OLP model was comparable between patch-loaded CP 
and that delivered in solution, despite a greater amount of CP entering the basolateral 
lower chamber for solution than the patch form as determined by HPLC analysis. It 
can be postulated that the smaller amount of CP delivered in the patch form was still 
sufficient to inhibit the level of T cell secreted IL-2, which may reflect the potency of 
CP. In addition, the formulations of CP showed different absorption characteristics 
where tissue absorption of CP in solution was rapid whereas patch-loaded CP 
exhibited a slower tissue uptake. This difference in rate of tissue absorption is likely 
due to the release profile characteristics of the patch-loaded CP compared to CP free 
in solution. In a soluble form CP is freely mobile and which allows fast and direct 
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absorption (Chillistone and Hardman, 2017; Gautami, 2016). In contrast, in the patch-
loaded form, CP is held within the polymer fibers in an amorphous form (Colley et al 
2018). Hydration and collapse of the polymer complex is required in order for the CP 
to be released that is in part controlled by levels of RS100. Therefore, patch-loaded 
drugs are delivered much more slowly to tissues than drugs in free solution (Gilhotra 
et al., 2014; Boddupalli et al., 2010: Artusi et al., 2003). Indeed, the ability to control 
the rate of drug release is a distinct advantage for treating oral lesions.   
 
The disappearance or lower drug recovery in the tissue or receptive medium might be 
due to its biotransformation into metabolites when catalysed by cytochrome P450 
enzymes that likely exist in the epithelium of the tissue (Smith et al., 2017; Zanger and 
Schwab, 2013). Noteworthy, the treatment of TEOM with the placebo patch also 
reduced IL-2 levels significantly compared to TEOM treated with buffer alone after 4 
hours. The reason for this is uncertain, as the patches contain no previously detected 
bioactive molecule. It is plausible that polymers derived from the mucoadhesive layer 
may traverse the epithelium to directly affect T cells, although the size of these 
polymers make this unlikely, or activate the epithelium which then responds by 
secreting a factor that can inhibit IL-2 secretion from T cells. Further research is 
required to ascertain the reason for this finding.   
 
A major limitation of this study was the efficiency of the extraction procedure used for 
quantifying the amount of compound in the TEOM; which sometimes caused low 
recovery of the compound and was largely responsible for the large standard 
deviation in the individual datasets. It was troublesome to get a clear separation 
between the supernatant and cell pellets. The interference of the cell residue 
impacted the HPLC analysis, which occasionally caused failure of the instrument. To 
address this issue, tissue supernatants were filtered to remove any cell residue and 
minimise the occurrence of the problem. It was previously reported that the 
interaction between analytes, lipids and proteins may cause low drug recovery (Silva 
et al., 2012). In addition, only reduction of IL-2 as a marker of T cell activation was 
measured. Although a good marker, several others are available including the cell 
surface marker CD69 along with other cytokines. Time permitting, it would have been 
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advantageous to measure a decrease in the expression or secretion of other activation 
markers as well decreased activation of signal transduction pathways such as NFκB, 
AP-1 and NFAT.  
 
6.5 Summary 
In this chapter an in vitro model of OLP was created using TEOM with underlying 
activated T cells secreting IL-2 in order to show the efficacy of topically delivered CP, 
with particular emphasis on electrospun patch-loaded CP as a drug delivery system. 
The amounts of CP that permeated into the tissue and accumulated in the receptive 
medium increased in a time and dose-dependent manner, irrespective of CP 
formulation.  CP-loaded patches released the drug into tissue and receptive medium 
that was in sufficient levels to decrease T cell activation, if placed onto a lesion in vivo, 
this is highly likely to result in targeted therapy with the ability to reduce T cell 
activation in the connective tissue as well as in the basal epithelium, sites where 




















   CHAPTER 7 
 
GENERAL DISCUSSION, CONCLUSION AND FUTURE WORK 
 
7.1 General discussion 
The standard procedure in drug development typically starts with the screening of a 
candidate compound in pre-clinical studies prior to clinical trials, which are finally 
followed by commercialisation of the compound (Breslin and O’Driscoll, 2013; DiMasi 
and Grabowski, 2007). In pre-clinical studies there are several alternative biological 
model systems that are commonly used including various forms of two-dimensional 
(2D) cell culture and animal models (Gazdar et al., 2016; Denayer et al., 2014). 
However, each of these model systems has drawbacks that have contributed to the 
low success rate (≈10%) of tested compounds in clinical trials (Denayer et al., 2014). 
Most tested compounds fail due to their low efficacy and/or undesirable toxicity 
(Hopkins, 2008), mainly because the pre-clinical experimental systems failed to 
provide sufficient critical information that is required for prediction of drug efficacy 
and safety (Brajša et al., 2016; Kim, 2005).  In order to reduce the considerable costs 
associated with clinical trials, it is best to eliminate test compounds that are less 
efficient or show undesirable toxicity as early as possible, ideally prior to animal 
testing (Edmondson et al., 2014).  
 
One way to address the limitations observed in 2D and animal model systems is by 
establishing 3D culture systems. If developed and validated correctly, these model 
systems can accurately mimic the in vivo conditions by enabling cells to interact in a 
biological environment that better reflects native tissues both structurally and 
physiologically. Such 3D environments drastically differ from 2D model systems where 
cell often grow as monolayer cultures on plastic surface that are far removed from in 
vivo conditions (Antoni et al., 2015; Edmondson et al., 2014). Animal models are 
commonly employed over in vitro models because, being living organisms, it is 
supposed that these better reflect the human in vivo situation (Antoni et al., 2015). 
However, the use of experimental animal models is associated with ethical issues, as 
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well as unpredictable responses that may be far removed by those experienced by 
humans due to species variation. They can also be costly and time-consuming 
(Langhan, 2018; Antoni et al., 2015; Sivaraman et al., 2005). Ex vivo human tissue can 
also act as a model system and this is biologically closest to the in vivo situation. 
However, problems encountered include maintaining tissue viability and access to 
tissue making this model difficult for routine testing purposes (Antoni et al., 2015). 
Tissue engineered 3D model systems offer a solution in terms of ethical and economic 
reasons as well as minimising the use of animals in research. It is argued that these 
models also provide more predictive data for in vivo tests prior to clinical trials 
(Edmondson et al., 2014). 
 
Most tissue engineered model systems use primary human cells, but like human tissue 
access to these is restricted and data in repeat experiments may vary widely due to 
genetic background differences of the cell donors. More recent research has moved 
to use immortalized human cells that can proliferate almost indefinitely whilst 
retaining the morphology of normal cells, usually by over-expression of TERT-2, 
although such studies for the oral mucosa are limited (Buskermolen et al., 2016; 
Jennings et al., 2016; Dongari-Bagtzoglou and Kashleva, 2006).  
 
Data provided in chapter 3 demonstrate that full-thickness TEOM can be successfully 
constructed from FNB6 oral keratinocytes. These TEOM display a histological structure 
that is very similar to the normal oral mucosa, having a stratified squamous 
epithelium, basement membrane and connective tissue. Indeed, it seems that FNB6 
TEOM exhibit better growth and differentiation of the epithelial layers when 
compared to the TEOM constructed using other oral mucosal immortalised cells 
(Buskermolen et al., 2016; Dongari-Bagtzoglou and Kashleva, 2006). FNB6 TEOM also 
showed normal expression of proteins involved in keratinocyte differentiation (CK4, 
CK13 and CK14) and proliferation (Ki-67) processes within different layers of the 
epithelium, confirming that cell immortalisation does not cause any alteration in 




The crucial aspect to this study, which is largely based on drug delivery into and across 
the mucosa, was to ensure that the epithelial integrity and permeability barrier 
function of the TEOM are present. Data in chapter 3 showed that the TEOM displayed 
a normal expression pattern of structural and integrity molecules such as E-cadherin 
and Claudin-4, which form tight junctions (De Vicente et al., 2015). TEOM also 
displayed intercellular junction-related structures such as desmosomes as well as 
hemidesmosomes that are important in cell to basement membrane adhesion (Squier 
and Brogden, 2011: Kinikoglu et al., 2009; Niessen, 2007). In addition, data obtained 
for TEER and permeability against dextrans confirmed the integrity status of the 
TEOM, showing that TEOM constructed of immortalised FNB6 cells are fit to be used 
for drug delivery experiments, particularly if long-duration experiments are intended. 
 
Corticosteroids are the treatment used for mucosal lesions such as OLP (Córdova et 
al., 2014) and RAS (Scully and Porter, 2008). To date several types of corticosteroids 
are used in treatment regimes, with these corticosteroids ranging from mild to very 
potent. However, the increasing level of potency of the corticosteroid used has been 
associated with increasing degree of side effects (McKenzie and Stoughton, 1962). This 
assertion was exemplified in data provided in chapter 4, which showed that highly 
potent corticosteroids such as CP had a lower IC50 values towards oral keratinocytes 
and fibroblasts than milder corticosteroids. In fact, data provided in chapter 4 showed 
that there was a distinct correlation between potency of corticosteroid as defined in 
the British National Formulary and toxicity towards oral keratinocytes, fibroblasts and 
TEOM. However, most notably the toxicity toward TEOM was lower than for 
monolayer cultures because of its multilayered nature and permeability barrier that 
are absent in 2D systems. This highlights the usefulness of TEOM over monolayer 
culture, suggesting that TEOM is the most appropriate in vitro experimental model to 
use in order to predict the response of drugs as close to in vivo conditions.  
 
The current oral drug delivery systems for corticosteroids such as mouthwashes, 
creams or ointments are dramatically affected by the conditions in the oral cavity, 
such as saliva flow rate and mechanical forces causing the drug to have minimal 
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contact time with the oral lesion. This inevitably leads to inefficient drug absorption 
and distribution (Madhav et al., 2012; Sankar et al., 2011).  
 
Development of electrospun mucoadhesive oral patches has given rise to the prospect 
of drug delivery via drug-loaded patches (Santocildes-Romero et al., 2017). The use of 
mucoadhesive oral patches with a protective backing layer will ensure that delivery of 
the drug is unaffected by the conditions of the oral cavity with unidirectional release 
of drug directly to the lesion (Patel et al., 2011; Alur et al., 1999). This may increase 
lesion healing and thus increase patient compliance because it is a more convenient 
route of administration (Satheesh Madhav et al., 2012). The absorption of the drug is 
likely to be improved and so frequency of dosing could be reduced as well as off-target 
and systemic side effects of the drug (Sankar et al., 2011; Patel et al., 2011; Alur et al., 
1999). The side effects of corticosteroids are unavoidable, irrespective of their 
potency level, but this may be controllable. Thus, the use of highest potent 
corticosteroids (e.g. CP) in a clinical setting is sensible as long as the dose of the drug 
and the duration of the treatment are controlled (Stanbury and Graham, 1998). Data 
provided in chapter 5 show that CP-loaded patches are homogeneous as far as 
physical characteristics are concerned, are non-toxic and can be manufactured with 
increasing drug content. Moreover, the drug is released efficiently from the patches 
in a time and dose-dependent manner. Recently published data also demonstrate 
their adhesiveness to human buccal, gingival and tongue mucosa in a first human 
study, where the patches were acceptable to wear over prolonged periods (Colley et 
al., 2018). Moreover, the patches rapidly hydrate and swell upon contact with 
aqueous solution such as saliva, which not only causes their mucoadhesiveness but 
also initiates drug release from the polymers. Data in chapter 5 show that CP was 
released from the patch into the TEOM in a time and dose-dependent manner. These 
data are the first to show electrospun polymer patch delivery of a corticosteroid to 
TEOM in pre-clinical experiments.   
 
The development of a disease model TEOM to test novel therapeutic formulations is 
an attractive approach. Experiments in chapter 6 showed the use of a simple 
adaptation of the TEOM system by the addition of activated T cells at the basolateral 
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surface of the connective tissue. Although a similar model was used to mimic atopic 
dermatitis (Sriram et al., 2018), this is the first to be developed to mimic oral lesions 
such as OLP. Ideally the T cells should reside just below the basement membrane in 
the connective tissue and be dispersed within the lower epithelium where they exert 
their cytotoxic effects causing epithelial cell destruction. However, due to time 
limitations, the activated T cells were placed in the receptive medium basolateral to 
the connective tissue. It is highly likely that more complex models will be developed 
in future.   
 
The use of the OLP-like TEOM model constructed in this study provided a good assay 
in providing evidence for the efficacy of immunosuppressant effects of corticosteroids 
particularly patch-loaded CP for OLP treatment. Such a tissue engineered OLP model 
may be suitable to be utilised to study the more mechanistic aspects of the disease, 
instead of using animal experimental models (Van De Worp et al., 2010; Yamada and 
Cukierman, 2007). While the use of IL-2 as a biomarker for OLP may be valuable in 
diagnosing the status of the disease with greater ease and accuracy and at a lower 
cost. Importantly, data in chapter 6 show that CP-loaded patches were able to reduce 
the activation status of activated T cells by significantly reducing IL-2 levels. Moreover, 
this was achieved at much lower doses than that for CP in a solution. Some of the data 
provided in this thesis have been instrumental in the development of the novel 
electrospun patch drug delivery system. Data provided by the TEOM model was 
mirrored by those observed using a mini-pig model, validating its usefulness in drug 
delivery research (Colley et al., 2018). Indeed, the use of TEOM as a model assay 
system has strengthened the case for the use of such a novel delivery formulation for 
oral lesions. At present, the CP-drug loaded oral patches have entered phase 2 clinical 









7.2 General conclusion 
The in vivo-like conditions of 3D model systems has broadened the opportunities to 
new, highly versatile assay systems in the various field of research. As proven, this 
study has extended the applications of TEOM in drug delivery and toxicity as well as 
in therapeutic applications that have been used to assess the use of corticosteroids 
for OLP treatment. As a more humane alternative, the use of TEOM allows 
experiments to be performed on tissue that more accurately mimics the human in vivo 
situation.  
 
The oral mucosa provides an alternative route for drug delivery as it offers many 
advantages that could address some of the limitations of conventional drug 
administration through oral and other routes (e.g. parenteral). The possibility of 
retentive drug delivery for an extended period of time to the oral mucosa shows 
favourable opportunities for the application of the new formulation of mucoadhesive 
bilayer patches containing CP, which is less affected by conditions in the oral cavity as 
compared to current formulations. Thus, this novel therapeutic approach could 
increase drug absorption and patient compliance as it accessible and non-invasive, 
whilst also reducing the frequency of dosing as well as lowering the costs.  
 
 
7.3 Future work 
7.3.1 Factors affecting drug absorption in the oral cavity 
The conditions of oral cavity display some significant obstacles where the physiological 
aspects of the oral cavity such pH, fluid volume and composition (saliva) have become 
the barriers for drug delivery (Patel et al., 2011). The enzymes that present in the saliva 
such as aminopeptidase could affect the absorption of the drug (Nielsen and Rassing, 
2000). The simulation of oral cavity like-environments in the TEOM could be 
performed by the addition of enzyme-containing artificial saliva onto the surface of 
TEOM prior to the application of corticosteroid and this might be a way to assess the 




Permeability of the drug through oral mucosa is also affected by the different lipid 
composition of the epithelium, even if it is keratinised (e.g. ceramides and 
acylceramides) or non-keratinised, (e.g. cholesterol sulfate and glucosyl ceramides) 
(Squier and Wertz, 1996; Consuelo et al., 2005) and also affected by the existence of 
membrane coating granules (MCG) in the epithelium (Harris and Robinson, 1992; 
Galey et al., 1976). Thus, a comparative analysis could be performed using the 
lipophilic (e.g. cyclosporin A) and hydrophilic (e.g. ranitidine) drug that would also 
validate the composition of the lipids and MCG in the TEOM. 
 
7.3.2 Strategies to improve drug absorption  
The emergence of technologies such as permeation enhancers and enzyme inhibitors 
could be a potential approach to address the obstacles in delivering the drug in the 
oral cavity (Sudhakar et al., 2006). Therefore, incorporation of permeation enhancers 
(e.g. bile salts) and enzyme inhibitors (e.g. aminopeptidase inhibitors) (Jani et al., 
2012; Ueno et al., 2007) in the formulations could improve the absorption of the 
corticosteroids across the oral mucosa.  
 
7.3.3 Drug-metabolising cytochrome P450 enzymes expression 
The variability in pharmacokinetic and response of corticosteroids may be partly 
related to the activity of drug-metabolising cytochrome P450 enzymes in the oral 
epithelium or connective tissue. It has been reported that cytochrome p450 enzymes 
such as CYP3A4 and CYP3A5 are involved in regulating the level of glucocorticoids 
(Dvorak and Pavek, 2010; Vondracek et al., 2001). Therefore, understanding of 
cytochrome p450 enzyme activities in the oral mucosa is likely to be relevant in clinical 
practice. Understanding drug-drug interactions, different metabolic enzyme activity in 
different individuals may also help prevent the potential adverse effects (Martin and 
Fay, 2001). 
 
7.3.4 Oral lichen planus-like model development 
The use of primary T cells for OLP-like model construction is necessary as a comparison 
to the use of immortalised Jurkat T cells. This comparative analysis is needed in order 
to evaluate any differential response of the cells against stimulants as well as assessing 
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the sustainability of IL-2 release by the activated T cells. In addition, placing activated 
T cells in the connective tissue and juxtapose basal keratinocytes would further mimic 
OLP. More advanced models could use matched keratinocytes, fibroblasts and 
activated T cells from OLP patients so that the disease model could be replicated in 
full. It is also possible that OLP models could be generated using induced pluripotent 
stem cells derived from OLP patients.  
 
The immunosuppressive effects of corticosteroids against OLP are mediated by 
inhibiting the IL-2 release produced by the activated T cells as well as the signal 
transduction through IL-2 receptors (De Jong et al., 1999; Paliogianni et al., 1993). 
Therefore, the analysis of the expression of IL-2 receptors could validate the 
pathogenesis of the disease and also evaluate the efficiency of the corticosteroids 
therapy against OLP. In addition, expression analysis of other biomarkers of OLP is 
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HPLC calibration standard for (A) clobetasol-17-propionate, (B) betamethasone-17-valerate 



















Standard curve of interleukin-2 (IL_2) 
 
 
